2.0 LPBI Group News
2021
UPDATED on 10/22/2021
How LPBI Group plans to use the Spanish Translation of its BioMed e-Series: Cover page of 18 e-Books and electronic Table of Contents of these e-Books?
https://lnkd.in/ekWGNqA
In November 2021 – I will start to convert the Spanish eTOCs to Sound files and will start to publish
LPBI Group’s
Medical eBooks New Genre Edition !!!!
- Spanish in Audio format,
- Bi-Lingual Text,
- NLP, Results and Domain Knowledge Expert Interpretations, and
- English Editorials in Audio format
Application of LPBI Group’s New Genre Edition of Medical Books:
Each Series: A, B, C, D, E – ONE Volume per Series – 5 volumes in Total
- Series A: Six volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
- Series B: Two volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
- Series C: Two volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
- Series D: Four volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
- Series E: Four volumes, All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
Each Volume: in each Series – 18 volumes in Total
- Part A: Bi-Lingual eTOCs,
- Part B: NLP, Results and Domain Knowledge Expert Interpretations
- Part C: Editorials English Audio
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
http://www.amazon.com/dp/B071VQ6YYK
https://www.amazon.com/dp/B075CXHY1B
https://www.amazon.com/dp/B076HGB6MZ
https://www.amazon.com/dp/B078313281
https://www.amazon.com/dp/B078QVDV2W
https://www.amazon.com/dp/B07MGSFDWR
https://www.amazon.com/dp/B07MKHDBHF
https://www.amazon.com/dp/B08385KF87
http://www.amazon.com/dp/B08VTFWVKM
I am so excited about the
Medical eBooks New Genre Edition !!!!
UPDATED on 10/16/2021
It is with the highest OWE that I have issued today
LPBI’s first Cerficicate in Medical Text Analysis for COMPLETION OF 18 Months of Academic Training, the Completion of NLP of an entire book
GENOMICS VOLUME 2
Latest in Genomics Methodologies for Therapeutics:
Gene Editing, NGS & BioInformatics,
Simulations and the Genome Ontology
2019
Volume Two
https://www.amazon.com/dp/B08385KF87
Deep Learning NLP
performed by
MADISON DAVIS
Thank you very much for completion of Genomics Volume 2 – This is a COLLOSAL accomplishment.
Genomics, Volume 2 will be LPBI’s 1st e-Book in
LPBI’s NEW GENRE EDITION of Scientific Books with the following format
- Part A: eTOCs in Spanish AUDIO and Bi-Lingual Spanish and English TEXT – Text Source: ORIGINAL Book
- Part B: Deep Learning NLP by Madison Davis – Graphic Visualization
- Part C: Editorials in English AUDIO – Text Source: ORIGINAL Book
AFTER we finish PART B, above, I am advising Madison:
- to consider to start to work on Synthetic Biology Software for Molecular Design for Galectins
https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
- Starting a NEW Internship leading to a New Certificate in Synthetic Biology Software for Molecular Design for Galectins
Detailed description to be found on each Internship page, below
- Medical Text Analysis (Deep Learning NLP)
- IS, IT, CS and Data Science Internship
- Blockchain Knowledge Graph Database Design with Interface to Wolfram NLP
- Finance Internship: Financial Modeling
-
Synthetic Biology Software for Drug Design in Glycobiology Internship
- Journalism and Marketing Communications in Pharmaceutical Media
I am encouraging all INTERNS to complete their assignments
- GET Certificate(s)
- Move to Another Internship – ALL ARE TUITION FREE
UPDATED on 10/7/2021
Tweets and Re-Tweets of Tweets by @pharma_BI @AVIVA1950 at 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021, #WMIF2021
UPDATED on 10/4/2021
Tweets and Re-Tweets of Tweets by @pharma_BI @AVIVA1950 at EmTech MIT 2021, #EmTechMIT, Technology Review’s flagship event, September 28-30, 2021
UPDATED on 10/2/2021
LPBI covered in Real Time the Virtual MIT Technology Review’s flagship event, September 28-30, 2021 – EmTech MIT 2021
- EmTech MIT 2021 – Agenda Overview & Speakers: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
https://event.technologyreview.com/emtech-mit-2021/agenda
- Day 1: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
- Day 2: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
- EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
UPDATED on 9/27/2021
First day for Satwik Sunnam, Research Assistant 3 in our Team LPBI India is 9/27/2021
Assignment 1: Replacement to Dr. Pati on Cancer Volume 1, Chapters: 7,8,9,10,11,12
- Produce Hypergraph V1 – One for each Chapter for Cancer Volume 1, Chapters: 7,8,9,10,11,12
- Produce Tree Diagram Plots – One for each Chapter for Cancer Volume 1, Chapters: 7,8,9,10,11,12
Assignment 2: Replacement to Ms. Amandeep Kaur on Genomics Volume 1, Chapters: 1-21
- Ms. Kaur completed Data preparation Chapters: 1,2,3,4,5 and 21
- Your assignment #2 include:
- Produce Data preparation for Chapters 6 -20
- Produce Deep Learning NLP for Chapters 1 to 21.
UPDATED on 9/22/2021
On 9/20 LPBI had issued the following Certificates:
First Certificate issued in the domain of
Medical Text Analysis with Deep Learning Natural Language Processing
Recipient: Yash Choudhary
On 9/17/2020, LPBI issued the following three Certificates in the domain of
IS, IT and Data Science
for the following Contributions:
Recipients: Abhisar Anand and Srinivas Sriram
for their contribution to IT system solution design for Data Extraction of Article Views
Problem definition:
To extract the views for each of the 6,000+ articles for different time periods. Must be done in a time-efficient manner that retrieves the necessary data for LPBI.
Conceptual solution:
Create a multiple-step process that involves web scraping the data in multiple processes to enhance the speed of the extraction, and use data analysis libraries in Python to format the data in the correct format.
Code Implementation: https://pharmaceuticalintelligence.com/sop-web-stat/
Recipients: Ethan Coomber
For his contributions to Text To Sound conversion of 150 Interviews with Scientific Leaders and for Twitter Analytics on LPBI’s two Twitter handles: @pharma_BI @AVIVA1950
UPDATED ON 9/6/2021
A long weekend ahead of us. Lots of good things to look forward to.
• Labor Day with all its meaning.
• For my culture, the High Holidays.
Blessed to be healthy, very creative and very productive.
What is New at LPBI Group:
1. We got this week all our 18 #books in #medicine translated to #spanish
• Cover Page
• electromic Table of Contents
2. We created the first products using Wolfram #deeplearning
Natural Language Processing #nlp
3. We made advances regarding launching a #blockchain #knowledge #graphdatabases for our
• +6,080 scientific articles
• 18 Books in Medicine (English and Spanish)
• 100 e-Proceeding oh Top Tier Biotech Conferences
• +6,000 Biological Images
4. Completed +150 conversion Text to Sound #TTS, I.e., Podcasts of Interviews with Scientific Leaders
5. Received the code for our Information System allowing for #data–#analytics #extraction of #articles #views per Year
YES: +2MM Views – #bigdata 3.3 Giga Bytes !!!!
6. Made strides in further defining our platform for #syntheticbiology in #drugdiscovery
#biotech #research #language #datascience #translation #ai
So much GOODNESS in one week
UPDATED ON 9/5/2021
Milestones reached on 3Q 2021
- IT & Data Science Internship – LPBI gained the code to run Article Views by any date, 2012 – 2021 – Contributions by Srini and by Abhisar
- Text to Sound: 150 of the 270 Interviews with Scientific Leaders were converted to Podcasts – Contribution by Ethan
- Sign up agreement with SpeechKit – Text to Sound conversion for (a) $204 for 360 podcasts per year (b) Archive bulk conversion 20 cents per Podcast (c) Use API for Spanish Text to Spanish Sound
- ALL 18 BOOKS have a COVER PAGE and an eTOCs in Spanish – Montero competed its Contract and was paid by a Loan Aviva made to LPBI. On 9/1/2021 wired the funds to cover the Invoice.
- Instructions by Madison for all INTERNS on Deep Learning NLP using Yash’s code – is almost ready
- Proof-of-Concept for Cardiovascular text with Deep Learning NLP is ready by Yash using Adina’s Data preparation
- PowerPoint SLIDE DECK for 2.0 LPBI is Ready – Text by Aviva and PPT by Srini and Abhisar
- Completion of Internship Definition and Certificate Design on 9/2/2021 – Joint Work with Robin and Beth https://pharmaceuticalintelligence.com/certificate-1-year/
- LPBI India is seeking additional Leadership to Dr. Saha and additional INTERNS for (a) Medical Text Analysis using Wolfram Deep Learning NLP and (b) Synthetic Biology Software for Drug Discovery
- Synthetic Biology in Drug Discovery – Mission #4 for LPBI USA is Mission #2 for LPBI India: Updated by Dr. Williams on 8/20/2021. He will present on 9/14/2021. See update https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
UPDATED ON 8/31/2021
August 31, 2021 is a GREAT day for both organizations:
- Montero, Language Services, Madrid for COMPLETION of the Spanish Translation of LPBI Group’s EIGHTEEN Books in Medicine: Books Page Cover and electronic Table of Contents (eTOCs) per Volume
- LPBI Group, Boston for having the EIGHTEEN products of the Spanish Translation as agreed upon
This Spanish Translation serves our quest to
- (1) have the opportunity to REACH to the Medical communities in Spanish speaking countries and to Spanish speaking physicians and allied health professionals in the US, and
- (2) having the ability to re-Publish every book and every e-Series as a New Genre of Scientific Books in several new formats:
Series A, B, C, D, E – per each Series:
- Never published before as eTOCs of all Volumes in a Series
- Never published before in Spanish: Text or Audio
- Never published before in English Audio
All volumes in each Series – Bi-Lingual and Audio eTOCs
Cover Page and electronic Table of Contents
- Spanish & English Bi-Lingual eTOCs in Text – Today the FINAL products delivered
- Spanish eTOCs Translation in Audio [Text to Sound]
- English eTOCs in Audio [Text to Sound]
Per Volume for each of the 18 Books – New Genre of Scientific Books
- Part A: Bi-Lingual eTOCs: Spanish Audio and English Audio
- Part B: Results of Deep Learning Natural Language Processing with Domain Knowledge Expert Interpretation in [English text work-in-progress] and Spanish text to be translation of this English Text [Future Plan]
- Part C: Book original Editorials in English Audio [Text to Sound]
UPDATED ON 8/16/2021
Proof-of-Concept yielded LPBI’s SOPs on Natural Language Processing – How we will use Deep Learning NOT Statistical NLP !!!!!!!!
- Yash’s code.nb
- Deep learning methods
- 25 keywords
- Code file: code.nb
- Hypergraph1.pdf
- Treeplot.pdf
UPDATED ON 8/7/2021
#1:
LPBI Group announces 5th Academic INTERNSHIP as a Verifiable Certificate Program in Financial Modeling
These are the FOUR ACADEMIC INTERNSHIPS as verifiable Certificate Programs One year or One semester: Volunteer base
- NLP – Medical Text Analysishttps://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
- Synthetic Biology in Drug Discovery targeting Galectinshttps://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
- IT Projects and Administration of IP Asset Classes. we developed a Plan for SOPs for LPBI Group’s IT & Data Science Management Projects https://pharmaceuticalintelligence.com/2021/07/11/plan-for-sops-for-lpbi-groups-it-data-science-management-projects/ Informations technology & systems of LPBI: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images. All the platforms: Authoring, publishing and portals. Business analytics for Internet platforms presence: Twitter Analytics +1,100 followers of two handles and LinkedIn ~8,000 1st degree connections of LPBI’s Founder, including +500 CEOs.
- BLOCKCHAIN Architecture Design: Interface to NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY. Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN. NLP-Blockchain IT Infrastructure is needed. The NLP inferences are part of a knowledge graph database In BurstIQ case is a LifeGraph – the larger architecture of the system functionality [the voice of Erich G., Chief Architect, LPBI Blockchain Mission #2].
#2:
LPBI and Linguamatics are schedule to meet with
- LPBI’s and Linguamatics’ potential NEW two clients:
- Director of Research at an HMO &
- COO/CEO of a Healthcare INSURER on
- August 18, 2021 at 3PM EST
#3:
LPBI’s GLOBAL Monthly Zoom Meeting is on August 10, 2021 at11AM EST to 4PM EST – Please ATTEND
Presentations by
- Dr. Williams
- ALL 2021 SUMMER INTERNS
- Aviva
- External Presenter TBA
AGENDA for August 10, 2021 at 11AM EST to 4PM EST
Link sent on 8/9 at 5PM and on Link REMINDER on 8/10 at 9AM
https://pharmaceuticalintelligence.com/calendar/
UPDATED ON 8/3/2021
LPBI TEam in LPBI India include: 3,4,6,7,8,10,11
UPDATED ON 7/26/2021
We are excited to have new Interns coming onboard with inquisitive minds and motivation to learn new skills and invest in their careers by Experientional learning methods.
LPBI Group runs FOUR MAJOR INTERNSHIPS: Volunteer base
- NLP – Medical Text Analysis
- Synthetic Biology in Drug Discovery targeting Galectins
- IT Project and Administration of IP Asset Classes: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images
- BLOCKCHAIN Architecture design: Interface of NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY.
Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN.
- NLP-Blockchain IT Infrastructure is needed.
- The NLP inferences are part of a graph database
- In BurstIQ case is a LifeGraph – the larger architecture of the system functionality.
LPBI has you and your education goals in mind:
- We Offer esteemed Affiliation, Mentorship by Scientists
- NEW skills development in NLP, ML, AI applications to Medical Text Analysis
- Skills in Synthetic Biology for Drug Discovery
- References and Resume paragraph on accomplishments and goals during the INTERNSHIP
- Opportunity to contribute to Publications and Podcasting
- Explorations of opportunities in Life Sciences in the US
UPDATED ON 7/26/2021
LPBI’s VALUATION is the stream of INNOVATIONS to date while being DEBT free:
- 4/2012 – LPBI is the Launcher of Scientific Curation Methodology for the e-Scientific Publishing industry https://pharmaceuticalintelligence.com/ As late as in 2016 no big publisher, i.e., Elsevier, John Wiley had curation-based publications: Journal, Books, e-Proceedings, Gallery of +6,000 Biological Images as an IP asset class
- At LPBI, Curation of scientific findings was performed in +6,000 articles with +2MM e-Views by Global e-Readers
- 6/2013 – LPBI was the Publisher of the 1ste-book in Medicine in Kindle Store on the Life Sciences & Medicine Shelf – Upload to this shelf by Amazon.com
- 2/2021 – Completion of the 18 volumes, BioMed e-Series in five Specialties in Medicine
- On Amazon.com on 7/2021 – e-books in Medicine enjoy +128,100 PAGE DOWNLOADS – the ONE and ONLY publisher in that range of page downloads
- LPBI launched NLP in 1/2020. Linguamatics/IQVIA performed NLP on 33 articles and 20 Biological Images. RESULTS: +670 entity relations DISCOVERED by Linguamatics and unknown to Pharma and to Insurers, entity relations between:
- Gene-Disease
- Gene-Drug
- Disease-Drug
- These results were presented to a Healthcare Insurer, SLC, UT on 7/13/2021
- LPBI and BurstIQ are architecting NOW the first NLP-Blockchain IT infrastructure in existence
- Linguamatics did not hear of Blockchain and BurstIQ did not have a request for NLP – LPBI PUT THESE TWO TECHNOLOGIES AND PARTIES TOGETHER
- On 7/19/2021 – LPBI had launched LPBI India for Synthetic Biology for Drug Discovery targeting Galectins – Collaboration with Dr. Raphael Nir, ABI Lab and SBH Sciences, Inc., Natick, MA
- On 7/25/2021 – LPBI announced it will have the NEWLY to be published BioMed e-Books As ANEW Publishing GENRE of SCIENTIFIC BOOKS
- Bi-Lingual eTOCs, English & Spanish with Montero Language Services, Madrid and Content promotion by GTO, Madrid
- NLPs results of Medical Text Analysis with domain knowledge expert Interpretations in Foreign Languages and Audio: Spanish and other
- Original English Book – Only Editorials(Preface, Introductions, Summaries and Epilogue] because the Bi-Lingual part is the eTOCs of the e-Book
- New architecture of MULTIMEDIA SCIENTIFIC e-Books
- Based on the Price List for LPBI 1.0 digital products and of LPBI 2.0 – NLP Products https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/we are building
- Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up alliances: Alliances are Labor component and LPBI is Materials – 25% on top paid by the B2B customer
- B2C on Blockchain will use the Price List.
UPDATED ON 7/19/2021
Official launch of LPBI India – Zoom meeting
On July 19, 2021 at 11AM EST
UPDATED AGENDA
|
Member Name |
Geographical region in India Or Place of Birth in India if now outside of India |
Distance from New Delhi |
LANGUAGES |
|
Dr (Lt Col) Vivek Lal |
Ambuja Nagar, Kodinar (Sasan-Gir) Gujarat. |
1300 kms |
English, Hindi |
|
Yash Choudhary |
Dewas (Madhya Pradesh) |
800 kms |
English, Hindi |
|
Dr. Premalata Pati |
Bhubaneswar, Odisha |
1764 kms |
English, Hindi, Odia |
|
Dr. Sudipta Saha |
Kolkata, West Bengal |
1500 kms |
English, Hindi, Bengali |
|
Dr. Ajay Gupta |
Place of birth: New Delhi |
0 |
English, Hindi |
|
Amandeep Kaur |
Kolkata, West Bengal |
1500 kms |
English, Hindi, Punjabi, Bengali |
|
Indraneel Ghosh |
Vadodara, Gujarat | 1025 kms |
English, Hindi, Bengali, Marathi, Gujarati
|
|
Aditya Bahl |
Lucknow, UP | 500 |
English, Hindi, Punjabi |
|
Srinivas Sriram |
Place of Birth: Chennai, Tamil Nadu |
2,187 kms |
English, Tamil |
|
Abhisar Anand |
Place of Birth: Muzaffarpur, Bihar |
1,042 kms |
English, Hindi |
ANNOUNCEMENT
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, MA
is Launching LPBI India on 7/19/2021
LPBI India Official Launch
on Zoom on July 19, 2021 at 11AM EST
- I wish to invite you to attend this Zoom meeting using the Zoom Link, above
LPBI India LAUNCH
is on Monday July 19, 2021 at 11AM EST
Aviva – Founder 1.0 LPBI and 2.0 LPBI
- Justifying the Launch of LPBI India today is the Interaction between LPBI USA and LPBI India which is taking place multiple times every day
- Senior level executive talent in India expressed interest to JOIN LPBI USA while living in India
- It was Dr. Lal and Dr. Ghosh interest in joining LPBI USA that impacted Aviva’s Decision toward the Launch of LPBI India: Leadership + Professional Staff
- Interactions among all members across India is mostly encouraged
- We are preparing a MAP with all the locations in India of our VIRTUAL organization
- We are a community of inclusion and excellence challenging and aspiring for expression and growth of the best of our abilities without borders and/or pre-determinants of any kind: age, race, religion or gender
- Interactions with Alumni of LPBI USA is mostly encouraged – we are very proud of each of you,
Congratulatory Remarks, each presenter from their own perspective:
- LPBI USA Board member, Prof. Marc W. Feldman, Stanford University [7/18/2021 – Medical Emergency] <<< – WE WISH YOU SPEEDY RECOVERY, next Global Zoom on August 10, 2021 – Congratulatory remarks will be delivered
- LPBI USA Board member, Prof. Stephen J. Williams, Temple University
- Dr. Ajay Gupta of UC, Irvine, LPBI USA, External Scientific Relations
- Mr. Aditya Bahl, MBA, LPBI USA, External Business Relations to LPBI USA since 1/2020. Mr. Bahl is ex-Novastis and ex-J&J, the Founding Director at RAS Life Science Solutions, based in Frankfurt, Germany
- Dr. Raphael Nir, Founder, ABI Lab and President, SBH, Inc in Natick, MA – We will have in 4Q’2021 a JOINT meeting dedicated to Mission #2, below
Mission #1:
Medical Text Analysis with Natural Language Processing (NLP), Machine Learning (ML), Artificial Intelligence (AI)
The Medical Text includes FOUR corpuses of content created by the Team at LPBI USA since 4/2012:
- Scientific Curation Articles published in our Open Access Journal http://pharmaceuticalintelligence.com
N = +6,070, Views = +2Million, with an ontology of +730 categories of Research in the Life Sciences, Medicine, Pharmaceutics and Healthcare
2. 18 e-Books in Medicine https://lnkd.in/ekWGNqA
128,000 page download on Amazon.com – Cover Pages and electronic Table of Contents (eTOCs) of the 18 books are been translated to Spanish in Madrid, now
3. 100 e-Proceedings of Global Medical and Biotech Conferences generated in Real Time, 2013 – 2021 https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/
4. +6,200 Biological Images with text legend in use by the +6,000 articles – in the Media Gallery of LPBI on WordPress.com cloud. Mission #1 has increased the number of Biological images from 5,100 to +6,200
At LPBI India, been considered for the Leadership function for Mission #1: Dr. Vivek Lal, MD
STRATEGIC PLAN for Mission #1
For scaling up the Text Analysis of these 3.3 Giga Bytes of data we are in alliance with Linguamatics/IQVIA, London https://www.linguamatics.com/what-text-mining-text-analytics-and-natural-language-processing
- We jointly presented their NLP results on our content in oncology to a Top HMO/Healthcare Insurer in UT on July 13, 2021. We are invited for additional meetings with both organizations: the HMO and the Healthcare Insurer
- LPBI USA developed a ten-phase Protocol for our own content been subjected to Medical Text Analysis with NLP, ML, AI using Wolfram language for BioSciences
- LPBI India will be involved in all of the ten-phase Protocol in using NLP, ML, AI
- LPBI is in alliance with BurstIQ, Denver, CO https://www.burstiq.com/ for Blockchain design for a Transactions Network for Content monetization: B2B and B2C. That process involve Indexing and data migration. LPBI India will play a role in these tasks as well
Mission #2:
Applications of Synthetic Biology Software to Galectins for design of new drug molecules.
- Collaboration with Dr. Raphael Nir of ABI Lab and SBH, Inc in Natick, MA. We will have in 4Q’2021 a dedicated meeting on Mission #2.
- LPBI India will play a role in these tasks, please review:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877766/
- LPBI USA has interest in Synthetic Biology Software for Drug Discovery and has two scientists with expertise in Galectins as therapeutic targets
- Scientists love Synthetic Biology – designing drug molecules using Software – igem.org
A repository of open source software tools.
Community driven data exchange standards.
Specific software frameworks built explicitly for synthetic biology.
- LPBI USA will have a DropBox Folder with all the Synthetic Biology Software accessible to LPBI India
- Mentorship and training will be offered by LPBI USA
At LPBI India, been considered for the Leadership function for Mission #2: Dr. Indraneel Ghosh, PhD
STRATEGIC PLAN for Mission #2
- We will have in 4Q’2021 a JOINT meeting between LPBI USA, LPBI India with Dr. Raphael Nir of ABI Lab and SBH, Inc in Natick, MA on Mission #2.
- A collaboration between Dr. Ghosh and Dr. Nir is expected
AGENDA
Zoom of LPBI INDIA Launch on Monday July 19, 2021 at 11AM EST
PRESENTATIONS
- Prof. Stephen J. Williams, LPBI USA, Chief Scientific Officer and Board Member is with LPBI USA since 9/2012 will have presentations
- Aviva will have presentations
Senior Level at LPBI India:
- LPBI India TEAM Members BIO Presentations: Each of the members of LPBI India will present their BIO in <5 minutes, starting with
Dr. Sudipta Saha, PhD Prof. at Amity University, New Delhi. Dr. Saha is with LPBI USA since 9/2012, Expert, Author and Co-Editor
http://www.amazon.com/dp/B08VTFWVKM
Available on Amazon.com since 2/2/2021
https://www.amazon.com/dp/B075CXHY1B
On Amazon.com since September 4, 2017
Dr. Vivek Lal, MD, COO, Ambujanagar Multi-specialty Hospital, Ambujanagar, Dist. Gir-Somnath, Gujarat, India.
- Paper collaboration with Dr. Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN on 9/2013, article has ~15,000 e-Readers https://pharmaceuticalintelligence.com/2013/09/23/do-novel-anticoagulants-affect-the-ptinr-the-cases-of-xarelto-rivaroxaban-and-pradaxa-dabigatran/
Dr. Indraneel Ghosh, PhD – Weizmann Institute PhD, 2000-2007, Hebrew speaker
- CV on LPBI USA Website – Work-in-Progress
Dr. Ajay Gupta of UC, Irvine, Scientific Advisor to LPBI USA, frequent presentation on LPBI’s SCIENCE SIDE – Global Monthly Zoom
- Ten Minutes on on Clinical Trials for RAMATROBAN – Opportunities for Collaboration between His Company in USA & LPBI India, Dr. Lal’s Hospital and other Hospitals in India
Ramatroban is a thromboxane receptor antagonist. It is also a DP₂ receptor antagonist. It is indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma. Wikipedia
ChemSpider ID: 110413
Molar mass: 416.47 g·mol−1
Formula: C21H21FN2O4S
Members of Technical Staff (MTS) at LPBI India & LPBI USA:
- All LPBI India MTS currently working on Mission #1 and
- All LPBI USA MTS currently working on IT/Data Science Projects
-
- will be invited to considered Mission #2.
- An Up-to-date CV in Biological Sciences REQUIRES DEMONSTRATION of making contributions with mentorship in both areas: Mission #1 and Mission #2
LPBI India and LPBI USA MTS – BIO Presentations: PostDocs, Masters and Students will present their Bios in <4 minutes:
- Dr. Pati, PostDoc. NLP – One year Academic Training
- Ms. Kaur, MSc. NLP – One year Academic Training
- Mr. Choudhary, Student IITK – Summent intern, 6/15/ – 8/15/2021
- Mr. Sriram, Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
- Mr. Anand, Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
- Mr. Ethan Coomber, Middlebury College, VT – Research Assistant 3, Text to Audio Conversion and Twitter Analytics
- Ms. Vaishnavee Joshi, MSc – Joining LPBI India on 8/15/2021
Alumni of LPBI USA are invited to join us on Monday, July 19, 2021, 11AM EST
- Dr. Probodh Kandala, PhD, Regulatory Affairs Manager @ IQVIA Biotech; Drug Development Leader, Expert, Author, Writer with scientific reporting articles in multiple of LPBI e-Books, chiefly Cancer and Immunology
- Dr. Ritu Saxena, PhD, Astellas Pharma US, Co-Editor, LPBI’s Series C, Volume 1 http://www.amazon.com/dp/B013RVYR2K
- Dr. Aviral Vatsa, MD, NHS Education for Scotland, Co-Editor, LPBI’s Series A, Volume 1 http://www.amazon.com/dp/B00DINFFYC
- Aashir Awan, Research Scientist, Bristol Myers Squibb, Expert, Author, Writer (EAW) for PharmaceuticalIntelligence.com
- Anamika Sarkar, Regeneron, EAW at LPBI 2014-2016
Alumni of LPBI USA: Please catch up with us, we thank you for your contributions made to LPBI USA
- Please review our portfolio of Intellectual property of 10 Asset Classes in 2021 https://pharmaceuticalintelligence.com/2019-vista/
- Please review our six strategies for 2021-2025 https://pharmaceuticalintelligence.com/vision/
@@@@@@@@ ALL NEED TO PLAN TO ATTEND 7/21, 2021 – LPBI USA – BUSINESS SIDE
UPDATED ON 7/5/2021
ANNOUNCEMENT of NEW SUMMER INTERN in Medical Text Analysis with NLP – Cardiovascular Content – 2021 Summer Internship in NLP – LPBI India
Yash Choudhary, Research Assistant 3
UPDATED ON 6/20/2021
ANNOUNCEMENT of NEW SUMMER INTERN
Ethan Coomber, Research Assistant III, Data Science and Podcast Library Development
UPDATED ON 6/16/2021
ANNOUNCEMENT of TWO NEW SUMMER INTERNS who also plan to start in 9/2021 the LPBI 2021-2022 Academic Training in NLP for Medical Text Analysis
Abhisar Anand, Research Assistant I
Srinivas Sriram, Research Assistant I
UPDATED ON 5/17/2021
LPBI management wants you to be PROUD about
1. The Spanish Translation 18 volumes (Cover Pages, eTOCs all books) – Alliance with Montero Language Services, Madrid, Spain and their’s Marketing Communication Agency for
1.1 Plans for Content Promotion in Spanish Speaking Countries
1.2 Other Marketing Communications needs of 2.0 LPBI
2. NLP plan for IP Asset Classes I,II, III, V – Consideration of Alliance with Linguamatics/IQVIA for Indexing of +6,000 articles
3. Blockchain Transaction Network for Content monetization system design for Digital Store in a Healthcare Digital Marketplace: B2B, B2C – Collaboration with BurstIQ
4. Insurer Contact and Proof-of-Concept READY for joint Presentation with Linguamatics/IQVIA
5. IB in NYC preparing Proposal for LPBI becoming their Client
6. Working with few Sources to identify C-Suite new Members
- New Management
- New Ownership
- New Company – incorporation as ‘C’
UPDATED ON 5/5/2021
One Pager for 2.0 LPBI Group
For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.
You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers +6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 18 books have been downloaded ~135,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).
- Bold vision for the coming five years includes: All content will be converted by Machine Learning algorithms to search for all hyper-graphs and their expression in WordClouds.
- From text we will convert content to Audio. From English Text we will translate to foreign languages like Japanese, Spanish and Russian.
- From Open Access we will transition to Blockchain transaction networks.
- From Digital Cloud-based biographies we will create audio and video Podcasts
- From a sole owner-operator status we will transition to Joint-Ventures to M&A and Partnerships
Our Transformational transition is two dimensional:
- Our deep expertise and innovations in media platforms and content creation will have new directions: we will focus on other Countries (x,y,z) and Geographical regions: i.e., EU and South-East Asia. Currently the Table of Contents of 18 books is being translated into Spanish for the 22 Countries speaking Spanish.
- Our created content will become the basis of our content mining and the subject of managed computerized text analysis under supervised learning guided by our own team of experts.
We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies https://pharmaceuticalintelligence.com/vision/
5/5/2021
LPBI Group’s Organizational Chart was updated on 5/5/2021
4/24/2021
REMINDER of important articles in our repository
e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point
Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL. Author and Curator: Aviva Lev-Ari, PhD, RN
Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76
4/14/2021
Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD
2/26/2021
2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021
Real Time coverage: Aviva Lev-Ari, PhD, RN
2/16/2021
Announcing two new members of the Medical Text Analysis with Machine Learning
Premalata Pati, PhD, PostDoc in Biological Sciences, Medical Text Analysis with Machine Learning
Amandeep Kaur, BSc., MSc. (exp. 5/2021) – Research Associate 2, Medical Text Analysis and IT Infrastructure Python Coder
2/12/2021
Need for Global Response to SARS-CoV-2 Viral Variants
Reporter: Aviva Lev-Ari, PhD, RN
Rise of a trio of mutated viruses hints at an increase in transmissibility, speeding the virus’ leaps from one host to the next
Reporter: Aviva Lev-Ari, PhD, RN
2/8/2021
LIVE – 50th Annual Lewis S. Rosenstiel Award to Katalin Karikó and Drew Weissman for work on messenger RNA, modification of Nucleic Acids applied in the development of COVID-19 Vaccines
Reporter & Real Time Coverage on 2/8/2021:
2/5/2021
Today Series D: Volume 4, LPBI’s #18 Volume is LIVE
Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases and Endocrinology
VOLUME 1: Metabolic Genomics and Pharmaceutics.
(Series D: BioMedicine & Immunology) Kindle Edition
On Amazon.com since 7/21/2015
http://www.amazon.com/dp/B012BB0ZF0
VOLUME 2: Infectious Diseases and Therapeutics
and
VOLUME 3: The Immune System and Therapeutics
(Series D: BioMedicine & Immunology) Kindle Edition. On Amazon.com since September 4, 2017
https://www.amazon.com/dp/B075CXHY1B
VOLUME 4: Human Reproductive System, Genomic Endocrinology and Cancer Types
(Series D: BioMedicine & Immunology) Kindle Edition.
On Amazon.com since February 2, 2021
http://www.amazon.com/dp/B08VTFWVKM
2/3/2021
-
Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc
-
Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD
-
Podcast with Prof. Marcus W. Feldman, PhD, Biology Department, Stanford University, Interview by Gail S. Thornton, PhDc
-
Partners in Health and Biz Radio Interview with Aviva Lev-Ari, Ph.D., R.N., Stephen Williams, Ph.D., and Irina Robu, Ph.D., on 5/2019 on topic of 3D Medical BioPrinting Technology: A Revolution in Medicine. Interview organizer: Gail S. Thornton, PhDc
2/1/2021
Milestone achieved today:
February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical
Thought on the transition
One Possible Strategy for an Acquisition is via a SPAC
1/8/2021
PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views
Hanoch Lev-Ari, PhD and Aviva Lev-Ari, PhD, RN
Total number of articles viewed in any given year depends on:
- The overall Average Article-Viewing Profile (AAVP)
- The number of articles published in the year of interest, and in each one of the preceding years.
In statistics, the article viewing process is known as a “marked point process”: the time-instants of article publication are the events described by the point process, while the “mark” is the subsequent process of viewing each particular article, ongoing from the moment of publication into the future over many years. The article viewing process is assumed to be statistically-independent from the publication time-instants.
1/6/2021
2.0 LPBI Team Welcomes to our Medical Text Analysis Team
Amandeep Kaur, BSc., MSc. (exp. 5/2021) – Research Associate 2, Medical Text Analysis and IT Infrastructure Python Coder
1/6/2021
REUTERS NEXT (Jan 11-14) kicks off 2021 by gathering global leaders and forward thinkers to reimagine solutions to the challenges the new year brings
Reporter: Aviva Lev-Ari, PhD, RN
1/3/2021
Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III,V
Author: Aviva Lev-Ari, PhD, RN
Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities
Author: Aviva Lev-Ari, PhD, RN
1/1/2021
Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities
Author: Aviva Lev-Ari, PhD, RN
For your New Opportunity in 2021:
- Management,
- MarkComm and
- Scientific/Technical
CONTACT
Director & Founder
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
DESCRIPTION
https://pharmaceuticalintelligence.com/vision/
Announcement
Strategic Transition from 1.0 LPBI to 2.0 LPBI on
1/1/2021
We have transitioned from
- 1.0 LPBI was an electronic Scientific Publisher, 2012 – 2020
to
- 2.0 LPBI a Medical Text Analysis (NLP-ML-AI) – SaaS and Content Monetization (Blockchain) – BaaS. A new company profile, 2021 – 2025
Our New NEEDS in Business Development and M&A – Pursue with results:
- Equity Sharing based
Opportunities Map in the Acquisition Arena
Our New NEEDS in Marketing Communication, Media & PR – Produce new Digital mediums
- Equity Sharing based
- The Announcement of 2.0 LPBI Launch
- NEW Website for 2.0 – Initiative #2
- Podcast – Strategy #4 – we wish to publish 2 Podcasts per quarter
- Planning Advertisement for Amazon Books using Amazon Advertising
- NEW documentation on Strategy #2 – Monetization of Journal Articles
- NEW documentation on Strategy #2 – Monetization of other IP Asset Classes
- NEW documentation on Strategy #1, #3, #6
- Reporting on developments in Strategy #5: Joint Ventures & Partnership
Our New Scientific/Technical Opportunities in Natural Language Processing (NLP), Machine Learning (ML) and Artificial Intelligence (AI)
Seeking 10 Students INTERNS for a major Medical Text Analysis using NLP, ML, AI
This is a ONE year VIRTUAL STUDENT INTERNSHIP for
- Computer Science & Biological Sciences or
- PreMed students
- PostDocs will develop the interpretation for the hyper-graphs
This internship is not fee for service – but voluntary and offers
- Mentorship by Scientists
- Letter of recommendation
- Opportunity to publish with lead authors
- Hands on experience with software
- Opportunities to present in corporate business meetings
- Scientific Career guidance
- Access to contacts in Academe and Industry
DESCRIPTION
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
1.0 LPBI Group News
2020
12/31/2020
On December 31, 2020 the Open Access Online Scientific Journal PharmaceuticalIntelligence.com –
- 1,906,438 Views
- 7,524 Scientific Comments
- 5,978 articles
- 723 Research Categories
- 482,474 Views on Top Authors: Aviva Lev-Ari, PhD, RN
12/18/2020
Today’s Meeting of the Medical Text Analysis Team had reached the following conclusions:
| Item | WorditOut | Wolfram | Genomics | Cancer |
| WordCloud | +
Done for each article not for all the 16 article together |
+
All the 16 articles PENDING Madison + Danielle |
+ | + |
| # Words | +
PENDING Madison + Danielle |
+
PENDING Madison + Danielle |
+ | + |
| Visualization
In hyper-graph format with right angles arrow lines |
+
PENDING Madison Then Danielle |
+ | + | |
| Interpretation Hyper-graphs | +
PENDING Dr. Williams |
+ | + |
NEXT STEPS
- Madison & Danielle: Please CALL meeting to Review Visualization
- Madison & Danielle: Please place IMAGES in each Box above
- Dr. Williams will write the interpretation of the Hyper-graphs: GENOMICS and CANCER
- Madison & Danielle: Please CALL meeting to Review Visualization + Interpretation
- JOEL – Please call Customer in Salt Lake City, UT to set up TIME for Presentation
12/18/2020
VENDOR EXTERNAL MEETINGS:
Top Cloud Web Services Vendor:
12/18/2020
1/4 or 1/6 or 1/7
Top NLP Vendor:
12/7
1/18 or 1/20 or 1/21 or 1/25 or 1/27
Top Blockchain Vendor:
12/8, 12/21
Spain – Explorations
12/8 – e-Book Translation
12/23 – Education Sector in Medicine
12/18/2020
PostDoctorants: Computer Science, Pharmaceutical Sciences, Biological Sciences – Added to 2.0 Team
For 2.0 LPBI we are attracting PostDoc level trained young professionals:
-
Computer Science
-
Pharmaceutical Sciences
-
Biological Sciences
12/7/2020
LINGUAMATICS DEMO
12/7 11AM EST
Linguamatics and Pharmaceutical Intelligence
Hosted by Amanda Rudd
https://linguamatics.webex.com/linguamatics/j.php?MTID=m78eb9b7f4f6e826fbb42be13865744f1
Access to DEMO
Monday, Dec 7, 2020 11:00 am | 1 hour | (UTC-05:00) Eastern Time (US & Canada)
Meeting number: 128 983 0471
12/2/2020
Two Site Map Proposals for LPBI’s New Web Site
Curators: Gail S. Thornton, PhD(c) and Aviva Lev-Ari, PhD, RN
https://pharmaceuticalintelligence.com/2020/12/02/two-site-map-proposals-for-lpbis-new-web-site/
11/11/2020
Status of LPBI Documental on 11/10/2020
- 1.0 LPBI Brochure – Version with new Edits by Mr. Bahl received on 11/10/2020
- 2.0 LPBI Brochure
- 1.0 LPBI Prospectus – 200 pps document (+100 pps Appendices) – was edited by Mr. Bahl in May 2020, 26 additional pages were added
- Excel File, three spread sheets – 1.0 LPBI, 2.0 LPBI, COMBINED (1.0 + 2.0)
- Slide deck – Power Point 200 Slides [last 50 are made by Inbar Ofer from Table and Graphs selected by 4 FIT Members from 1.0 and 2.0 LPBI Brochures)
- Elevator Pitch – versions by 2.0 LPBI Team
Versions of LPBI Group’s Elevator Pitch: 2.0 LPBI Group’s Team – In Our Own Words
11/9/2020
- New addition to our INTERNSHIP in Medical Text Analysis
- Will work with Aviva on four IT-related projects before starting the Internship in January 2021
- PowerPoint Library
- 2.0 LPBI New Website
- Yumpu.com Digital Brochures for 2.0 LPBI and 1.0 LPBI
- Deep Web Searches for references on https://pharmaceuticalintelligence.com/ It is needed for one Wikipedia Entry we are working on
Inbar Ofer, Research Assistant 3 – Medical Text Analysis for 2.0 LPBI Group’s TNS #1 – 2021 Academic Internship in Medical Test Analysis (MTA)
Inbar Ofer, Research Assistant 3 – PERSONAL PAGE on 2021 Medical Text Analysis Portal
11/2/2020
Open Data Science Conference, Virtual and In-Person | October 27th – 30th, 2020, Natural Language Processing Track
https://pharmaceuticalintelligence.com/2020/10/26/open-data-science-conference/
10/8/2020
e-Proceedings 19th Annual Bio-IT World 2020 Conference, October 6-8, 2020 Boston
Virtual Conference coverage in Real Time: Aviva Lev-Ari, PhD, RN
Tweets & Retweets by @pharma_BI and @AVIVA1950 at #BioIT20, 19th Annual Bio-IT World 2020 Conference, October 6-8, 2020 in Boston
Virtual Conference coverage in Real Time: Aviva Lev-Ari, PhD, RN
9/29/2020
Precision Cardiology to Benefit from New Atlas of Cells of the Adult Human Heart
Reporters: Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
The Impact of COVID-19 on the Human Heart
Reporters: Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
https://pharmaceuticalintelligence.com/2020/09/29/the-impact-of-covid-19-on-the-human-heart/
9/12/2020
- PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views
- 2.0 LPBI Executive Summary | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
https://pharmaceuticalintelligence.com/leaders-in-pharmaceutical-business-intelligence/
Of relevance as background is
- 1.0 LPBI Executive Summary
https://pharmaceuticalintelligence.com/home-website-front-page/
9/9/2020
Bradykinin Hypothesis: Potential Explanation for COVID-19
9/4/2020
e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
Founder & Director, LPBI Group
Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
8/29/2020
2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020
Real Time press coverage: Aviva Lev-Ari, PhD, RN
Tweets by @pharma_BI and @AVIVA1950 @ 2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020
Real Time press coverage: Aviva Lev-Ari, PhD, RN
8/23/2020
PERSONAL PORTAL
Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
CV
ACTIVE Member of 2.0 LPBI
Knowledge PORTALS System (KPS) @LPBI
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
8/19/2020
An UPDATE Shared with ALL
We launched on 3/14/2020 the Coronavirus PORTAL https://pharmaceuticalintelligence.com/coronavirus-portal/ which covers 8 topics:
- Breakthrough News Corner
- Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus
- An Epidemiological Approach Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN Lead Curators – e–mail Contacts: sjwilliamspa@comcast.net and avivalev-ari@alum.berkeley.edu
- Community Impact Stephen J. Williams, PhD and Irina Robu, PhD Lead Curators – e–mail Contacts: irina.stefania@gmail.com and sjwilliamspa@comcast.net
- Economic Impact of The Coronavirus Pandemic Dr. Joel Shertok, PhD Lead Curator – e–mail Contact: jshertok@processindconsultants.com
- Voices of Global Citizens: Impact of The Coronavirus Pandemic, Gail S. Thornton, M.A. Lead Curator – e–mail Contact: gailsthornton@yahoo.com
- Diagnosis of Coronavirus Infection by Medical Imaging and Cardiovascular Impacts of Viral Infection, Aviva Lev-Ari, PhD, RN Lead Curator e-mail contact: avivalev-ari@alum.berkeley.edu
- Key Opinion Leaders Followed by LPBI Aviva Lev-Ari, PhD, RN and Dr. Ofer Markman, PhD Lead Curators e-mail contacts: oferm2015@gmail.com and avivalev-ari@alum.berkeley.edu
That effort took 2 months of most intensive work on my part.
STATEMENT
- The economic impact of of the Pandemic DOES HAVE A NEGATIVE EFFECT ON THE M&A MARKET
- In the INTERIM awaiting for more favorable conditions on the market
- we invested in INTERNAL development of IP
We launched FOUR additional PORTALS:
- ArtificiaI Intelligence in Genomics & Cancer
https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/
- 2020 Summer Internship Portal
https://pharmaceuticalintelligence.com/2020-summer-internship/
- Knowledge PORTALS System (KPS) @LPBI
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
- 2021 Medical Text Analysis (NLP)
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
- As an ADJUSTMENT for submitting the documentation to the Investment Banker in 10/2020 vs the original plan 4/2020, we are working on
- The Plan for 2021 – 2025. It involves six new strategies: TNS #1,2,3,4,5,6
TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market
Phase 1: Natural Language Processing(NLP) – 24 months FREE Microsoft AZURE for Health
Phase 2: Piloting the Proof of Concept on 4 of LPBI BioMed 16 volumes:
- Cancer, Volume 1 & 2 and Genomics, Volume 1 & 2
Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:
TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End
TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA
TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL
TNS #5: Joint venture with Dr. Nir for Drug Discovery:
TNS #6: e-Books Translations into Japanese, Spanish, Russian
These are two distinctive entities
- 0 LPBI, 1/2021 – 12/2024 – TNS #1,2,3,4,5,6, above. A new Executive Summary is work-in-progress
- 0 LPBI, 4/2012 – 12/2020 – Executive Summary https://pharmaceuticalintelligence.com/home-website-front-page/
Cumulative Revenue Potential PREDICTION of Journal Articles: Under Two Growth Assumption Regimes and Two Prediction Models
RED & BLUE Lines
A. Rate of Articles published in 2021-2025 is trending 2017, 2018, 2019, 2020 RED Line (Marked Point Process Model) $48MM for Journal Valuation & BLUE Line Conservative Assumption-based Growth Prediction (Joel)
vs
BROWN & GREEN Lines
B. No New Articles after 12/2020 BROWN Line (Marked Point Process Model) & GREEN Line (Joel)
Data Source:
WordPress.com Web Statistics of 1.8 Million Views of 6,000 Scientific Articles, 6/30/2020
[for the Annual 2020 data: the first 6 months x2].
4/2012 – 12/2020 – ACTUALS
2021 – 2025 – FORECAST 
Our portfolio of Intellectual Property (IP) include TEN asset classes
| Asset Classes | Type | Quantity |
| Asset Class
I |
The Journal
8/18/2020 Views 1,807,594 |
5,900 articles on 8/18/2020
Valuation [$XXM] done by Joel on Alex WP Data ____________ |
| Asset Class
II |
BioMed e-Series | 16 volumes
Valuation [$5M] done by Joel & Aviva ____________ |
| Asset Class
III |
eProceedings | 60 events
Valuation [$1.4M] done by Dr. Williams & Aviva ____________ |
| Asset Class
IV |
Platform, composition of methods and workflows for the content creation of scientific curations. See Platform:
https://pharmaceuticalintelligence.com/coronavirus-portal/
https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/
https://pharmaceuticalintelligence.com/2020-summer-internship/
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/ |
$4MM |
| Asset Class
V |
Gallery of Biological Images in use in Articles and Books | TBD
____________ |
| Asset Class
VI |
Team of Experts
See Platform: • Knowledge Platform System (KPS) https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/ |
BIOs Final Improvement Team (FIT)
$3MM ____________ |
| Asset Class
VII |
Royalties on BioMed e-Series:Page downloads, Book borrowings and Book sale | 113,716 page downloads in total on 6/14/2020 the equivalent of 49 books to have been sold
____________ |
| Asset Class
VIII |
Subscribers to the Website | 2,549 on 8/18/2020
____________ |
| Asset Class
IX |
INTANGIBLE ASSETS & Intrinsic Value = Good Will | TBD |
| Asset Class
X |
e-VOICES PODCASTING – Audio Library
e-VOICES Podcasting, 2019 – 2021 |
TBD |
We estimate revenue potential of each entity to be
~~ $XX Million for 1.0 LPBI [Above Ten IP Asset Classes]
- Graph above present the Valuation of IP Asset Class I
~~ $XX Million for 2.0 LPBI [Excel Sheet for Financial Projection was developed in 8/2020]
~~ $ XXX Million for 1.0 LPBI plus 2.0 LPBI
The feedback that we will get from the Investment Banker will guide the TIMING and the Strategy
- ALL ACTIVE Member of the Final Improvement Team (FIT) on record for the EXIT will be in constant communication regarding all of the above
- Personal PORTAL for each member of FIT is displayed on https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
- Meg Baker is considering a collaboration in the JOINT VENTURE (LPBI X%) and Dr. Raphael Nir (7X%) on Galectins & Synthetic Biology in Drug Discovery
- Our Podcast Library is growing – See Table, below
Development Plan for e-VOICES Podcasting, 2019 – 2021*
| Podcast Interviewer | INTERVIEWEE(S) | Subject | Date | Audio/Video/
Narrator |
| Gail S. Thornton | Dr. Stephen J. Williams, Dr. Irina Robu & Dr. Aviva Lev-Ari | 3D BioPrinting in Medicine | 5/2019 | Audio |
| Gail S. Thornton | Prof. Feldman | Evolution Biology and Population Genetics | 3/17/2020 | Audio |
| Gail S. Thornton | Dr. Larry H. Bernstein, MD, FCAP | Life Memoirs in Clinical Pathology Told | 7/2020 | Audio
Narrator: Dr. S.J. Williams |
| Gail S. Thornton | Dr. Justin D. Pearlman, MD, PhD | Cardiac Imaging – Evolution of Diagnostic Methods | 4Q 2020 | Audio |
| Gail S. Thornton | Dr. Raphael Nir | From Big Pharma to Biotech Entrepreneurship | 2021 | Audio |
| Gail S. Thornton | Dr. Meg Baker | GlycoBiology in Practice | 2021 | Audio |
| Gail S. Thornton | Dr. Ofer Markman | Memories of Pharmacia | 2021 | Audio |
*Dr. Williams and Aviva – will have their Podcasts in 2021.
8/11/2020
Contributions of Interns to LPBI Publications as Curators on PharmaceuticalIntelligence.com
Participants of LPBI Group’s 2020 Summer Internship in Data Curation and Data Annotation
- These three References will be added to the CV of each Intern upon content entry finalization of editing.
WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com
Curators: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD, Aviva Lev-Ari, PhD, RN
WordCloud Visualization of LPBI’s Top Sixteen Articles on CANCER in eight categories and by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com
Curator: Stephen J. Williams, PhD and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD and Aviva Lev-Ari, PhD, RN
WordCloud Visualization of LPBI’s Top Sixteen Articles on GENOMICS by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com
Curators: Stephen J. Williams, Aviva Lev-Ari, PhD, RN and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD
8/3/2020
Our 16 Books are announced in the Japanese Language
アマゾンおすすめ商品
価格の安い順番
価格の高い順番
レビューの評価順
出版年月が新しい順番
アマゾンおすすめ商品
価格の安い順番
価格の高い順番
レビューの評価順
出版年月が新しい順番
Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1) (English Edition)
Pharmacological Agents in Treatment of Cardiovascular Diseases (Series A: Cardiovascular Diseases Book 5) (English Edition)
Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3) (English Edition)
Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases (English Edition)
Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation (English Edition)
Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics (English Edition)
Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1) (English Edition)
Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1) (English Edition)
7/20/2020
AVIVA’S VISION on 7/19/2020
Three new entries for WIKIPEDIA are created in July-August 2020
Wikipedia entry #1:
1.0 LPBI
This entry was created by Zack and Aviva
- DRAFT is READY for posting by ZACH – Editing of DRAFT by GAIL
Using 12 Word Clouds for CHARTING the KNOWLEDGE MAPS in our 12 TOP VIEWED articles
Wikipedia entry #2:
Aviva Lev-Ari, PhD, RN – Wikipedia entry for
The Founder of 1.0 LPBI and 2.0 LPBI
This entry was created by Zack and Aviva
- DRAFT is ALMOST READY for posting by ZACH – Editing of DRAFT by GAIL
Using 12 Word Clouds for CHARTING the KNOWLEDGE MAPS in our 12 TOP VIEWED articles. Several of them are her own.
Wikipedia entry #3:
2.0 LPBI – 2021 and beyond
This entry will be created by Ofer, Daniel and Aviva
This ENTRY will cover the Three New Strategies (TNS)
TNS #1: Text Analysis with NLP, ML, AI
- Work to continue by Ofer and ALL the INTERNS: current & new
Using 12 Word Clouds for 2.0 LPBI’s HyperGraphDB construction: Biological Pathways, Therapeutics, Indications,
TNS #2: Blockchain infrastructure – The PLATFORM to sell Journal Articles, e-Books, e–Proceedings & Tweet Collections
- Work to start after 7/21/2020 to be led by Daniel and INTERNS: current & new
Using 12 Word Clouds for Wordsmithing the Message to be narrowcasted to communities of scientists on the Categories of Research covered and the Article Titles available for download for $30.
TNS #3: Audio-Video Podcasts Library
- Augmentation of the Work to be continued by Gail & Aviva & Dr. Williams & Irina
Using 12 Word Clouds for Topic Generation for to be initiated NEW Podcasts in 2021 and beyond
New Strategy for WEBSITE DESIGN
We are launching 2.0 LPBI – a NEW WEB SITE about our Three New Strategies
- Work to start by Gail, Aviva in August 2020
OUR HISTORY
- 1.0 LPBI is our Current Website http://pharmaceuticalintelligence.com
- It will become the BACKEND of the New Web Site, aka, 2.0 LPBI
OUR FUTURE
- 2.0 LPBI – will be our NEW WEB SITE about 2021 and BEYOND
- Calling 4/2012 to 12/2020 (1.0 LPBI) – OUR HISTORY
- Work on the New WEBSITE to start in August 2020 by Gail, Aviva
Details on 2.0 LPBI’s Three New Strategies (TNS #1, #2, #3)
TNS #1: Text Analysis with NLP, ML, AI
- Work to continue by Ofer and ALL the INTERNS: current & new
- On 7/21 at 2PM EST – TDP, Palo Alto, CA will present their platform for the Proof of Concept we need to build using our Genomics and Cancer e-Books
Using 12 Word Clouds for 2.0 LPBI’s HyperGraphDB construction: Biological Pathways, Therapeutics, Indications
On Sat, 8 Feb 2020 at 15:22 Aviva Lev-Ari <aviva.lev-ari@comcast.net> wrote:
UPDATED on 7/19/2020
The concept of HyperGraphDB and set of rules are needed to be created for the 1400 curations of Dr. Larry, more than half are about signaling pathways used in therapeutics using receptors.
THEN we will have the software for autoindependent semantic Text analysis of Dr. Larry’s UNIVERSE of articles – this was Dr. Williams great Idea.
(7/19/2020 – 5,875 (all articles) / 1400 (LHB’s Universe = 23.8%) of our IP in Journal articles.
Please read below, article and send me your comment on its relevance to our current search for a Partner with expertise in Machine Learning, Natural Language Processing, AI for text analysis.
https://www.wired.com/story/code-obsessed-novelist-builds-writing-bot-the-plot-thickens/
TNS #2: Blockchain infrastructure – The PLATFORM to sell Journal Articles, e-Books, e–Proceedings & Tweet Collections
- Work to start after 7/21/2020 to be led by Daniel and INTERNS: current & new
Using 12 Word Clouds for Wordsmithing the Message to be narrowcasted to communities of scientists on the Categories of Research covered and the Article Titles available for download for $30.
- We wish to monetize the IP Asset Classes created in 1.0 LPBI: Class I, II, III, IV, V
- Foundry Research is the community of Scientists built by BusrtIQ, Denver, CO – they will present on 7/21 at 3PM EST
The Voice of Daniel Menzin:
“How Blockchain Technology can Assist 2.0 LPBI in monetizing IP Asset Classes created in 1.0 LPBI: Class I, II, III, IV, V”
1. Blockchain may be able to provide us with an organized way to keep track of each 30 dollar transaction. I would imagine their system would provide us with useful data as well which we can analyze like we’ve done with Twitter and WordPress.
2. Since Blockchain is a shared ledger, it can distribute data across sites, institutions, or countries. This would allow us to organize all of our IP assets and transact with our buyer digitally, requiring less work to be done by the buyer in developing our existing infrastructure for their purposes I would imagine.
3. It appears to me that Blockchain would improve the efficiency and ability to track our business transactions and documentation during our exit process. Blockchain claims to provide a shared digital medium for tracking the paperwork and agreements existing between two business parties. It is a shared, immutable ledger meaning that “it is a consensus of replicated, shared, and synchronized digital data geographically spread across multiple sites, countries, or institutions. Unlike with a distributed database, there is no central administrator.” It is immutable, meaning that the data cannot be changed once a consensus is reached (to my understanding). It seems like an automated digital system which serves to improve the organization and efficiency of business transactions by creating “a system” of sorts which organizes information related to these processes.
The Voice of Aviva Lev-Ari, PhD, RN:
“How Blockchain Technology can Assist 2.0 LPBI in monetizing IP Asset Classes created in 1.0 LPBI: Class I, II, III, IV, V”
1. Blockchain may be able to provide us with a platform to narrowcast Word Clouds of 1.0 LPBI Journal articles to the Research Foundry Community
TNS #3: Audio-Video Podcasts Library
- Augmentation of the Work to be continued by Gail & Aviva & Dr. Williams & Irina
Using 12 Word Clouds for Topic Generation for to be initiated NEW Podcasts in 2021 and beyond
Gail’s work:
Interview with Professor Marcus Feldman, Stanford University by Gail S. Thornton
https://pharmaceuticalintelligence.com/audio-podcasts/
Forthcoming
Gail’s Interview with Dr. Larry H. Bernstein, MA, FCAP
- A Narrated Version – Tribute to his life long Contributions to Medicine
- LHB lost his voice in thyroid cancer in 2016, since then on Medical LEAVE @LPBI as CSO and Emeritus, Board Member
and
- On 3/12/2015 – Dr. Williams posted
Podcast Review: Quiet Innovation Podcast on Obtaining $ for Your Startup
Reporter: Stephen J. Williams, Ph.D.
- On 1/25/2016 – Aviva posted
Launching LPBI’s, Fourth Line of Business (D): FIVE Podcast – Audio Series in BioMed
Curator: Aviva Lev-Ari, PhD, RN
- On 3/17/2016 – Aviva posted
CRISPR: A Podcast from Nature.com on Gene Editing
Reporter: Aviva Lev-Ari, PhD, RN
https://pharmaceuticalintelligence.com/2016/03/17/crispr-a-podcast-from-nature-com-on-gene-editing/
7/13/2020
- State of Science on 7/21/2020
New Etiology for COVID-19: Death results from Immune-Mediation (virus-independent immunopathology: lung and reticuloendothelial system) vs Pathogen-Mediation causing Organ Dysfunction & Hyper-Inflammation – Immunomodulatory Therapeutic Approaches (dexamethasone)
Curators: Stephen J. Williams and Aviva Lev-Ari, PhD, RN
- State of Science on 5/19/2020
RNA from the SARS-CoV-2 virus taking over the cells it infects: Virulence – Pathogen’s ability to infect a Resistant Host: The Imbalance between Controlling Virus Replication versus Activation of the Adaptive Immune Response
Curator: Aviva Lev-Ari, PhD, RN – I added colors and bold face
Highlights
- SARS-CoV-2 infection induces low IFN-I and -III levels with a moderate ISG response
- Strong chemokine expression is consistent across in vitro, ex vivo, and in vivo models
- Low innate antiviral defenses and high pro-inflammatory cues contribute to COVID-19
Highlights
- ORF3b of SARS-CoV-2 and related bat and pangolin viruses is a potent IFN antagonist
- SARS-CoV-2 ORF3b suppresses IFN induction more efficiently than SARS-CoV ortholog
- The anti-IFN activity of ORF3b depends on the length of its C-terminus
- An ORF3b with increased IFN antagonism was isolated from two severe COVID-19 cases
7/6/2020
August 2020 we will STRATEGIZE How to Use Social Media for LPBI Books Promotion
See All Links here
How To Make Your Blog Look More Professional
https://blog.thesocialms.com/make-your-blog-look-more-professional/amp/?__twitter_impression=true
- Choose the right WordPress Theme
- Make your site load fast
- Edit your texts
- Structure your post
- Choose a great title
- Add Visuals
- Make it easy to share
How To Set Up Recurring Queues For Twitter With SocialOomph (And Why)
The Social Traffic Code
https://free.thesocialms.com/sales-page-from-thank-you
A Blogger’s Guide to Website Push Notifications (Traffic and More)
https://blog.thesocialms.com/website-push-notifications/amp/?__twitter_impression=tru
- LPBI June 2020 Newsletter by Push Notification to
- Website Subscribers
- All Followers of Twitter Two Handles
- eLPBI Facebook Page
- LinkedIn LPBI Company Page
- LinkedIn Connections – every FIT Member to connect the Newsletter with their connections
Scheduling Updates: 6 Tools That Keep Your Accounts Active While You Are Not
The 5 Most Important Social Networks for Marketing – And How to Get Started
https://blog.thesocialms.com/5-important-social-networks-marketing/amp/?__twitter_impression=true
7 Content Curation Tools To Stop You From Wasting Your Time
The Truth About Hashtags: When, Where, How and How Many
https://blog.thesocialms.com/truth-hashtags-when-where-how-many/amp/?__twitter_impression=true
Hashtag Analytics for Twitter, Instagram and Facebook – Keyhole
6/28/2020
The Castleman Disease Research Network publishes Phase 1 Results of Drug Repurposing Database for COVID-19
Reporter: Stephen J. Williams, PhD
6/28/2020
Corticosteroid, Dexamethasone Improves Survival in COVID-19: Deaths reduction by 1/3 in ventilated patients and by 1/5 in other patients receiving oxygen only
Reporter: Aviva Lev-Ari, PhD, RN – bold face and color fonts added
6/19/2020
LPBI’s Accomplishments 1Q 2020 & 2Q 2020 – LPBI’s Reorganization ANNOUNCEMENT on 6/23/2020
Reporter: Aviva Lev-Ari, PhD, RN
6/13/2020
6/3/2020
Top Articles in PharmaceuticalIntelligence.com by Number of Views > 3,500 Views, Author(s) Names and Article Type [6/2/2020 counting date]: Relations between Article Type and Article Views
Reporter: Aviva Lev-Ari, PhD, RN
Topic: Aviva Lev-Ari’s Zoom Meeting
Date: May 26, 2020 10:44 AM Eastern Time (US and Canada)
Meeting Recording:
https://us02web.zoom.us/rec/share/5PdpFej_6k5IHpHA12uPZYAoHoTGX6a80XJN_PRZmE5qms6vS-x19FSDWds8tuTA
Access Password: by request
5/30/2020
SARS-CoV-2 is pre-adapted to Human Transmission, branches of evolution stemming from a less well-adapted human SARS-CoV-2-like virus have been found: The Role of SARS-CoV-2 Virus Progenitors for Future Virus Disease Transmission and Pandemic Re-Emergence
Reporter and Curator: Aviva Lev-Ari, PhD, RN – all bold face and colors are my additions
5/29/2020
COVID-19: Novel Treatment Protocols using Approved drugs vs Standard of Care vs Vaccine and Antiviral new drug discovery and development – An LPBI Group Response and An LPBI Group & Affiliates Response
Curator: Aviva Lev-Ari, PhD, RN
5/29/2020
On 5/26/2020 LPBI organized a Symposium on New Therapeutics for COVID-19
AGENDA
- Dr. Raphael Nir, PhD, CSO, SBH, Sciences, Inc. – Drug Concept to mitigate Cytokine Storm in COVID-19 – ATTACHMENT
- Dr. Ajay Gupta, MD, Professor & Entrepreneur – Rhinitis drug approved in Japan – REPURPOSED for COVID-19 and Application for FDA Approval
- Dr. Yigal Blum, PhD, ex-SRI Int’l VP and Entrepreneur – AMORPHOUS CALCIUM CARBONATE (ACC) TREATMENT FOR COVID-19
- Dr. Orna Harel, PhD, Managing Partner, Agbiopro – Representation for – Prof. Saul Yedgar on the concept and state of preclinical efforts for COVID-19 drug development
- Aviva Lev-Ari, PhD, RN – The Potential of REVIVAL of Drug Discovery Initiative and Explorations of Joint Ventures with Biotech companies – An Interim Phase toward POST Coronavirus Pandemic Exit
DISCUSSION – Where and What is the INTERFACE between what our External Relations attempt to accomplish and the Capabilities of LPBI Group’s Team
In the concluding remarks, I pointed the attendees to the following two points:
1. State of Science
RNA from the SARS-CoV-2 virus taking over the cells it infects: Virulence – Pathogen’s ability to infect a Resistant Host: The Imbalance between Controlling Virus Replication versus Activation of the Adaptive Immune Response
Curator: Aviva Lev-Ari, PhD, RN – I added colors and bold face
https://pharmaceuticalintelligence.com/2020/05/23/rna-from-the-sars-cov-2-virus-taking-over-the-cells-it-infects-virulence-pathogens-ability-to-infect-a-resistant-host-the-imbalance-between-controlling-virus-replication-versus-activation-of-the/
2. LPBI Position
- T cells found in COVID-19 patients ‘bode well’ for long-term immunity | Science | AAAS
https://www.sciencemag.org/news/2020/05/t-cells-found-covid-19-patients-bode-well-long-term-immunity
- Clinical Trial for the Use of Nitric Oxide to Treat Severe COVID-19 Infection
https://pharmaceuticalintelligence.com/2020/04/14/clinical-trial-for-the-use-of-nitric-oxide-to-treat-severe-covid-19/
AGENDA – 6/16/2020 – Symposium on New Therapeutics for COVID-19, continued
Part I: Therapeutics for COVID-19
- Prof. Saul Yedgar – Holder of US Patents on Rhinitis, anti-inflatation and other indications – 40 minutes
- Dr. Ajay Gupta, MD – Rhinitis drug approved in Japan – FDA Application for Approval of Repurpusing to COVID-19 in the US – 40 minutes
- Discussion – 20 minutes
5/12/2020
Teams publications of COVID-19 Drug Development Efforts
From AVIVA AND HER TEAM
Other related articles in this Open Access Online Scientific Journal include the following:
- Promises on Covid-19 VaccinesReporter: Irina Robu, PhD
https://pharmaceuticalintelligence.com/2020/05/11/promises-on-covid-19-vaccines/
- Structure-guided Drug Discovery: (1) The Coronavirus 3CL hydrolase (Mpro) enzyme (main protease) essential for proteolytic maturation of the virus and (2) viral protease, the RNA polymerase, the viral spike protein, a viral RNA as promising two targets for discovery of cleavage inhibitors of the viral spike polyprotein preventing the Coronavirus Virion the spread of infection
Curators and Reporters: Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN
- Predicting the Protein Structure of Coronavirus: Inhibition of Nsp15 can slow viral replication and Cryo-EM – Spike protein structure (experimentally verified) vs AI-predicted protein structures (not experimentally verified) of DeepMind (Parent: Google) aka AlphaFold
Curators: Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN
- Promise of Synthetic Biology for Covid-19 Vaccine
Reporter: Irina Robu, PhD
https://pharmaceuticalintelligence.com/2020/03/23/promise-of-synthetic-biology-for-covid-19-vaccine/
- Glycobiology vs Proteomics: Glycobiologists Prespective in the effort to explain the origin, etiology and potential therapeutics for the Coronavirus Pandemic (COVID-19).
Curator: Ofer Markman, PhD
- Worldwide trial uses AI to quickly identify ideal Covid-19 treatments
Reporter : Irina Robu, PhD
- Updated listing of COVID-19 vaccine and therapeutic trials from NIH Clinical Trials.gov
Curator: Stephen J. Williams, PhD
- Actemra, immunosuppressive which was designed to treat rheumatoid arthritis but also approved in 2017 to treat cytokine storms in cancer patients SAVED the sickest of all COVID-19 patients
Reporter: Aviva Lev-Ari, PhD, RN
- Innate Immune Genes and Two Nasal Epithelial Cell Types: Expression of SARS-CoV-2 Entry Factors – COVID19 Cell Atlas
Reporter: Aviva Lev-Ari, PhD, RN
5/11/2020
VIEW VIDEOS from the event
https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg
From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>
Date: Tuesday, May 12, 2020 at 6:48 AM
To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>
Subject: REGISTRANT RECAP | World Medical Innovation Forum
Dear World Forum Attendee,
On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators. As promised, we wanted to also share visual Forum session summaries. You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning
We hope you will join us for the 2021 Forum!
Thanks again, Chris
e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET
Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET
4/1/2020 – First Conference in 2020 – all scheduled are postponed to August 2020 and October 2020
- COVID-19 and AI: A Virtual Conference – Human-Centered Artificial Intelligence Institute, Stanford University, 4/1/2020, 9AM PST – 3:30PM PST @StanfordHAI @pharma_BI @AVIVA1950
Real Time coverage: Aviva Lev-Ari, PhD, RN
- Tweets and Retweets @ COVID-19 and AI: A Virtual Conference – Human-Centered Artificial Intelligence Institute, Stanford University, 4/1/2020, 9AM PST – 3:30PM PST @StanfordHAI BY @pharma_BI and @AVIVA1950
3/25/2020
CORONAVIRUS PORTAL @LPBI
http://lnkd.in/ePwTDxm
Launched on 3/14/2020
OPEN TO GUEST AUTHORS
on Seven Selected Topics & Lead Curator for Contact:
1/13/2020
Reputation value growth drivers
- Capacity to innovate
- Quality of goods and services
- Quality of management
- Quality of marketing
- Financial soundness
- Ability to attract,
- develop and retain talent
- Value as a long-term investment
- Community and environmental responsibility
- Use of corporate assets
- People management
- Global competitiveness
SOURCE
http://www.reputationdividend.com/files/4713/4822/1479/Reputation_Dividend_WEC_133_Cole.pdf
1/8/2020
Global Projects PLAN for Post Completion of BioMed e-Series and during transition to Transfer of Ownership
- France – active relations with the equivalent of AMA for Journal subscription
Aviva’s Contact: JS
- Spain – Dean of Madrid School of Medicine – on consideration e-Books for Medical Education
Aviva’s Contact: Dr. AF
- Russia – ongoing Translation Project of all 16 e-Books to Russian
Aviva’s Contact: George
- LATIN AMERICA
Aviva’s Contact: Marina Jancso
- Japan – Asian largest Conference organizer in Medicine to use our e-Proceeding archive to plan Conference in 2021
Aviva’s Contact: SP
- England – same as Japan
Aviva’s contact: DN
- Germany – Contract with distributor to sale e-Books in Soft cover in Germany
Aviva’s Contact: Dr. BjornB
- Israel – AI in Pharma algorithms are applied to our 5,700 for drug repurposing and for alternative therapeutics for the most expensive indication a Payor covers at present insurance policy
Aviva’s Contact: Ofer Markman
- France – Lyon’s Biotech Hub gets access to LPBI IP for drug discovery research
Aviva’s Contact: Dr. BinahB
- US – 2020 Pipeline Plans as in
https://pharmaceuticalintelligence.com/audio-podcasts/
1/6/2020
Click on Calendar for 1/14/2020 Team Meeting
https://pharmaceuticalintelligence.com/calendar/
1/6/2020
Thank you, Dr. Williams for your article
Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transform Education
Curator: Stephen J. Williams, PhD.
see my two tweets about it
Aviva Lev-Ari
@AVIVA1950
·
1h
No more #knowledge #obsolete #explosion #expert #explains #updates #integrates #MEANING #context #relevance #relatedness #demo #archetype #modules #categories #ontologies #comments #tags https://pharmaceuticalintelligence.com/2020/01/05/old-industrial-revolution-paradigm-of-education-needs-to-end-how-scientific-curation-can-transform-education/ via
@Pharma_BI @bernstein_h @GailThornt @StephenJWillia2
@AVIVA1950
Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transfo…
Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transform Education Curator: Stephen J. Williams, PhD. Dr. Cathy N. Davidson from Duke University gives a t…
pharmaceuticalintelligence.com
Aviva Lev-Ari
@AVIVA1950
·
1h
2012 #launch #revolution #expert #author #writers #clinical #interpretation #scientific #findings #basic #life #sciences #investigation How #Scientific #Curation Can #Transform #Education https://pharmaceuticalintelligence.com/2020/01/05/old-industrial-revolution-paradigm-of-education-needs-to-end-how-scientific-curation-can-transform-education/ via @Pharma_BI @AVIVA1950 @StephenJWillia2 @GailThornt
@bernstein_h
Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transfo…
Old Industrial Revolution Paradigm of Education Needs to End: How Scientific Curation Can Transform Education Curator: Stephen J. Williams, PhD. Dr. Cathy N. Davidson from Duke University gives a t…
pharmaceuticalintelligence.com
Who to follow
CLICK on every Reference
The REFERENCES to this article published in this Open Access Online Scientific Journal curated by Aviva and Dr. Williams
- eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model
- Analysis of Utilizing LPBI Group’s Scientific Curation Platform as an Educational Tool: New Paradigm for Student Engagement
- Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
- Democratizing Data Science Education (Video)
- e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point
- Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences
are about CURATIONS of Scientific basic research findings and clinical interpretation by EXPERTS
—>> Such curations are what LPBI Group created since 4/2012
—>> Such curations the value we bring to a potential acquirer in the LifeSciences, Medicine, pharmaceutical domain.
—>> we did it in three channels for knowledge dissemination OF OUR COLLABORATIVE formulations:
1. One Article Format of Curation by Experts was replicated by collaborations with other team members >5,700 TIMES
2. Expert Editors created electronic Table of Contents (eTOCs) for our 1st e-Book published 6/2013. We REPLICATED the process on eTOCs creation by Expert Editors SIXTEEN TIMES, 12/28/2019, last volume placed on the Medicine & Life Sciences in Kindle Store – our Genomics Volume 2 on AI in Medicine
3. 4/2013 was first BioIT Aviva covered in real time and created the first e-Proceedings, Dr. Williams created Twitter Analytics for it, WE IMPROVED AND REPLICATED this process >70 TIMES
These three CORPUSES are seeking Transfer of Ownership and monetization in 2020.
@@@@@@@@@
12/18/2019
How to Make a Shortened URL Using TinyURL.com or Tiny.cc
For a Website
- Copy the URL that you want to shorten.
- Go to tinyurl.com.
- Paste the long URL and click the “Make TinyURL!” button.
- The shortened URL will appear. You can now copy and paste it where you need it.
For a Google Doc
- Set sharing to “anyone with the link” and either “can edit” or “can view” (depending on what your purpose is for the Doc)
- Copy the “shareable link”
- Go to #2 below
For a Google Form
- After creating your form, click Send (you will not actually send it). You’ll have the option to collect usernames and to send the form by email, a link, or embedding – click the link icon and copy the link
- In another browser tab, go to http://tinyurl.com
- In the field titled Enter a long URL to make tiny, paste the link to your Google form.
Before clicking the Make TinyURL button, you have the option to enter the custom alias (the end of the URL that you want to give to your users – for example, PISD_Watson or Vines-Eng-1). Note that you can’t have spaces in this field. - Click the Make TinyURL button and you will have a much friendlier URL to say aloud, write on the board, or send in an email.
SOURCE
https://www.pisd.edu/domain/1391
11/25/2019
AGENDA for January 14, 2020 Bi-monthly Skype Meeting is posted on CALENDAR
https://pharmaceuticalintelligence.com/calendar/
11/25/2019
2020 – What was/is and will be PharmaceuticalIntelligence.com – The answer is “NOT NEWS.”
- It covers Breakthrough in Life Sciences and Medicine in MULTIPLE domains of Healthcare: Pharmaceutical, Medical Devices, Life Sciences,Medical Technology AND FIVE Specialties in the field of Medicine
AND
- it covers Original Content NOT only Reporting (I.e., News)
AND
- It covers Originally Curated Content (I.e, Interviews with Patients, Industry KOLs, Scientific Leaders)
AND
- It Publishes e-Books in Medicine made of Original eTOCs
AND
- It Publishes Conference e-Proceedings using MADE HERE Systems and Methods
11/15/2019
eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA
Tweets and Retweets by @AVIVA1950 and by @pharma_BI for 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
8/13/2019
Agenda for SKYPE on 8/13, 2019 at 11AM EST – ALL FIT MEMBERS – Attendance is a MUST
Part A: Scientist Unit – FIT Members provide updates
- Dr. Williams
- Genomics Volume 2, Part 7 & Part 8 Updates
- WordPress.com – removal of Ads from a Scientific Journal on a Business account
- Ongoing article publishing and article updates
- Professor Feldman
- Genomics Volume 2, Part 5: Evolution and Genomics – NGS
- Editorials for Genomics Volume 2
- Interview with Gail – last week in Auagust
- Dr. Dror Nir
- Genomics Volume 2, Part 3: AI, Section 3.5 ML Algorithms in Medicine
- Dr. Saha and Dr. Irina Robu
- Please make list of all your articles in the Journal SINCE 6/11/2019 – Update for https://pharmaceuticalintelligence.com/2019-vista/fit-members-who-works-on-what/
- Any comments
Part B: Business Unit
- Rick – Latest on
- IB Briefing to the Team
- Lessons from Section #13
- Vision on Business Development
- Questions to the Board & Aviva
- List of Accomplishments since 6/11/2019 – Update for https://pharmaceuticalintelligence.com/2019-vista/fit-members-who-works-on-what/
- Gail – Latest on
- Implications of IB Briefing to the Team on Marketing Communication role
- Lessons from Section #13
- Vision on Marketing Communication
- Questions to the Board & Aviva
- List of Accomplishments since 6/11/2019 – Update for https://pharmaceuticalintelligence.com/2019-vista/fit-members-who-works-on-what/
- Amnon – Latest on
- Implications of IB Briefing to the Team on Strategy
- Lessons from Section #13
- Vision on Strategy
- Questions to the Board & Aviva
- List of Accomplishments since 6/11/2019 – Update for https://pharmaceuticalintelligence.com/2019-vista/fit-members-who-works-on-what/
Part C: Board Members and Aviva
ALL FIT MEMBERS – PLEASE STUDY and be ready to discuss your own inputs and comment on all other contents related to PRICING as presented in the LINK, below
All Inputs in Consideration for Pricing LPBI Group’s IP Three Classes of Assets
7/31/2019
7/28/2019
The Origin of Cancer and Carcinogenesis: New conceptual paradigm by @BjoernBruecher et al – Three Articles endorse by @AVIVA1950 @pharma_BI, Editors of
- Cancer Biology & Genomics for Disease Diagnosis.
http://www.amazon.com/dp/B013RVYR2K
- Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
http://www.amazon.com/dp/B071VQ6YYK
Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer
https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-019-1163-7
Epistemology of the origin of cancer: a new paradigm
https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-331
Disruption of homeostasis-induced signaling and crosstalk in the carcinogenesis paradigm “Epistemology of the origin of cancer”
https://www.4open-sciences.org/component/toc/?task=topic&id=1080
7/28/2019
Vast #IntellectualProperty #Portfolio in #LifeSciences, #Medicine, #Scientific #Publishing and #Media #ExecutiveSummary pharmaceuticalintelligence.com/2019-vista/exe… via @pharma_BI
7/23/2019
-
Our 2nd ALL FIT MEMBER Skype will take place on Tuesday, August 13, 2019 at 11AM EST – Agenda will be shared before the Skype
- It is a MUST attend once in two month Session during the Exit phase announced on 2/6/2019.
- Each ACTIVE FIT Member will present their contributions to our Venture since June 11, 2019
- LAST CALL for Contributions to Genomics Volume Two – Part 7 and Part 8
- Dr. Dror Nir works on 3.5 – ML Algorithms in Medicine; Dr. Williams works on Part 7&8 and Editorials; Prof. Feldman works on Part 5 and Editorials
- ALL posts written after 6/11/2019 on AI in Medicine — ARE in Genomics Volume 2 – check to see Your NAME – e-mail me if I missed one – chach all Parts !!
- ALL Scientists: Continue to Submit Posts for Part 7 & Part & and Part 3: AI in Medicine – All goes into this Volume – OUR LAST BOOK !!!!!!!!
-
Executive Summary – Updated
https://pharmaceuticalintelligence.com/2019-vista/executive-summary/
-
Founder’s Vision
https://pharmaceuticalintelligence.com/vision/
7/19/2019
We will cover in REAL TIME these most prestigious events in the second half of 2019
- MinneBOS 2019, Field Guide to Data Science & Emerging Tech in the Boston Community, August 22, 2019, 8AM to 5PM at Boston University Questrom School of Business, 595 Commonwealth Avenue, Boston, MAhttps://pharmaceuticalintelligence.com/2019/07/31/minnebos-2019-field-guide-to-data-science-emerging-tech-in-the-boston-community-august-22-2019-8am-to-5pm-at-boston-university-questrom-school-of-business-595-commonwealth-avenue-boston/
- Charles River Laboratories – World Congress, Delivering Therapies to the Clinic Faster, September 23 – 24, 2019, Cambridge, MA
- 2019 Warren Alpert Foundation Award Ceremony and Acceptance Lectures by Awardees, October 3, 2019, Harvard Medical School, Boston, MAAward goes to Four Scientists for Seminal DIscoveries in OptoGenetics – Illuminating the Human Brain
- 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA
- The New England Venture Summit being held December 4th 2019 at the Hilton in Boston Dedham
HANDS OFF on 7/15/2019 –>>>>>> Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology
- This is a monumental moment in the life of the BioMed e-Series of LPBI Group, Boston
All the 16 volumes by LPBI Group’s Experts, Authors, Writers published on AMAZON.COM are on the Kindle Store bookshelf on Medicine and Life Sciences
https://lnkd.in/ekWGNqA
and
Image Source: symplur.jpg, April 13, 2019
World Medical Innovation Forum 2019 – Artificial Intelligence in Medicine
#WMIF19 Influencers:
- Ranked 4th in Top 10 by “Mentions”
@pharma_BI – LPBI Group’s – Official Twitter Account
- Ranked 2nd in Top 10 by “Tweets”
@AVIVA1950 – Aviva Lev-Ari, PhD, RN – Personal Twitter Account
- Our LAST Volume, the SIXTEENTH is been handed off, per plan, on 7/15/2019, to the very able hands of its two other editors for editorials: Prof. S.J. Williams and Prof. Marc W. Feldman
- This AMAZING volume in Genomics — Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology is the ONLY book and will remain as such for several years — the only book to cover in one Volume +200 articles on
Part 1: NGS
1.1 The Science
1.2 Technologies and Methodologies
1.3 Clinical Aspects
1.4 Business and Legal
Part 2: CRISPR for Gene Editing and DNA Repair
2.1 The Science
2.2 Technologies and Methodologies
2.3 Clinical Aspects
2.4 Business and Legal
Part 3: AI in Medicine
3.1 The Science
3.2 Technologies and Methodologies
3.3 Clinical Aspects
3.4 Business and Legal
3.5 Latest in Machine Learning (ML) Algorithms harnessed for Medical Diagnosis: Pattern Recognition & Prediction of Disease Onset
Part 4: Single Cell Genomics
4.1 The Science
4.2 Technologies and Methodologies
4.3 Clinical Aspects
4.4 Business and Legal
Part 5: Evolution Biology Genomics Modeling @Feldman Lab, Stanford University – Written and Curated by Prof. Marc Feldman
5.1
5.2
5.3
5.4
Part 6: Simulation Modeling in Genomics
6.1 Mutation Analysis – Gene Encoding
6.2 Mitochondrial Variations
6.3 Variant Analysis
6.4 Variant Detection in Hereditary Cancer Genes
6.5 Immuno-Informatics
6.6 RNA Sequencing
6.7 Complex Insertions and Deletions
6.8 Evolutionary Biology
6.9 Simulation Programs
6.10 A comparison of tools for the simulation of genomic next-generation sequencing data
Part 7: Applications of Genomics: Genotypes, Phenotypes and Complex Diseases
7.1 Genome-wide associations with complex diseases (GWAS)
7.2 Non-coding DNA and phenotypes—including diseases like cancer
7.3 Epigenomic associations with phenotypes including cancer
7.4 Rare variants and diseases
7.5 Population-level genomics and the meaning of group differences
7.6 Targeting drugs for complex diseases
Part 8: Epigenomics and Genomic Regulation
8.1 Genomic controls on epigenomics
8.2 The ENCODE project and gene regulation
8.3 Small interfering RNAs and gene expression
8.4 Epigenomics in cancer
8.5 Environmental epigenomics
FIVE Forthcoming Books on CRISPR in 2019-2020: Flooded market or CRISPR-fatigued readers – Not to Worry!!!!!
Author: Aviva Lev-Ari, PhD, RN
6/16/2019
eProceeding 2019 Koch Institute Symposium – 18th Annual Cancer Research Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA
Tweets, Pictures and Retweets at 18th Annual Cancer Research Symposium – Machine Learning and Cancer, June 14, 2019, MIT by @pharma_BI and @AVIVA1950 for #KIsymposium PharmaceuticalIntelligence.com and Social Media
6/15/2019
My week on Twitter 
: 5 Mentions, 2.59K Mention Reach, 37 Likes, 41 Retweets, 186K Retweet Reach. See yours with https://sumall.com/performancetweet?utm_source=twitter&utm_medium=publishing&utm_campaign=performance_tweet&utm_content=text_and_media&utm_term=982cd4ccfc5b4b8fbd4f691a …
6/15/2019
Thanks to Gail Thornton for arranging the Audio Podcast: On Air Now – 3D BioPrinting
Medical 3D BioPrinting – The Revolution in Medicine
Technologies for Patient-centered Medicine:
https://www.amazon.com/dp/B078QVDV2W
BioPrinting 2019 FINAL
From: Partners in Health and Biz Radio Show
https://www.spreaker.com/user/pihandbiz/bioprinting-2019-final
6/14/2019
Gail wrote on 6/10/2019
- The audio podcast on the 3D-Bioprinting e-book will air this Saturday, June 15 @10am. I will send you the link once I receive it from Partners in Health & Biz.
And then we can write a short article and post it to the LPBI Group online journal.
6/10/2019
WHAT ARE LPBI Group’s NEEDS in June 2019
Aviva’s BOLD VISION on June 11, 2019
Task 1: Artificial Intelligence in Medicine
– Weekly engagement
Majority of healthcare organizations are testing out AI
June 05, 2019 | Amy Baxter | Connected Care
https://www.aiin.healthcare/topics/connected-
Task 2: Promotion of BioMed e-Series to Med Schools
– Monthly engagement
Task 3: Going DIRECT for finding an M&A partner
– Quarterly engagement
Team Members’ Tasks Assignment
6/10/2019
Books in use at US Medical Schools:
6/2019 – Susan B. Klein, PhD, Department of Physics, Indiana University, Bloomington
(another Berkeley alum) will be using for her forthcoming book on Radiation Biology, World Scientific Press, 2023, articles from the following three LPBI Group’s BioMed e-Series:
- Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics.
On Amazon.com since 11/29/2015
http://www.amazon.com/dp/B018PNHJ84
- Volume 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015
http://www.amazon.com/dp/B018DHBUO6
- Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
- Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017
http://www.amazon.com/dp/B071VQ6YYK
- 250 Medical Schools in the US
- Europe
In 2019, Class II, e-Books are in Use in Medical Schools in the State of Pennsylvania for curriculum development:
Series A: Volume 3 – Epigenetics, Genetics and Genomics [Jefferson Medical School, Philadelphia]
Series B: Volume 1 – Genomics & Personalized Medicine [Temple University, Philadelphia]
Series C: Volume 1,2 – Cancer [Temple University, Philadelphia]
Series E: Volume 1 – Voices of Patients [Jefferson Medical School, Philadelphia]
Case Western Medical School – need to follow up on a contact from the Conference that I covered at Harvard Law School on Genomics and Ethics on 5/17/2019.
@PharmaceuticalIntelligence.com Journal: Article Publication by LPBI Group’s FIT Members, January 2019 – June 2019
Reporter: Aviva Lev-Ari, PhD, RN
| Curator’s Name | 1/1/2019 – 6/30/2019 | 7/1/2019 – 12/31/2019 |
| Dr. Sudipta Saha | 20 | |
| Dr. Stephen J. Williams | 37 | |
| Dr. Irina Robu | 19 | |
| Dr. Dror Nir | 4 | |
| Gail S. Thornton | 7 | |
| Amnon Denzig | 1 | |
| Rick Mandhal | 1 | |
| Dr. Aviva Lev-Ari | 94
[51.37%] |
|
| Total | 183 |
| 1/22/2019 | e-Readers | # Articles | Scientific Comments | Research Categories |
| LPBI Group | 1,563,240 | 5,469 | 7,308 | 666 |
| Aviva Lev-Ari, PhD, RN | 393,545 | 3,245 |
| 6/10/2019 | e-Readers | # Articles inclusion in Article Scoring System
for Journal Valuation |
Scientific Comments | Research Categories |
| LPBI Group | 1,632,642 | 5,621
+all are in a DB with e-Readers per article +all articles views in each e-Book will be completed in June’19 +Length per article work in progress |
7,346 | 682 |
| Aviva Lev-Ari, PhD, RN | 409,063 | 3,303 |
Top Authors for all days ending 2019-06-10 (Summarized)
All Time
Managing social media – AgoraPulse.com
under consideration
Schedule your content, get reports, and engage followers with one simple tool.
- Engagement & Monitoring
- Priority Inbox
- Advanced Sync
- Inbox Assistant
- Inbox Filters
- Unlimited Listening Searches
- Assign Inbox Items
- Ad Comments Monitoring
- Internal Notes
- Publishing
- Unlimited Scheduled Posts
- Unlimited Queued Posts
- Queue Categories
- Assign & Approve Posts
- Chrome Extension
- Bulk Scheduling
- Bit.ly Integration
- UTM Parameters
- Label Content
- Reporting
- Unlimited Report Exports
- Facebook ROI Calculator
- Facebook Competitor Analysis
- Data Retention
- Social CRM
- Customer History
- Custom Notes
- Custom Labels
- Automated Badges & Ranking
- Other Benefits
- Team Workflow
- Mobile App
- 24/7 Support
- Workshop
- Account Manager
-
- 10 social profiles, 3 users
- Add-on Profile US$12/mo
- Add-on User US$39/mo
- 300 Active Ads per profile
- 6 Months
- Email Support
US$239
-
- 40 social profiles, 12 users
- Add-on Profile US$6/mo
- Add-on User US$39/mo
- 1000 Active Ads per profile
- 24 Months
- Priority Email & Chat Support
- Onboarding Workshop
US$459
-
- 70 social profiles, 20 users
- Add-on Profile US$4/mo
- Add-on User US$15/mo
- 2000 Active Ads per profile
- 24 Months
- Priority Email, Chat & Phone Support
- Custom Training
- Dedicated Account Manager
Real Time Coverage of BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center; Philadelphia PA
Reporter: Stephen J. Williams, PhD @StephenJWillia2
eProceedings for BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center; Philadelphia PA, Real Time Coverage by Stephen J. Williams, PhD @StephenJWillia2
5/29/2019
From: Harvard Medical School <pgme@hms.harvard.edu>
Reply-To: <pgme@hms.harvard.edu>
Date: Wednesday, May 29, 2019 at 1:16 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Registration Pending Approval – Media & Medicine: How to Tell Stories That Make A Difference (Media & Med) 2020
Wednesday, May 29, 2019
Dear Aviva Lev-Ari,
Thank you for submitting your application for the Media & Medicine: How to Tell Stories That Make A Difference (Media & Med) 2020. Your application has been received and is under review. You will be notified of your application status within four weeks of submission.
Please note that only completed applications will be reviewed for admission.
Click here to view your application details.
You will be asked to enter your confirmation number: DVNQ382RYR4
Please add pgme@hms.harvard.edu to your safe senders or contacts list to ensure you receive updates on your application and program announcements. Do not hesitate to contact us if you have any questions.
Thank you for your application to Media & Med Program.
Sincerely,
The Admissions Team
Postgraduate Medical Education
Harvard Medical School
5/28/2019
Most recent five articles on Schizophrenia in pharmaceuticalintelligence.com
- Molecular basis for schizophrenia
Larry H. Bernstein, mD, FCAP, Curator
https://pharmaceuticalintelligence.com/2016/05/08/molecular-basis-for-schizophrenia/
- Schizophrenia, broken-links
Larry H. Bernstein, MD, FCAP, Curator
https://pharmaceuticalintelligence.com/2016/04/05/schizophrenia-broken-links/
- Schizophrenia genomics
Larry H. Bernstein, MD, FCAP, Curator
https://pharmaceuticalintelligence.com/2016/03/15/schizophrenia-genomics/
- Imaging Schizophrenia Brain
Larry H. Bernstein, MD, FCAP, Curator
https://pharmaceuticalintelligence.com/2015/10/27/schizophrenia-brain/
- Outstanding Achievement in Schizophrenia Research
Larry H. Bernstein, MD, FCAP, Curator
https://pharmaceuticalintelligence.com/2015/09/06/outstanding-achievement-in-schizophrenia-research/
5/24/2019
Resources on Artificial Intelligence in Health Care and in Medicine: Articles of Note at PharmaceuticalIntelligence.com @AVIVA1950 @pharma_BI
https://www.linkedin.com/pulse/resources-artificial-intelligence-health-care-note-lev-ari-phd-rn/
5/22/2019
Leaders in Pharmaceutical Business Intelligence Group (“LPBI Group”) is an electronic scientific publishing venture that has developed proprietary, advanced platform architecture methodologies and business models, i.e., combination drug therapies, conceptual drug designs and forecasting demand models. Through the creation of original scientific content using a methodology of curation of scientific findings that they have developed and implemented since 4/2012, LPBI Group became a powerhouse for curation of scientific findings and methodology development for e-scientific publishing, growing its journal archive to +5,500 articles.
The Group has three interrelated healthcare content products: an open-access online scientific journal; a series of 16 BioMed e-books; and real-time coverage of BioMed scientific and medical conferences. Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). Please visit us at http://pharmaceuticalintelligence.com and on Twitter (@pharma_BI, @Aviva1950).
5/21/2019
Updated Profile of Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Expertise of our Team members includes functional areas of the e-Scientific Publishing segment https://lnkd.in/ejXnvUN
• Our IP is most valuable for several industrial sectors and economic segment as described https://lnkd.in/dNHYWGH
• We offer several Media Distribution Channels for Contents and Events as described https://lnkd.in/dnHVBKv
• We welcome partnerships and inter-organizational interfaces for collaboration purposes. We are seeking Joint Ventures, M&A and other structures to leverage our IP and the deep expertise of our Team Contact us
5/20/2019
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Newton, MA is a venture launched on April 2012.
LPBI Group is a start up that developed content in the following domains:
Our DOMAINS in Scientific Media
I. Pharmaceutical: Biologics, Small Molecules, Diagnostics
II. Life Sciences: Genomics and Cancer Biology
III. Patient-centered Medicine: Focus on #1: Cardiovascular, #2: Cancer, #3: Physiology Metabolomics, Immunology
IV. Biomedicine, BioTech, and MedTech (Medical Devices)
V. HealthCare: Patient-centered Medicine and Personalized/Precision Medicine
OUR three health care Intellectual Property (IP) Content Asset Classes:
- IP Asset Class I: Corpus of 5,600 Scientific Articles in the Open Access Journal @PharmaceuticalIntelligence.com
- IP Asset Class II: Corpus of 16 Volumes in LPBI Group’s BioMed e-Series
- IP Asset Class III: Corpus of +60 Conference eProceedings
https://pharmaceuticalintelligence.com/press-coverage/
5/17/2019
LIVE 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, Friday, May 17, 2019 from 8:00 AM to 5:00 PM EDT
Tweets and Re-Tweets by @Pharma_BI and @AVIVA1950 at 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, Friday, May 17, 2019 from 8:00 AM to 5:00 PM EDT @Harvard_Law
5/12/2019
LIVE 13th Annual BioPharma & Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA
Tweets and Retweets by @AVIVA1950 and by @pharma_BI for @USAIC and #USAIC2019 at the 13th Annual BioPharma & Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA
5/6/2019
Dr. Lev-Ari was solicited by MIT Inclusive Innovation Challenge (MIT IIC) to register for 2019 applicant pool of entrepreneurs developing digital technologies for the workplace.
The IIC is the flagship program of the MIT Initiative on the Digital Economy, annually celebrating entrepreneurs who are using technology to create innovative solutions to global challenges. Global Winners will receive the award at the Global Grand Prize Gala at MIT. In the last three years, the IIC has awarded 100 organizations around the world. View past winners.
https://challenge.mitinclusiveinnovation.com/applications/2900/printable
5/2/2019
#usaic19 @pharma_BI @AVIVA1950 13th Annual BioPharma & Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA https://pharmaceuticalintelligence.com/2019/04/30/13th-annual-biopharma-healthcare-summit-thursday-may-9-2019/ … via @Pharma_BI
5/1/2019
@Pharma_BI @AVIVA1950 Make this World a better place, students you are the FUTURE. 20 final teams finalists to pitch in 15 seconds #human #health #Lab to #bedside 5 finalist Flotherm, GC therapeutics, Kinnos, Lima BioSciences, longsleeve,
-
You Retweeted
@Harvard#innovationLab 8th Annual President’s Innovation Challenge Award Ceremony begins Change the World @jodigoldstein#Leaders#culture#innovation#celebrate#failure $1.5Billion raised 54% female applicants 50% applicant of color ingenuity Awards @Pharma_BI0:3318 views -
You Retweeted
-
You Retweeted
@Harvard 2019 President’s Innovation Challenge Showcase & Award Ceremony 4 categories:#HealthLifeScience#socialImpact#OpenTrack#LaunchLabX@AVIVA1950 @Pharma_BI
-
You Retweeted
@Pharma_BI@AVIVA1950#PIC2019#SocialImpact category Coding it Forward, JustFix is the Winner, Generus, MDaas Global MRI to Africa, New Teachers Thriving (GDE),
-
You Retweeted
#PIC2019 @Pharma_BI@AVIVA1950#OpenTrack LeverEdge, MyToolBox- is the winner, http://Porto.ai , ReThink- Grand Prize, Voodles,
-
You Retweeted
#PIC2019 @Pharma_BI@AVIVA1950 five teams solutions for CHANGING THE WORLD, Jamber-Grand Prize winner, Legacy, Nilus, Sophia -the winner, Zubale,
-
You Retweeted
#PIC2019 INGINUITY Award, 300 applications 200 advisors. Awards for ingenuity: Three ideas $2500 increase Teachers, GES, $2500 child care edu, GSB, $5,000 Steel manufacturing waste silicon instead of CO2. @Pharma_BI@AVIVA1950
4/30/2019
-
@MGHCancerCenter#AI to read memo grams for prediction of future cancer age family history prior procedure 42% density out 212K 8 have dense deep neural network model image vs model image +RF DL white vs non white high Risk Density bias free @Pharma_BI@AVIVA1950
-
@MIT @kochinstitute @Pharma_BI@AVIVA1950#breastcancer o accurate tools for early detection or predicts future disease progression or remission 6 out of 200,000 images will are cancer variation of image interpretation breast density for notification
4/25/2019
Tweets by @pharma_Bi and @AVIVA1950 at #GenMed2019 on Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York
LIVE – Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
4/22/2019
|
@AVIVA1950 SUMALL Weekly Digest |
04/07/2019 – 04/13/2019
#WMIF19 04/08/2019 – 04/10/2019 |
| Likes | 125 |
| Followers | 391 |
| Friends | 1.5K |
| Mentions Reach | 23.7K |
| Mentions | 14 |
| Replies | 0 |
| Retweet Reach | 130.4K |
| Retweets | 66 |
| Tweets | 154 |
SOURCE
From: SumAll <sumall@sumall.com>
Date: Monday, April 22, 2019 at 4:35 AM
To: “<Aviva Lev-Ari>”, <PhD>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: My Weekly Digest: Week of Apr 14, 2019
4/22/2019
We met a MILESTONE on 4/19/2019 – we sent out to NY two documents of great significance.
The CHARTER during an Interim Period – AVIVA’s VISION POST 4/19/2019
a. Create strategic directions for current LPBI Group IP Asset Classes: I, II, III
b. Lay out the foundation for LPBI Group’s newly defined pipelines in Document #2 – our future legacy following the 16th e-Book completion in 2019.
b.1 Potential emergence of e-Book #17
—->>>> Major discovery in Cell Journal @UCSF on B cells impact on immunology and vaccine design – let to a new project I launched yesterday:
- MWF to get Full Document
- Dr. Saha to write new curation
- Dr. Williams to comb the archive on B Cells research
- Dr. Irina to Update 6 existing B cell articles in the Journal with URL of Dr. Saha’s new curation
- Dr. Irina to write impact of Dr. Saha’s curation content on Vaccine Design
- Dr. Larry to review all of the above
- If Dr. Williams is fetching a pool of existing B Cell articles in our Journal to be >60, THEN
- Aviva to launch Series D, Volume 4 on B Cell in Vaccine Design
Series D, Volume 4: Editors: Saha, Williams, Irina, Aviva
THIS WILL BE THE FIRST BOOK IN EXISTENCE on the 2019 discovery @UCSF on new roles for B cells beyond production of antibodies
c. Gradually build capabilities of LPBI Group’s Specialty in Consulting using IP Asset Class IV: Business Methods applIed in Biotech for Biotech and Pharma, where Business Side and our Scientists (newly, to be recruited) work jointly on Client assignments using our IP Asset Classes: I, II, III, IV.
—>>> Business side get engagements —>>> Scientists side develop and deliver on engagement
ALL,
Till we learn from IB about
—->>>>> “are we a NEW Client of xxxx, Investment Banker, NY: yes or no”
- We may get second round of RFI from the IB before that decision is made
WE shift focus to OTHER activities:
1. Gail’s Marketing Communications initiatives:
1.1 Podcasts on our e-Books:
– 3D BioPrinting, May 3
– Voices of Patients, date TBD
1.2 Newsletter — I update LPBI Group News, Gail uses this content and other content
2. WE focus all FIT Scientists on @UCSF Discovery on B Cells, as above
3. WE work to publish Genomics Volume 2 in 2019.
4. Amnon and Rick continue to work on Business Development concepts – Plan B
5. KICK OFF SKYPE SESSION ALL FIT MEMBERS in May 2019 – Date/Time: TBD, Organizer: Irina
4/20/2019
CONGRATULATIONS to Amnon, Gail and Rick for bringing to completion thie OWN initiative to create a Business Plan for LPBI Group.
Amnon:
I am happy that you demonstrated to me your thought process. You were given a difficult challenge, taking the ball and running with it, is a very high bar to jump, you did it beautifully on several levels:
1. You challenged yourself
2. You produced artifacts that I could use “as is” into my own work on Document #2 – key 🔑 for me to extend my capabilities
3. Now, I know HOW to activate you for high qualitative outcomes in concept formation
THANKS to Gail and Rick:
4. You on your own, with my suggestion, activated Gail and Rick to produce significant artifacts
5. Together, the three produced the first version of the LPBI Group’s Business Plan
6. It had the originality I am seeking when I say, “teach me something new.” Because, I always need more building blocks to generate new IP
7. Taking it all together, I gained the confidence that Business Side on LPBI Group’s FIT can and will continue to build IP Asset Class IV: Business Methods which has few potentials
4/14/2019
The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
4/13/2019
Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated
On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752
On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654
- In 48 days # Follower increases from 359 to 390 – Growth rate of 8%
- Three new “I” Followers were selected to be added in 48 days since 4/24/2019 = 25,667 Followers of Followers
- Eight new “P” Followers were selected to be added in 48 days since 4/24/2019 = 425,971 Followers of Followers
- Total “I” + “P” on 2/24/2019 was 2,580,051
- Total “I” + “P” on 4/13/2019 was 3,031,689
- Growth Rate of Followers’ Followers 17.5% in 48 days
Thus, on 4/13/2019 the Followers DATA in the Excerpt is base on 117 on 2/24/2019 plus 11 [2 and 3, above] = 128 Followers
4/13/2019
@symplur‘s #Healthcare Hashtags – Twitter Analytics published for http://bit.ly/WMIF19
- [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]
- [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
Pinned Tweet
More
As World #Medical #Innovation Forum comes to a close, here are TOP #WMIF19 #influencers via @symplur‘s #Healthcare Hashtags
to organizers for a stellar event & to all on #MedTwitter for a robust conversation! #AI @PHSInnovation @ChrisMarkCOBURN
Partners HealthCare, GE Healthcare, Brigham Digital Innovation Hub and 6 others
3 replies
12 retweets
15 likes
Direct message
4/11/2019
Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPN for #WMIF19 by @PHSInnovation at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019
Tweets, ReTweets and Likes by @AVIVA1950 and by @pharma_BI using @PHSInnovation and #WMIF19 during Day One, Two and Three of World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019
LIVE Day One – World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Westin Copley Place, Boston, MA USA, Monday, April 8, 2019
LIVE Day Two – World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 9, 2019
LIVE Day Three – World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 10, 2019
4/2/2019
Total 2,241,388
- [Media 375,606]
Institutions (I) – Total 1,786,443
- [Media Companies 341,716]
Individuals (P) – Total 430,725
- [Media Individuals 13,390]
LPBI Group is mostly honored to have its Founder’s Twitter handle @AVIVA1950 been followed by top Scientific research organization who are leaders in e-Scientific content production, chiefly,
| Technion Israel | @TechnionLive | 47,800 followers | |
| Broad Institute | @MIT @HARVARD @broadinstitute | 46,000 followers | |
See all @AVIVA1950 that we declared as “mostly honored to be followed by”
- Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
3/29/2019
TWEETS and Retweets by @pharma_BI and @AVIVA1950 on Day One and Day Two: 2019 MassBio Annual Meeting, State of Possible Conference, Sonesta Hotel, Cambridge, March 27, 2019
LIVE Day Two: 2019 MassBio Annual Meeting, State of Possible Conference, Sonesta Hotel, Cambridge, March 28, 2019
LIVE Day One: 2019 MassBio Annual Meeting, State of Possible Conference, Sonesta Hotel, Cambridge, March 27, 2019
3/21/2019
Announcement
Amnon Danzig, FIT member, our Strategic Thinker, will be presenting a 20 minute Conference Presentation at the Second Global Conference on Creating Value on May 14-15, 2019 at Fordham University’s Gabelli School of Business at 140 West 62nd Street in New York City.
The details of the conference program will be listed on the conference website soon. For updates, please check
http://www.creatingvalue.co/creating-value-conference-programme/
SOURCE
From: Global Creating Value 2019 <creatingvalue2019@fordham.edu>
Date: Wed, Mar 20, 2019, 15:32
Subject: Second Global Conference on Creating Value – Presenter Information
To: Fordham Creatingvalue2019 <creatingvalue2019@fordham.edu>
Sertan Kabadayi, PhD
Conference Co-chair
Area Chair – Marketing
Professor of Marketing
Gabelli School of Business
Fordham University- Lincoln Center
140 West 62nd Street, Suite 446
New York, NY, 10023
Phone: 212.636.7804
Email: Kabadayi@Fordham.edu
3/21/2019
Announcement
LPBI Group will be covering in Real Time 2019 18th BioIT Conference on 4/16/2019 – 4/18/2019 at Seaport World Trade Center, Boston, MA.
Aviva Lev-Ari, PhD, RN
will be in attendance in Real Time generating the conference e-Proceedings and on Social Media using
#BioIT2019
and
pharmaceuticalintelligence.com
Official LPBI Twitter account
Aviva Lev-Ari, PhD, RN Private Twitter account
SOURCE
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
3/12/2019
Our WEBSITE is NOW on a Business Site Plan – What does that mean
We need to
- CUSTOMIZATION of the Website
- e-Mail @pharmaceuticalintelligence.com
Our WEBSITE is NOW on a Business Site Plan – What does that mean
powerful tools and support included in enhanced WordPress.com plans that can help fast-track the success of your site, whatever your goals may be.
With an upgraded site you can:
- Impress your friends with your very own domain name (instead of having WordPress.com in your URL).
- Quickly resolve any roadblocks by connecting with our all-star customer service team through live-chat support.
- Bring your design vision to life with over 100 professionally designed templates to choose from.
- Gain complete control of your site when you unlock custom CSS capabilities (Premium, Business, and eCommerce plans).
- Build your community, connect with customers, or grow your business with enhanced marketing and eCommerce tools.
Hi 2012pharmaceutical,
We’re excited that you purchased the Business plan on pharmaceuticalintelligence.com. It’s the perfect way to supercharge your site with advanced SEO tools, Google Analytics, free Premium themes, and more.
As part of your Business plan, you can schedule a free, personalized concierge session with one of our Happiness Engineers for real-time, one-on-one help. Just choose a time that works for you in the link below:
|
We’ll answer any questions you have, and we’ll show you some of the awesome features that come with your Business plan. You can also reply to this email with any questions, or reach us via live chat at https://wordpress.com/help/contact.
Professional email and so much more
Make the right first impression and promote your website every time you send an email with an account @pharmaceuticalintelligence.com.
|
We’ve teamed up with Google Cloud to offer you professional email and a suite of productivity tools, including:
| Gmail for @pharmaceuticalintelligence.com
Professional ad-free email that works with most email clients. |
|
| Keep all your files secure Get 30GB of storage for all your files, and access them from your phone, tablet, or computer. |
|
| Docs, spreadsheets and forms
Create and edit documents at the same time as others to get your work done faster. |
|
| Connect with your team Use text chats, voice calls, or video calls, with built in screen sharing. |
Don’t wait — get the first two months free when you add G Suite to your site today.
|
| The WordPress.com Team |
|
|
|||||
|
3/12/2019
Covering this event in Real Time @pharma_BI @AVIVA1950
2019 Koch Institute Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA
3/2/2019
- Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
-
Institutional Follower’s Followers = 1,354,885
-
Individual (person) Follower’s Followers =1,157,741
-
Number of Followers of @AVIVA1950 117 Followers –>>>>> Total 2,512,626
| HIGHEST HONOR to be followed by [From an Excerpt of 117 Followers of @AVIVA1950
(from the List of 359 Followers)] by the Number of their Followers |
Aviva Lev-Ari | Institutional Follower’s Followers = 150,617 Individual (person) Follower’s Followers = 345,000 Total = 495,617 | |
| Tweets
8,060 |
Following 1,412 | Followers 359 | Likes 2,752 |
| I = Institution P = Person RED = Highest HONOR to be Followed by | Follower Name | Twitter Handle | # of Followers |
| I | Technion Israel | @TechnionLive | 47,800 |
| I | Broad Institute | @MIT @HARVARD @broadinstitute | 46,000 |
| I | NFCR | @NFCR | 36,100 |
| I | Technion T³ | @TechnionT3 | 16,900 |
| I | BCM_CVRI | @BCM_CVRI | 2,249 |
| I | Partners Innovation | @PHSInnovation | 1,121 |
| I | Discovery on Target | @BostonDOT | 298 |
| I | PM Conference | PM Conference | 149 |
| Total of “I” | 150,617 | ||
| P | Dr Atanas G Atanasov | @_atanas_ | 107,000 |
| P | Eric Rodgers | @ericfrodgers |
87,700 |
| P | Dr. GP Pulipaka | @gp_pulipaka | 54,400 |
| P | Jan Oldenburg | @janoldenburg | 23,000 |
| P | BioInformant | @StemCellMarket | 21,300 |
| P | Dr. Stefan Gruenwald | @sgruenwald | 21,100 |
| P | John Belmont | @jwbelmon | 17,900 |
| P | Richard G. Lanzara | @rlanzara | 8,740 |
| P | Dr. Thomas Wilckens | @Thomas_Wilckens | 2,596 |
| P | Yuval Cohen | @CEOCorbus | 1,264 |
| Total “P” | 345,000 | ||
FIT Members Tweet to Followers of
@AVIVA1950
Tweet by Prof. Feldman
@broadinstitute @BioWorld @Biotech365 @pharma_BI @AVIVA1950 e-Journal pharmaceuticalintelligence.com ebooks https://lnkd.in/ekWGNqA Conference eProceedings DELIVERABLES & Social Media Analytics #RealTime #Press Looking forward to continued collaboration with @pharma_BI @AVIVA1950 supporting mutual efforts to promote #pharmanews #biotech #personalized #medicine #BioMedical #biotechnology #biopharma #science #research #pharmaceutical
Tweet by Dr. Williams
@TechnionLive @BostonDOT @PharmaVoice Looking forward to continued collaboration with @pharma_BI @AVIVA1950 supporting mutual efforts to promote #pharmanews #biotech #personalizedmedicine @StephenJWillia2
TWEET by Rick Mandahl
@NFCR @pharma_BI @AVIVA1950 e-Journal pharmaceuticalintelligence.com #cancer #biology #oncology #genomics #curations #realtime #cancer #researchers #globally #exploratory #discussions for #collaboration ebooks https://lnkd.in/ekWGNqA Conference eProceedings DELIVERABLES & Social Media Analytics
TWEET by Rick Mandahl
@PMC #Conference @harvardmed #patients #researchers #policymakers #health #pharma #execs #insurers – dedicated to improving #patient #outcomes #genomic #science #medicine #Collaborate #president @PMC #announcements #Realtime covered #Annual #Conference over 2 million LPBI followers #personalized #medicine to improve #Global #health @pharma_BI @AVIVA1950
TWEET by Rick Mandahl
@TechnionT3 #scientific #engineering #medical #research @Israel #innovation @global #progress @Boston @pharma_BI @AVIVA1950 e-Journal pharmaceuticalintelligence.com #cancer #biology #oncology #genomics #curations #realtime #cancer #researchers #globally #exploratory #discussions for #collaboration ebooks https://lnkd.in/ekWGNqA Conference eProceedings DELIVERABLES & Social Media Analytics over 1.6 million #global #eReaders including @TechnionT3 consider #strategy using @pharma_BI #IP for #progress of @TechnionT3 #dynamics. Let’s explore #joint #venture
Irina Robu, PhD
@broadinstitute @PHSInnovation @BostonDOT @StemCellMarket Looking forward to continuous partnership with @pharma_BI @AVIVA1950 supporting common efforts to promote #tissue engineering #biomaterials #stemcells #biotech #cell therapy #personalized #medicine @irirobu
TWEETS by AMNON to @AVIVA1950 Most Honored to be followed by Followers
@TechnionLive @amnon_danzig Two #strategic #structural #risks in @Scientific #Publishing for all #Scientists: #Information #Explosion, and the high rate of #Information #Obsolescence #Curation #Methodologies and #Data #Science serves as #mitigating #factors pharmaceuticalintelligence.com @pharma_BI curation methodology developed by @AVIVA1950 https://lnkd.in/eEyn69r is a #leader in the #complex #BioMed #field https://lnkd.in/ekWGNqA
@TechnionT3 @amnon_danzig Technology transfer requires the most relevant and up-to-date knowledge of all technologies pharmaceuticalintelligence.com @pharma_BI #curation #methodology developed by @AVIVA1950 https://lnkd.in/eEyn69r is a #leader in the #complex #BioMed #field https://lnkd.in/ekWGNqA #KnowledgeGap needs be narrowed for #successful #TechnologyTransfer
@PHSInnovation @amnon_danzig #invention or #innovation? Invention is a #technological #breakthrough while most #Innovation are born by #interdisciplinary cross #fertilization #Leaders in #curation #methodology developed by @AVIVA1950 https://lnkd.in/eEyn69r in #BioMed #fields https://lnkd.in/ekWGNqA pharmaceuticalintelligence.com @pharma_BI in #Medicine #LifeSciences #HealthCare #MedTech #BioTech #DrugDiscovery #PharmaceuticalIntelligence
2/18/2019
- Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
- FIT Members Contribute to Opportunities Map
2/3/2019
LIST OF ASSETS
- Launched Open Access Online Scientific Journal @PharmaceuticalIntelligence.com, 4/2012
- Launched BioMed eSeries, 16-Volumes in Life Sciences and Medicine, 10/2012
Launched 6 Volumes #Cardiovascular e-Series, Bundled on Amazon for $515
Launched 10 Volumes in #Medicine #Genomics 1,2 #Cancer 1,2 #Immunology 1,2,3 #PrecisionMedicine 1,2,3,4
- Launched Real Time Press Coverage of Biotech Conferences, 3/2013
https://pharmaceuticalintelligence.com/press-coverage/
Part One: The Process of Real Time Coverage using Social Media
Part Two: List of BioTech Conferences 2013 to Present
Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics
2/1/2019
TWITTER Handles
@pharmaceuticalintelligence.com
@pharma_BI
@AVIVA1950
https://lnkd.in/erfbayJ
1/31/2019
TWEETS by @pharma_BI and @AVIVA1950 at #IESYMPOSIUM – @kochinstitute 2019 #Immune #Engineering #Symposium, 1/28/2019 – 1/29/2019
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
1/29/2019
LIVE Day One – Koch Institute 2019 Immune Engineering Symposium, January 28, 2019, Kresge Auditorium, MIT
LIVE Day Two – Koch Institute 2019 Immune Engineering Symposium, January 29, 2019, Kresge Auditorium, MIT
1/26/2019
Team Tweets
#1 – ALL BioMed 16 Volumes
@Amazon BUNDLED @pharma_BI @AVIVA1950 https://lnkd.in/eEyn69r
6 Volumes #Cardiovascular for $515 https://lnkd.in/e6WkMgF
UNBUNDLED 10 Volumes in #Medicine https://lnkd.in/ekWGNqA
#Genomics 1,2 #Cancer 1,2 #Immunology 1,2,3 #PrecisionMedicine 1,2,3,4
#2 – Please Tweet – about Series E
@Amazon @pharma_BI BUNDLES for $274 #Patients #Voices #Precision #Medicine #Physiology #Genomics #Therapeutics #3D #BioPrinting: Series E: Volumes 1,2,3,4 by Editors: Larry H Bernstein @bernstein_h Gail Thornton @GailThornt Aviva Lev-Ari @AVIVA1950 https://lnkd.in/ekWGNqA
#3 – Please Tweet – about Series C
Amazon @pharma_BI BUNDLES for $175 Series C: #Cancer #Oncology
VOLUME 1 Cancer #Biology #Genomics http://www.amazon.com/dp/B013RVYR2K
VOLUME 2 #Therapies Genomics #Interventional #Immunotherapy #Nanotechnology in #Drug #Delivery http://www.amazon.com/dp/B071VQ6YYK
#4 – Please Tweet – about Series D
@Amazon @pharma_BI BUNDLES for $190 Series D: #Metabolomics #Immunology #Infectious #Diseases VOLUME 1 http://www.amazon.com/dp/B012BB0ZF0 VOLUME 2 & VOLUME 3 https://www.amazon.com/dp/B075CXHY1B
| 1/22/2019 | e-Readers | # Articles | Scientific Comments | Research Categories |
| LPBI Group | 1,563,240 | 5,469 | 7,308 | 666 |
| Aviva Lev-Ari, PhD, RN | 393,545 | 3,245 |
On 1/22/2019
#Updates to 2018 1,562,778 e-Readers @pharma_BI @AVIVA1950 https://lnkd.in/eEyn69r 393,431views
#Bundled #CVD #Diseases – 6 Volumes https://lnkd.in/e6WkMgF
#Bundled #Cancer 1,2 #immunology 1,2,3 #PrecisionMedicine 1,2,3,4 https://lnkd.in/ekWGNqA
On 1/20/2019 – 280 character Tweet
@Amazon.com BUNDLED for $515 @pharma_BI a Six-volume e-Series on #Cardiovascular #Diseases https://www.amazon.com/dp/B07MVF34ZC/ref=sr_1_1?s=digital-text #Genomics #Cancer #Metabolomics, #Immunology, #Infectious #Diseases #Patient #Voices #Precision #Medicine 4 Volumes https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari @AVIVA1950
On 1/16/2019
BUNDLED FOR $515 BY AMAZON.COM INTO A SIX-VOLUME SERIES
SERIES A: Cardiovascular Diseases
https://www.amazon.com/dp/B07MVF34ZC/ref=sr_1_1?s=digital-text
2019
- Koch Institute 2019 Immune Engineering Symposium, January 28-29, 2019, Kresge Auditorium, MIT
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
https://calendar.mit.edu/event/immune_engineering_symposium_2019#.XBrIDc9Kgcg
- World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
https://worldmedicalinnovation.org/agenda-list/
- Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
- 13th Annual US-India BioPharma & Healthcare Summit, May 9, 2019, Marriott, Cambridge
Agenda Pending
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
- 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, May 17, 2019, Harvard Law School
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
http://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference
2018
On 12/23/2018 and on 12/24/2019 we published two e-Books in Series A: Cardiovascular Diseases
Pharmacological Agents in Treatment of Cardiovascular Diseases (Series A: Cardiovascular Diseases Book 5) Kindle Edition
by Justin D. Pearlman (Author), Larry H. Bernstein (Author),
Aviva Lev-Ari (Author)
On Amazon.com since 12/23/2018
Pharmacological Agents in Treatment of Cardiovascular Diseases (Series A: Cardiovascular Diseases Book 5)
Dec 23, 2018 | Kindle eBook
by Justin D. Pearlman and Larry H. Bernstein
Subscribers read for free.
$115.00$ 115 00 to buyKindle Edition
Get it TODAY, Dec 25
Sold by: Amazon Digital Services LLC
On Amazon.com
https://www.amazon.com/dp/B07MGSFDWR
Electronic Table of Contents (eTOCs) for Volume 5 on LinkedIn
https://www.linkedin.com/pulse/pharmacological-agents-treatment-cardiovascular-book-aviva/
Detailed eTOCs
Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment (Series A: Cardiovascular Diseases Book 6) Kindle Edition
by Justin D. Pearlman (Author), Larry H. Bernstein (Author), Aviva Lev-Ari (Editor)
On Amazon.com since 12/24/2018
https://www.amazon.com/dp/B07MKHDBHF
Interventional Cardiology for Disease Diagnosis and Cardiac Surgery for Condition Treatment (Series A: Cardiovascular Diseases Book 6)
Dec 24, 2018 | Kindle eBook
by Justin D. Pearlman and Larry H. Bernstein
Subscribers read for free.
$100.00$ 100 00 to buyKindle Edition
Get it TODAY, Dec 25
Sold by: Amazon Digital Services LLC
Electronic Table of Contents (eTOCs) for Volume 6 on LinkedIn
https://www.linkedin.com/pulse/interventional-cardiology-disease-diagnosis-cardiac-lev-ari-phd-rn/
Detailed eTOCs
@@@@
The Future of Precision Cancer Medicine, Inaugural Symposium, MIT Center for Precision Cancer Medicine, December 13, 2018, 8AM-6PM, 50 Memorial Drive, Cambridge, MA
New LINK, 12/4/2018:
2019 Strategic Marketing of LPBI Group’s Intellectual Property: Strength & Markets
- LIVE eProceedings Day One – The 14th Annual Personalized Medicine Conference: PREPARING FOR THE NEW POSSIBLE, November 14, 2018, HMS, Boston
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
- LIVE eProceedings Day Two – The 14th Annual Personalized Medicine Conference: The Business of Personalization, November 15, 2018, HMS, Boston
Real Time Coverage: Aviva Lev-Ari, PhD, RN
- Tweets by @pharma_BI and @AVIVA1950 for The 14th Annual Personalized Medicine Conference: The Business of Personalization, November 15, 2018, HMS, Boston
Tweeter and Real Time Conference Press Coverage: Aviva Lev-Ari, PhD, RN
LIVE 2018 The 21st Gabay Award to LORENZ STUDER, Memorial Sloan Kettering Cancer Center, contributions in stem cell biology and patient-specific, cell-based therapy
REAL TIME Reporter: Aviva Lev-Ari, PhD, RN
Nomination for 2018 Yidan Prize, recognition in the field of MEDICAL education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN
The History, Uses, and Future of the Nobel Prize, 1:00pm – 6:00pm, Thursday, October 4, 2018, Harvard Medical School – Did not attend due to conflict
Reporter in Real Time: Aviva Lev-Ari, PhD, RN
New Posts in 2018
17th annual Summer Symposium: Breakthrough Cancer Nanotechnologies: Koch Institute, MIT Kresge Auditorium, June 15, 2018, 9AM-4PM
-
IDEAS for Partnership and Funding to Advance our Mission —>> LPBI Group for the following purposes:
1 Revitalize the Drug Discovery concepts for R&D in conjunction with Dr. Nir
2 back-funding the IP value created for enabling near future transfer of ownership to a
not-for-profit organization or an NGO: I.e.,
– Mass Academy of Sciences,
– Hadassah Medical Sciences Department, HUJI, Jerusalem
– Technion Medical School
– UC, Berkeley’s Genomics Institute
– UC, Berkeley’s Public Health Department or
– UCSF
– Stanford Medicine Institutes
3. Finding for-profit potential acquirers: I.e.,
– Wolfram Kruwel, owner of UpToDate,
– KKR, holding company of WebMD
– eScientific Publishers: John Wiley, Pearson or Internationals in Japan, Germany,
- SYNOPSIS – 17th annual Summer Symposium: Breakthrough Cancer Nanotechnologies: Koch Institute, MIT Kresge Auditorium, June 15, 2018, 9AM-4PM
- Original Tweets Re-Tweets and Likes by @pharma_BI and @AVIVA1950 at #kisymposium for 17th annual Summer Symposium: Breakthrough Cancer Nanotechnologies: Koch Institute, MIT Kresge Auditorium, June 15, 2018, 9AM-4PM
- Survival Calls during Careers in the Digital Age
https://pharmaceuticalintelligence.com/2018/06/13/survival-calls-during-careers-in-the-digital-age/
- Reactions to Original Tweets by @Pharma_BI and by @AVIVA1950 from #BIO2018
- Re-Tweets and Likes by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC
- Original Tweets by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC
- Thriving at the Survival Calls during Careers in the Digital Age – An AGE like Other, also known as, DIGITAL
- Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018
- Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76
- Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers
- Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83
- Professional Self Re-Invention: From Academia to Industry – Opportunities for PhDs in the Business Sector of the Economy
- Key Opinion Leader (KOL) in Pharmaceutical Business Intelligence – Aviva Lev-Ari, PhD, RN, as evidenced by
- Data Science is the Greatest Science! It is the Greatest Science for Women, as well
About the Open Access Online Scientific Journal pharmaceuticalintelligence.com
- e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point – Updated on 4/2/2018
List of BioTech Conferences in 2018
covered in REAL TIME by Aviva Lev-Ari, PhD, RN
2018 MassBio Annual Meeting March 21, 2017 8:00 AM – March 22, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA – Due to Snow Storm Warning I did not attend.
AI & Machine Learning in Clinical Trials, APRIL 12, 2018 PFIZER INNOVATION RESEARCH LAB – CAMBRIDGE, MA
2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts | Westin Copley Place
The Convergence of Medical Devices & Drugs: Advances in Drug Delivery May 3, 2018 12:00 PM – 5:00 PM, Westin Hotel, Waltham, MA
12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge
2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center
BIO 2018! June 4-7, 2018 at Boston Convention & Exhibition Center
17th annual Summer Symposium: Breakthrough Cancer Nanotechnologies: Koch Institute, MIT Kresge Auditorium, June 15, 2018, 9AM-4PM
CHI’s Discovery on Target, Sheraton Boston, Sept. 25-28, 2018
The 14th Annual Personalized Medicine Conference, November 13 – 15, 2018, Joseph B. Martin Conference Center, HARVARD MEDICAL SCHOOL, Boston
http://www.personalizedmedicinecoalition.org/Events
List of BioTech Conferences in 2013 – 2018
covered in REAL TIME by Aviva Lev-Ari, PhD, RN on Press Pass
| Year | # Conferences covered in Real Time | Conference Organizers |
| 2020 | ||
| 2019 | ||
| 2018 | 10 | MassBio, AI,ML&CL, MassBio-Devices&Drugs, WMIF-AI-Partners, US-India BioPharma, BioIT, BIO 2018!, Koch@MIT, , CHI-DiscoveryonTarget, PMC-HMS |
| 2017 | 12 | MassBio, WMIF-CVD-Partners, US-India BioPharma, BioIT, Koch@MIT, CHI-IO CHI OncoVirus IO, WarrenLecture-HMS, HubWeek, Koch@MIT, EmTech@MIT, PMC-HMS |
| 2016 | 8 | MassBio, WMIF-Cancer-Partners, US-IndiaBioPharma, CHI-IO, CHI-OncoVirus IO, CHI DiscoveryonTarget, EmTech @MIT, PMC-HMS |
| 2015 | 5 | PMWC-SiliconVallley, MassBio, BioIT, EmTech@MIT, PMC-HMS, |
| 2014 | 7 | SacksAssoc-NY, MassBio, BioIT Koch@MIT, SacksAssoc-Basel, Brandeis, PMC-HMS, |
| 2013 | 1 | BioIT |
- Tweets Impression Analytics, Re-Tweets, Tweets and Likes by @AVIVA1950 and @pharma_BI for 2018 BioIT, Boston, 5/15 – 5/17, 2018
- 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge
- Synopsis Day 1: 2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts | Westin Copley Place
- Synopsis Day 2: 2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts | Westin Copley Place
- Synopsis Day 3: 2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts | Westin Copley Place
- Synopsis for AI & Machine Learning in Clinical Trials, APRIL 12, 2018 PFIZER INNOVATION RESEARCH LAB – CAMBRIDGE, MA
- Tweets for AI and Machine Learning in Clinical Trials April 12th, 2018 hosted at Pfizer’s Innovation Research Lab in Cambridge, MA @AVIVA1950 @pharma_BI
3/31/2018
Aviva Lev-Ari, PhD, RN was nominated for the 2018 XXXXXX Prize for contributions to YYYYYYY Development
List of Conferences to be attended and covered in Real Time in 2018, includes the following Conferences:
- AI & Machine Learning in Clinical Trials, APRIL 12, 2018 PFIZER INNOVATION RESEARCH LAB – CAMBRIDGE, MA
- 2018 Annual World Medical Innovation Forum Artificial Intelligence April 23–25, 2018 Boston, Massachusetts | Westin Copley Place
- The Convergence of Medical Devices & Drugs: Advances in Drug Delivery May 3, 2018 12:00 PM – 5:00 PM, Westin Hotel, Waltham, MA
- 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge
- 2018 CHI’s BioIT World conference & Expo, May 15 – 17, 2018, Boston, MA – Seaport World Trade Center
- CHI’s Discovery on Target, Sheraton Boston, Sept. 25-28, 2018
- The 14th Annual Personalized Medicine Conference, November 13 – 15, 2018, Joseph B. Martin Conference Center, HARVARD MEDICAL SCHOOL, Boston
http://www.personalizedmedicinecoalition.org/Events
2017
12/30/2017
Volume Four: Medical 3D BioPrinting – The Revolution in Medicine, Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices
Editors: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Available on Kindle Store @ Amazon.com since 12/30/2017
https://www.amazon.com/dp/B078QVDV2W
List of Contributors
1.1, 1.2, 1.3, 1.4, 1.5, 1.7, 1.9, 2.3, 3.3, 3.10, 4.1, 4.2, 4.3, 4.8, 5.4, 7.1, 7.2, 7.3, 7.4, 7.5, 7.9, 7.10, 8.1, 8.2, 8.5, 9.1, 12.1, 12.2, 12.3, 12.8, 13.6
1.8, 1.14, 2.1, 2.2, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 2.10, 2.11, 3.1, 3.2, 3.4, 3.6, 3.7, 3.8, 3.9, 3.10, 4.10, 4.17, 5.2, 5.3, 6.3, 6.4, 6.5, 6.6, 6.11, 7.1, 7.6, 7.7, 8.2, 9.2, 9.3, 9.4, 9.6, 10.1, 10.2, 10.3, 11.4, 11.5, 12.5, 13.1, 13.4, 13.7
1.6, 1.12, 1.12.1, 1.12.2, 1.13.1, 1.15, 1.16, 4.4, 4.4.1, 4.5, 4.6, 4.9.1, 4.11, 4.12, 4.14, 4.14.1, 4.15, 4.16, 5.1, 5.5, 6.9, 6.12, 6.13, 7.8, 8.3, 8.4, 9.7, 9.8, 10.4, 12.1.1, 12.1.2, 12.4, 12.8.1, 12.8.2, 12.8.3, 12.9, 12.10, 13.3, 13.5
1.10, 6.1, 6.2, 6.7, 6.10, 12.7, 13.2
1.11, 4.7, 4.9, 6.8, 9.5, 10.5, 11.1, 11.6
1.13
3.5, 4.13
5.2, 9.3, 11.3
11.2
12.6
Gail S. Thornton, M.A., PhD(c)
4.18, 4.19
12/20/2017
LPBI Group Accomplishments 4/2012 – 12/2017 for Open Access Online Scientific Journal
http://pharmaceuticalintelligence.com
1,354,866 e-Readers
7,282 Scientific Comments
5,231 Scientific Articles,
610 Research Categories in Medicine and Life Sciences
9,719 Tags
2,284 Subscribers
Accomplishments 4/2012 – 12/2017 for BioMed e-Series
electronic Table of Contents (eTOCs) of each Volume in the SIXTEEN Volume BioMed e-Series
https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/
WE ARE ON AMAZON.COM
https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
http://www.amazon.com/dp/B071VQ6YYK
https://www.amazon.com/dp/B075CXHY1B
https://www.amazon.com/dp/B076HGB6MZ
https://www.amazon.com/dp/B078313281
11/17/2017
- Tweets by @pharma_BI and @AVIVA1950 for #PMConf at The 13th Annual Personalized Medicine Conference, From Concept to the Clinic, November 14–16, 2017, Joseph B. Martin Conference Center, Harvard Medical School
- Day 1 – 13th Annual Personalized Medicine Conference, From Concept to the Clinic, November 14–16, 2017
- Day 2 – 13th Annual Personalized Medicine Conference, From Concept to the Clinic, November 14–16, 2017
11/9/2017
Mr. Sweeney,
Thank you for having me as MEDIA on this OUTSTANDING event – 2017 EmTechMIT
- LIVE Day Two and Day One – 17th Annual EmTech @ Media Lab, MIT – November 7 – 8, 2017, Cambridge, MA – This Year’s Themes, Speakers and Agenda
- All my Tweets for 11/7 and 11/8 at @AVIVA1950
- #EmTechMIT – only some are featured , not all – Why?
- All my Tweets for 11/7 and 11/8 at @pharma_BI
Kind regards,
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
e-Mail: avivalev-ari@alum.berkeley.edu
https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN
SkypeID: HarpPlayer83 LinkedIn Profile Twitter Profile
10/24/2017
Koch Institute Immune Engineering Symposium on October 16 & 17, 2017, Kresge, MIT
LIVE HubWeek – Harvard, MIT, MGH, Boston multiple locations, 10/10 – 10/15, 2017
Lectures by The 2017 Award Recipients of Warren Alpert Foundation Prize in Cancer Immunology, October 5, 2017, HMS, 77 Louis Paster, Boston
10/16/2017
Series E: Patient-centered Medicine
Content Consultant: Larry H Bernstein, MD, FCAP
Volume 1: The VOICES of Patients, Hospitals CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures
Author, Curator and Editor: Larry H Bernstein, MD, FCAP and Gail Thornston, PhD(c)
On Amazon.com since 10/16/2017
https://www.amazon.com/dp/B076HGB6MZ
9/8/2017
List of LIVE Press Coverage of BioTech Conferences in 2017
The 13th Annual Personalized Medicine Conference, NOVEMBER 14 – 16, 2017, Joseph B. Martin Conference Center, HARVARD MEDICAL SCHOOL, Boston
17th Annual EmTech @ Media Lab, MIT – November 7 – 8, 2017, Cambridge, MA – This Year’s Themes, Speakers and Agenda
Koch Institute Immune Engineering Symposium on October 16 & 17, 2017, Kresge, MIT
Lectures by The 2017 Award Recipients of Warren Alpert Foundation Prize in Cancer Immunology, October 5, 2017, HMS, 77 Louis Paster, Boston
CHI’s Oncolytic Virus Immunotherapy and ADOPTIVE CELL THERAPY, August 28-29, 2017 Sheraton Boston Hotel | Boston, MA
CHI’s 5th Immune Oncology Summit – CHI’s 4th Oncolytic Virus Immunotherapy, August 28-29, 2017 Sheraton Boston Hotel | Boston, MA
16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 2017, 9AM – 5PM, Kresge Auditorium, MIT
BioInformatics: Track 6: BioIT World Conference & Expo ’17, May 23-25, 2017, Seaport World Trade Center, Boston, MA – On an Unplanned Overseas Trip
11th US-India BioPharma & Healthcare Summit, Thursday, May 18, 2017, Boston Marriott Cambridge, 50 Broadway, Cambridge
2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston
2017 MassBio Annual Meeting March 30, 2017 8:00 AM – March 31, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA
9/6/2017
MON, September 4, 2017 we published on Amazon.com
The Immune System, Stress Signaling, Infectious Diseases and Therapeutic Implications: VOLUME 2: Infectious Diseases and Therapeutics and VOLUME 3: The Immune System and Therapeutics (Series D: BioMedicine & Immunology) Kindle Edition
by Larry H. Bernstein (Author), Aviva Lev-Ari (Author), Stephen J. Williams (Author), Demet Sag (Author), Irina Robu (Author), Tilda Barliya (Author), David Orchard-Webb (Author), Alan F. Kaul (Author), Danut Dragoi (Author), Sudipta Saha (Editor)
https://www.amazon.com/dp/B075CXHY1B
MON, June 2017 – Aviva presented to Number 1 in the Scientific Publishing Corporation
Resources used included the following:
5/18/2017
OUR NEW CANCER e-Book on Amazon.com
Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2) – Kindle edition, on Amazon since 5/18/2017
Our 9th e-Book on CANCER, 2800 pages – is LIVE on Amazon.com – first day, 5/18/2017
https://www.amazon.com/dp/B071VQ6YYK
See all ours other 8 e-Books in Medicine on Amazon.com
WE ARE ON AMAZON.COM
5/5/2017
-
World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA
(a) Real Time Highlights and Tweets: Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA
(b) e-Proceedings for Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA
(c) Tweets by @pharma_BI and @AVIVA1950 at World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA
4/1/2017
e-Books in Medicine
- Larry Mulligan, PhD has joined LPBI Group as Co-Editor for Series A, Volume 5 [may be Volume 6??]
- Dr. Justin Pearlman, MD, PhD is working as Editor for a FOUR Volume Hard Copy Series in Cardiology
- Gail Thornton, MSc, PhD(c), Co-Editor for Series E, Volume 1 – is bringing to completion this volume
- Marzan Khan, BSc, Research Associate and Translator for Series E, Volume 2 – is in midst of volume Format conversion [may be Series e, Volume 4??]
- Tilda Barlyia, PhD, Senior Editor of Series C, Cancer, Volume 2 – completed proof reading the entire 3,000 page Volume following Format conversion by Kelly Perlman. This volume is scheduled for upload to Amazon.com on the first week in April 2017.
- Seeking Co-Editor for Genomics, Volume Two
- Series D: Biomedicine:
VOLUME 1,
- Metabolic Genomics and Pharmaceutics, on Amazon since 7/21/2015
http://www.amazon.com/dp/B012BB0ZF0
VOLUME 2,
- Infectious Diseases and Therapeutics
Author, Curator and Editor: Sudipta Saha, PhD
VOLUME 3,
- The Immune System and Therapeutics
Author, Curator and Editor: Larry H Bernstein, MD, FCAP
3/13/2017
List of BioTech Conferences we cover in Real Time in 2017
The 13th Annual Personalized Medicine Conference, NOVEMBER 14 – 16, 2017, Joseph B. Martin Conference Center, HARVARD MEDICAL SCHOOL, Boston
16th Annual Cancer Research Symposium, Koch Institute, Friday, June 16, 2017, 9AM – 5PM, Kresge Auditorium, MIT
BioInformatics: Track 6: BioIT World Conference & Expo ’17, May 23-25, 2017, Seaport World Trade Center, Boston, MA
2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston
2017 MassBio Annual Meeting March 30, 2017 8:00 AM – March 31, 2017 4:00 PM, Royal Sonesta Boston, Cambridge MA
1/23/2017
e-Books in Medicine
- Larry Mulligan, PhD has joined LPBI Group as Co-Editor for Series A, Volume 5 [may be Volume 6??]
- Dr. Justin Pearlman, MD, PhD is working as Editor for a FOUR Volume Hard Copy Series in Cardiology
- Gail Thornton, MSc, PhD(c), Co-Editor for Series E, Volume 1 – is bringing to completion this volume
- Marzan Khan, BSc, Research Associate and Translator for Series E, Volume 2 – is in midst of volume Format conversion [may be Series e, Volume 4??]
- Tilda Barlyia, PhD, Senior Editor of Series C, Cancer, Volume 2 – is proof reading the entire 3,000 page Volume following Format conversion by Kelly Perlman
- Seeking Co-Editor for Genomics Volume 2
DrugDiscovery & DrugDelivery @LPBI Group
- Our Team – DrugDiscovery @LPBI Group, is developing a new Mechanism of Action for Panceatic Cancer and Several other Cancers honing hybrid exosome-lysosome technology for an Oncolytic Viral Therapeutics solution
Aviva Lev-Ari, PhD, RN
https://pharmaceuticalintelligence.com/contributors-biographies/aviva-lev-ari/
Dr. Raphael Nir – Drug Discovery: Expertise in Cancer
Dr. David Orchard-Webb – Drug Discovery: Expertise in Pancreatic Cancer
Dr. Irina Robu – Drug Delivery – Expertise in Nanotechnology, Polymers, Hybridization: Liposome, Exosome, Lysosome
Dr. Aashir Awan – Drug Discovery: Expertise in Salivary Adenoid Cystic Carcinoma and cilia: motile cilia and nonmotile, or primary cilia, which typically serve as sensory organelles, In vivo and In vitro wet lab studies
Dr. Tilda Barlyia – Scientific Consultant to Aviva and to Our Team: DrugDiscovery @LPBI Group
Expertise in Molecular Biology, Cancer, Nanotechnology, Ophthalmology
Ms. Marzan Khan – Lab Biochemistry and Physics
Funding Early Stage Start Ups
a. We will continue to develop the concepts of mutual interest between
- A company on the West Coast
- Dr. Nir of ABI-LAB, SBH Sciences, Inc., SBH Diagnostics, Inc.
and
- Our Team – DrugDiscovery @LPBI Group:
b. Aviva, Alpha Senzsor, Inc. and an Investor are exploring two industries in France
c. Aviva and WJ, an Investor are exploring opportunities in the US, UK
d. Aviva and Arie Berger and Maggie You are exploring opportunities in China
1/7/2017
OPPORTUNITIES for Business Development EXEC – BioTech, Medical Devices, Publishing – CONTACT: avivalev-ari@alum.berkeley.edu
— BD to Sell the e-Scientific Journal to a European or Japanese Scientific Publisher
— BD to Sell the BioMed e-Series of 15 e-Books in Medicine to a European or Japanese Scientific Publisher
— BD to Sell the Methodology to a European or Japanese International Biotech Conference Organizer.
— BD to develop markets for several US Patent Holder for Licensing and Commercialize the technologies: Biologics and Medical Devices Patents
— BD to develop a Market for an e-Book on 3D BioPrinting
— BD to PROSPECT for FUNDING or M&A with existing Biotech in Biologics: Drug Discovery
— BD to develop FUNDING for 13 Ventures in Early Stage Biotech Start Ups: MEDICAL DEVICES & Biologics
2016
12/26/2016
Year End 2016 Statement on Yearly Progress by LPBI Group
Curator: Aviva Lev-Ari, PhD, RN
LPBI Group has Three Enterprise Types and Five Subsidiaries as described, below.
Image Source: Google Images
We are in Knowledge-based Informational Services
Line-of-Business #1:
Open Access OnLine Scientific Journal
- 1,121,301 e-Readers, Site Statistics on 12/26/2016
June 19, 2016 – We Celebrate reaching over One Million e-Readers @PharmaceuticalIntelligence.com
Editor-in-Chief: Aviva Lev-Ari, PhD, RN
- 5,005 Scientific Articles, Site Statistics on 12/26/2016
We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!
Curator and Open Access Journal Editor-in-Chief: Aviva Lev-Ari, PhD, RN
Curator: Aviva Lev-Ari, PhD, RN
- 7,267 Comments by Scientists, Site Statistics on 12/26/2016
- 2,183 Subscribers, Site Statistics on 12/26/2016
Line-of-Business #2:
BioMed e-Series, Five Series in Medicine, 8 e-Books on Amazon.com, 7 e-Books in 2017
Editor-in-Chief, Aviva Lev-Ari, PhD, RN
Line-of-Business #3:
Real Time Press Coverage of BioTech Global Premier Conferences, Portfolio of ~30 events
Curator: Aviva Lev-Ari, PhD, RN
Line-of-Business #4: No Progress in 2016
Audio-Podcast Series in Medicine, 5 tracks
&
-
Subsidiary 4: Intellectual Property Asset Management
Line-of-Business #5: New Patents issued to Bill Zurn
Representation of US Patent Holders for Commercialization, Licensing and Partnerships
We are in Research Biotech Businesses
-
Subsidiary 3: R&D in 3D BioPrinting
Line-of-Business #6:
Tissue Engineering, Gene Therapy: Stem Cells & Gene Editing, Medical Devices: Product Concepts
Curator: Aviva Lev-Ari, PhD, RN
Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices
&
-
Subsidiary 5: Pharmaceutical R&D: Drug Discovery and Drug-Devices Development
Line-of-Business #7:
Team developing new mechanism of action for Therapeutics and Diagnostics for Early Detection of Pancreatic Cancer
Line-of-Business #8:
Team developing solutions with Nanoparticles and with Exosomes
We are in Business Financial Transactions (No Securities Traded)
-
Subsidiary 2: Funding Early Stage Businesses, IP Licensing and Business Partnerships:
Line-of-Business #9:
MEDICAL DEVICES
Pharmaceutical Informational PLATFORMS
INVENTIONS IN BIOLOGICS
Representation of 13 ventures for the purpose of prospecting for funding. Seeking business partner to developing FUNDING of the following Ventures, if interested to further explore jointly, please e-mail me:
avivalev-ari@alum.berkeley.edu
-
LPBI Group’s Portfolio of Clients include the following:
- Woodland Pharmaceutical
https://gust.com/companies/woodland_pharmaceuticals
- BioTerm Pharmaceuticals
- Akshaya Bio Inc. – Portfolio of 28 Patents in vaccine – viral infection
- com
http://www.valvecure.com/Home.html
- Alpha Sensors, Inc.
- AlphaIP, Inc.
- SBH Sciences, Inc
- Telerescue
- New Medicine, Inc.
- LPBI Group – Aviva Lev-Ari, PhD, RN – Founder
10a. DrugDiscovery @LPBI Group – Aviva Lev-Ari, PhD, RN – Co–Founder and Raphael Nir, PhD – Co–Founder
https://pharmaceuticalintelligence.com/drugdiscovery-lpbi-group/
- Portfolio of Patents of S.Y. in Anti-Inflammatory, A Macro Molecule of a Multifunctional NSAID – Portfolio of 13 US Patents
- Portfolio of Patents under management of Y. M.
- Vyriad – Oncolytic Virotherapy for the Treatment of Cancer
Vyriad – http://www.vyriad.com/
12/19/2016
We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!
12/15/2016
Super RECORD of REAL TIME Coverage of Biotech and Medicine Conferences by LPBI Group in 2016
Curator: Aviva Lev-Ari, PhD, RN
2017 World Medical Innovation Forum: Cardiovascular, May 1-3, 2017, Partners HealthCare, Boston, at the Westin Hotel, Boston
Reporter: Aviva Lev-Ari, PhD, RN
ANNOUNCEMENT
Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover the event in REAL TIME
Aviva Lev-Ari, PhD, RN will be streaming live from the floor of the Westin Hotel in Boston on May 1-3, 2017
9/22/2016
Updated Business Synopsis
In 4/2012, Aviva Lev-Ari, PhD, RN has launched LPBI Group. She is an Executive-Entrepreneur with high energy and passion. Followed by 6200 Biotech professionals on LinkedIn, Group Manager of three Groups on LinkedIn in (1) Pharmaceutical Intelligence, (2) Cardiovascular Disease and (3) Innovations in Israel. Her business acumen is at the intersection of (a) electronic Scientific Media, (b) Drug Discovery and (c) Venture Funding.
LPBI Group is an early stage start up in three domains:
(1) Knowledge-based Informational Services
Open Access OnLine Scientific Journal The Site Statistics on 9/14/2016: (1,053,618 e-Readers, 2,142 Subscribers, 4,892 Scientific Articles, ~8000 Comments by Scientists)
BioMed e-Series, Five Series in Medicine, 8 e-Books on Amazon.com, 4 e-Books in 2016 and 3 e-Books in 2017
Real Time Press Coverage of BioTech Global Premier Conferences, Portfolio of ~30 events have been covered in the last 3 years. In 2016, Dr. Lev-Ari has launched an
Audio-Podcast Series in Medicine, 5 tracks.
Representation of US Patent Holders for Commercialization, Licensing and Partnerships
(2) Dr. Lev-Ari guides a Team of Scientists in Drug Discovery & Drug Delivery Research
- Drug Discovery with 3D BioPrinting
- Drug Delivery System – One solution for many agents for many indications
(3) As a Key Opinion Leader (KOL) Dr. Lev-Ari and her Team are involved in Business Financial Transactions (No Securities Traded)
· Funding Early Stage Ventures and Businesses, IP Licensing and Business Partnerships for MEDICAL DEVICES, Pharmaceutical Informational PLATFORMS and INVENTIONS IN BIOLOGICS.
9/1/2016
- Oncolytic Virus Immunotherapy Unlocking Oncolytic Virotherapies: From Science to Commercialization CHI’S 4TH ANNUAL IMMUNO-ONCOLOGY SUMMIT – AUGUST 29-30, 2016 | Marriott Long Wharf Hotel – Boston, MAhttps://pharmaceuticalintelligence.com/2016/07/15/agenda-for-oncolytic-virus-immunotherapy-unlocking-oncolytic-virotherapies-from-science-to-commercialization-chis-4th-annual-immuno-oncology-summit-august-29-30-2016-marriott-lo/
Real Time Coverage and eProceedings of Presentations on August 29 and August 30, 2016 CHI’s 4th IMMUNO-ONCOLOGY SUMMIT – Oncolytic Virus Immunotherapy Track
LIVE Tweets via @pharma_BI and by @AVIVA1950 for August 29 and August 30, 2016 of CHI’s 4th IMMUNO-ONCOLOGY SUMMIT – Oncolytic Virus Immunotherapy Track, Marriott Long Wharf Hotel – Boston
7/14/2016
ANNOUNCEMENT
Leaders in Pharmaceutical Business intelligence will cover in Real Time using Social Media
The CHI’S 4TH ANNUAL IMMUNO-ONCOLOGY SUMMIT – Personalized Immunotherapy
Personalized Oncology in the Genomic Era: Expanding the Druggable Space
http://www.immuno-oncologysummit.com/
Aviva Lev-Ari, PhD, RN
will be streaming LIVE from the Marriott Long Wharf Hotel in Boston, MA
6/8/2016
- We added a Potential Scientific Partner to DrugDiscovery @LPBI Group
- We added a New Candiddate for Funding Biologics Translational Research @LPBI Group
- Akshaya Bio, Inc.: Chimigen® Technology – Rajan George, PhD, President and CSO
Re-educating Immune System to Fight Diseases
- Unique technology platform
- Improved antigen presentation
- – “Mimics Body’s Own Natural Immune Response Process”
- – No adjuvant, avoids adverse reactions
- Rich product pipeline
– HBV, HCV, HIV, Cancer, Malaria, Biodefense, Influenza, TB, Ebola
6/2/2016
Electronic Proceedings for 10th US-India BioPharma & Healthcare Summit, June 2, 2016, Marriott Cambridge, MA
Curator: Aviva Lev-Ari, PhD, RN
LIVE Tweets via @pharma_BI and by @AVIVA1950 for 10th US-India BioPharma & Healthcare Summit, June 2, 2016, Marriott Cambridge, MA
Curator: Aviva Lev-Ari, PhD, RN
5/24/2017
10th US-India BioPharma & Healthcare Summit, Thursday, June 2, 2016, Marriott Cambridge, MA
5/17/2016
LPBI Group will cover in Real Time The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA
5/17/2016
We have progress made
1. We diversified – now we handle 9 types of businesses
https://pharmaceuticalintelligence.com/drugdiscovery-lpbi-group/
2. We are Co-Partnering with CHI, the largest Life Sciences Conferences organizers in the US on the following event:
3. Commercialization of US Patents
- I was awarded representation from YISSUM, HUJI’s Technology Transfer Office, Prof. Saul Yedgar’s –13 US patents
- I will represent 26 +2 Patents in Immunology by Dr. R. George
- I continue with new sources for funding for Early stage.
4. We branched into Drug Discovery
https://pharmaceuticalintelligence.com/drugdiscovery-lpbi-group/
5. We published EIGHT e-Books in Medicine on Amazon.com
WE ARE ON AMAZON.COM
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
6. We are working on an e-Book on 3D BioPrinting
7. We are working on an e-Book on Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology (Work-in-Progress)
8. We are working on an e-Book on The VOICES of Patients, HealthCare Providers, Care Givers and Families: Personal Experience with Critical Care and Invasive Medical Procedures (Work-in-Progress)
4/28/2016
we plan to attend
From: “W. Eric L. Grimson PhD ’80, MIT Chancellor for Academic Advancement” <techbfast@mit.edu>
Date: Thursday, April 28, 2016 at 10:52 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Technology Breakfast, June 2
Dear Aviva,
Please join me on Thursday, June 2, for our next Technology Breakfast. It will be held in the new Samberg Conference Center in the Morris and Sophie Chang Building (E52). The MIT Technology Breakfast series brings together alumni, faculty, and friends to hear distinguished members of the MIT community speak on topics at the forefront of today’s technology.
Our featured company will be Luminoso. Founded in 2010 and headquartered in Cambridge, Massachusetts, Luminoso is an artificial intelligence-based software company that applies natural language processing and machine learning technologies to data analytics. Cofounder and chief executive officer Catherine Havasi ’03, MNG ’04 and cofounder and chief technology officer Jason Alonso ’04, SM ’08 will join us.
Coffee and buffet breakfast will be available at 7:00 am. The program will begin at 8:00 am and conclude at 9:00 am. Upon request, parking will be reserved for you at the MIT Hayward Lot. To confirm your attendance, please respond by Thursday, May 26, via reply e-mail. If you have questions, feel free to contact Brenda Richard at 617.253.0022 or brendar@mit.edu.
I look forward to seeing you on June 2.
Sincerely,
W. Eric L. Grimson
Chancellor for Academic Advancement
————————————————–
EVENT DETAILS
MIT Technology Breakfast
Thursday, June 2, 2016
Samberg Conference Center, 7th floor
The Morris and Sophie Chang Building (E52)
50 Memorial Drive
Cambridge, Massachusetts
7:00 am Coffee and buffet breakfast available
8:00 am Program begins
9:00 am Program concludes
Please respond by May 26 and include your NAME, TITLE, and COMPANY as you would like this information to appear on your name badge and in the program brochure.
Kindly indicate whether you will require parking.
For the location of the MIT Samberg Conference Center, please refer to: http://whereis.mit.edu/?go=E52
For the location of the MIT Hayward Lot, please refer to: http://whereis.mit.edu/map-jpg?selection=P5&Parking=go
————————————————–
About Catherine Havasi and Jason Alonso
Catherine Havasi is a cofounder and the chief executive officer of Luminoso. Luminoso is based on nearly a decade of research at the MIT Media Lab on how natural language processing and machine learning could be applied to text analytics. Havasi also directs the Open Mind Common Sense Project, one of the largest common sense knowledge bases in the world, which she cofounded with Marvin Minsky and Push Singh in 1999. She earned an SB and an SM in electrical engineering and computer science from MIT, and a PhD in computer science from Brandeis University.
Jason Alonso is a cofounder and the chief technology officer of Luminoso. He joined the Open Mind Common Sense Project in 2006. In 2007, he cofounded and was the first CFO of Learning Unlimited, an education nonprofit with roots in the MIT Educational Studies Program. Alonso earned an SB in electrical engineering and computer science and an SM in media arts and sciences from MIT.
4/12/2016
- Announcing David Orchard-Webb, PhD joined LPBI Group as Expert, Author, Writer with expertise in Cancer Biology and “DrugDiscovery @LPBI Group” as Scientist II working on Anti-Cancer Drug Discovery: TCRL
- CHI proposal to co-Partner the CRISPR Conference in Boston,September 19-22,2016
4/5/2016
- Agreement with Yissum regarding 13 Patents of SY is on its way
- Mr. A.D. of Los Angeles will meet with Zur Technologies, CEO and with BioTerm Pharmaceutical regarding Funding Opportunities
4/4/2016
“DrugDiscovery @LPBI Group” is a Start Up in Health/Life Sciences in MA
VISIT our Web site
http://pharmaceuticalintelligence.com/drugdiscovery-lpbi-group/
The Team
Team Profile: DrugDiscovery @LPBI Group – A BioTech Start Up submitted for Funding Competition to MassChallenge Boston 2016 Accelerator
We are Applicants for MassChallenge Boston 2016 Accelerator
https://accelerate.masschallenge.org/startup/11021/team/
4/3/2016
- Announcing Contributing Editor and Author
Gail S. Thornton, PhD(c)
Series E Volume One – Sourcer for Patient Accounting on Voicing Post Invasive Interventions
4/3/2016
- I will announce Replacement to Adam Sonnenberg for the role of:
Research Associate on BioMed e-Series
– Content Digitization, e-Format Conversion and Complex Proof Reading
Debashree Chakrabarti, MSc (5/2016), Research Associate for Enterprise Technologies: E-Scientific Publishing and Drug Discovery
4/3/2016
From: MassChallenge <contact@masschallenge.org>
Reply-To: <contact@masschallenge.org>
Date: Saturday, April 2, 2016 at 3:17 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: MC Update – Applications Close
Click to Browse the 2016 Startup Applicants
We are DrugDiscovery@LPBI Group – Boston 2016 – Health/Life Sciences
– Three Indications:
- Diabetes – A Combination Drug Therapy to induce Insulin Production by Pancreatic Beta Cells (PPAR-gamma, Leptin, ..)
- Inflammatory Disorders: Inflammatory Bowel Diseases (IBD) – Crohn’s and Ulcerative Colitis (UC) and Others
- Anti-Cancer Drug Discovery @ LPBI Group’s Research Biotech Businesses
3/28/2016
From: MassChallenge <apply@masschallenge.org>
Date: Monday, March 28, 2016 at 1:11 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: MassChallenge <apply@masschallenge.org>
Subject: Your MassChallenge 2016 Jun-Oct Program Cycle Application for DrugDiscovery@LPBI Group has been Submitted
Hi Aviva,
Thank you for submitting your application for MassChallenge Boston 2016 Accelerator for your startup, DrugDiscovery@LPBI Group. It has been received and will be reviewed by MassChallenge judges.
Best,
The MassChallenge Team
3/24/2016
You Need a New Professional Opportunity or a Business to Manage? an Affiliation? a Bigger Challenge?
- we have a ROLE for you
——>>>>>> This is a PREP for Your 2016 Professional Renewal
Author: Aviva Lev-Ari, PhD, RN
3/23/2016
From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>
Date: Wednesday, March 23, 2016 at 1:56 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: Please run for me this to your LISTSERVE – I can promote any event of yours in reciprocity
Aviva,
I have posted your job ad on www.kdnuggets.com/news
and www.kdnuggets.com/jobs pages.
Please check
Will also share it on KDnuggets Twitter, Facebook page, LinkedIn group, Google+, and RSS , and include it in the next issue (Mar 30) of KDnuggets News email newsletter.
Gregory Piatetsky
President, KDnuggets
3/17/2016
BILL ZURN
Cardiovascular Medical Devices Inventor:
William Harrison Zurn
UPDATED on 3/17/2016
Bill Zurn is Founder and Chairman of the Board “Vascular Devices” – LLC, a start-up company chartered to develop his patented, untethered human vessel catheter.
This catheter is the world’s first untethered catheter, a fifth generation device that produces a burst of laser energy to vaporize vessel blockages.
3/2/2016
GDE Enterprises changed name to LPBI Group
2/25/2016
Published on 2/25/2016:
- PROTOCOL for GDE’s Recruiting Strategy for R&D Scientists I,II,III and R&D Project Managers for Drug Discovery: Three Indications Considered
- PROTOCOL for Drug Screening of 3rd Party Intellectual Property Presented for Funding Representation
2/23/2016
- Discussed R&D in Anti-Cancer Drug development with TB & ZR on 2/13/2016
- Discussed R&D in Anti-Cancer Drug development with DOW & RT on 2/24/2016
- Nominated Dr. Larry H. Bernstein to PMC 2016 Award on 2/18/2016
- Touched basis with our Financial Placement Agency in NYC 2/19/2016
- Secured Alpha Szenszors, Inc. Presentation for our Financial Placement Agency in NYC on 2/22/2016
- In Discussions with a Medical Devices BD
- Invited Dr. Singer for 2 days in Boston for training on Demos of BioMed Series to Dean’s of Medical Schools
- Dr. Cohn’s Paper awaits posting in the Journal
- Mr. Zurn’s Presentation, 2/18 awaits Aviva’s editing, posting in the Journal and placement in Series E, Volume 4.
- Dr. Codrington will pursue her own venture, EAW’s Status changed to Inactive, 2/19
- Dr. Cohn – on leave of absence, EAW’s Status changed to Inactive, 2/19
2/18/2016
Aviva nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine
Letter of nomination for 12th Annual Award for Leadership in Personalized Medicine
Larry H. Bernstein, MD , FCAP
Dr. Bernstein had advanced the Personalized Medicine Paradigm in a pursuit of over 40 years of a career in Medicine.
In his own words:
My Life in Medicine: Larry H. Bernstein, M.D.
www.linkedin.com/pub/larry-h-bernstein/a/599/50
I retired from a five year position as Chief of the Division of Clinical Pathology (Laboratory Medicine) at New York Methodist Hospital-Weill Cornell Affiliate, Park Slope, Brooklyn in 2008 followed by an interim consultancy at Norwalk Hospital in 2010. I then became engaged with a medical informatics project called “Second Opinion” with Gil David and Ronald Coifman, Emeritus Professor and Chairman of the Department of Mathematics in the Program in Applied Mathematics at Yale. I went to Prof. Coifman with a large database of 30,000 hemograms that are the most commonly ordered test in medicine because of the elucidation of red cell, white cell and platelet populations in the blood. The problem boiled down to a level of noise that exists in such data, and developing a primary evidence-based classification that technology did not support until the first decade of the 21stcentury. READ MORE
http://pharmaceuticalintelligence.com/contributors-biographies/members-of-the-board/larry-bernstein/
In my own words:
The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS
Curator: Aviva Lev-Ari, PhD, RN
Of all the readings and reviews I completed to date, my appreciation got bonded to two Science and Medicine writers:
- a Young Surgeon, Atul Gawande, MD, MPH
and
- a Retired Pathologist, Pathophysiologist, Histologist, Bacteriologist, Chemical Geneticist, BioChemist, Enzymologist, Molecular Biologist, Mathematical Statistician and more, Larry H Bernstein, MD, FCAP
I am inviting the e-Readers to join me on a language immersion during a LITERARY TOUR in Science, Medicine and HealthCare Policy.
- Dr. Bernstein has expressed his views on Personalized Medicine in a series of articles on Predicted Cost of Care and the Affordable Care Act, Impact of 2013 HealthCare Reform in the US & Patient Protection and Affordable Care Act
- His views of advocacy for Personalized Medicine are expressed in EIGHT Books and another two in the Printing Process for 2016 publication, as follows:
2013 e-Book on Amazon.com
- Perspectives on Nitric Oxide in Disease Mechanisms, on Amazon since 6/2/12013
http://www.amazon.com/dp/B00DINFFYC
2015 e-Book on Amazon.com
- Metabolic Genomics and Pharmaceutics, on Amazon since 7/21/2015
http://www.amazon.com/dp/B012BB0ZF0
- Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015
http://www.amazon.com/dp/B013RVYR2K
- Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015
http://www.amazon.com/dp/B018DHBUO6
- Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics, on Amazon.com since 12/27/2015
http://www.amazon.com/dp/B019VH97LU
- Cardiovascular, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation, on Amazon since 11/30/2015
http://www.amazon.com/dp/B018Q5MCN8
- Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics, on Amazon since 11/29/2015
http://www.amazon.com/dp/B018PNHJ84
- Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases, on Amazon since 12/26/2015
http://www.amazon.com/dp/B019UM909A
Completed Volumes in PRINTING Process for 2016 Publication
Series C: e-Books on Cancer & Oncology
Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery
Authors, Curators and Editors:
Larry H Bernstein, MD, FCAP and Stephen J Williams, PhD
2016
Series E: Patient-Centered Medicine
Volume 2: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders
Author, Curator and Editor: Larry H Bernstein, MD, FCAP
2016
Nominator for the 12th Annual Award for Leadership in Personalized Medicine:
Aviva Lev-Ari, PhD, RN
Director & Founder
Leaders in Pharmaceutical Business Intelligence, Boston
Editor-in-Chief
http://pharmaceuticalintelligence.com
Co-Founder, GDE Enterprises,
Boston, USA and Lausanne, Switzerland
e-Mail: avivalev-ari@alum.berkeley.edu
SkypeID: HarpPlayer83
2/8/2016
Submission for Category: Book
Nomination of e-Book, Series A: Cardiovascular Diseases, Volume 2, Cases in Development of Scientific Curation Methodology
2016 Communication Awards Nomination Form Result #9143807
The National Academies of Sciences, Engineering, and Medicine
2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering
Nomination Confirmation
Thank you for submitting a nomination for the 2016 National Academies Communication Awards. Below please find the supporting materials necessary for your nomination category, as well as the address to which they should be sent.
|
Please select the category of your nomination: * |
Book |
|
Book Title: * |
Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation |
|
Publisher(s): * |
Amazon Kindle Direct |
|
Publication Date: (Please select one): * |
November 2015 |
|
Book Entry Summary (Please limit to 100 words): * |
The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology. |
|
Are you nominating an individual or team (up to four individuals)? * |
Team |
|
Is this a self- or third-party nomination? * |
Third-Party Nomination: I am nominating someone other than myself. |
|
First Name * |
Larry H |
|
Last Name * |
Bernstein, MD, FCAP |
|
Title * |
Chief Scientific Officer |
|
Organization * |
Leaders in Pharmaceutical Business Intelligence |
|
Street Address |
54 FIRETHORN LANE |
|
City |
NORTHAMPTON |
|
State |
MA |
|
Postal Code |
01060 |
|
Country |
USA |
|
E-Mail Address * |
|
|
Phone Number * |
|
|
URL |
|
|
First Name |
AVIVA |
|
Last Name |
Lev-Ari, PhD, RN |
|
Organization |
Leaders in Pharmaceutical Business Intelligence |
|
E-Mail Address |
|
|
First Name |
Justin D. |
|
Last Name |
Pearlman, MD, PhD, FACC |
|
Organization |
Leaders in Pharmaceutical Business Intelligence |
|
E-Mail Address |
|
|
First Name * |
Stephen J. |
|
Last Name * |
Williams, PhD |
|
Title * |
Editor |
|
Organization * |
Leaders in Pharmaceutical Business Intelligence |
|
Street Address |
7373 Ridge Avenue |
|
Apt/Suite/Office |
116 |
|
City |
Philadelphia |
|
State |
PA |
|
Postal Code |
19128 |
|
Country |
USA |
|
E-Mail Address * |
|
|
Phone Number * |
|
|
URL |
2/2/2016
Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Science, Engineering, and Medicine, Keck Futures Initiative
Editor-in-Chief: Aviva Lev-Ari, PhD, RN
- LPBI’s BioMed e-Series, 15 e-Books Titles in Medicine and Life Sciences on Amazon.com
- LPBI’s Open Access Online Scientific Journal, http://pharmaceuticalintelligence.com
- LBPI’s BioMed e-Series Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation as an ezample of the innovative methodology of curation in Medicine and Science
1/27/2016
#1 Launching LPBI’s, Fourth Line of Business D.
FIVE Podcast – Audio Series in BioMed in the following Domains of Medicine and Life Sciences:
- Series #1: Dr. S. Saha – Reproductive Genomics
A Podcast – Audio Series on Reproductive Genomics, Male infertility and Research Breakthroughs in Female Genomic Endocrinology
- Series #2: Dr. SJ Williams – Genomics & Gene Therapy
A Podcast – Audio Series on Gene Editing and 3D BioPrinting
- Series #3: Dr. SJ Williams – Genomics & Cancer
A Podcast – Audio Series on Immune-Oncology Molecules in Development
- Series #4: Dr. A. Lev-Ari – the ART of e-Scientific Curation of Scientific Findings
A Podcast – Audio Series on CONTENT CREATION for Scientific Digital Media: Journal, e-Books, Biotech Conference Coverage in REAL TIME
- Series #5: Dr. I. Robu – Tissue Engineering & 3D Printing Materials
A Podcast – Audio Series on Medical 3D BioPrinting
#2 LPBI’s BioMed e-Series was Submitted, Reference #: 9076095, on 1/27/2016 to
The Keck Futures Initiative – a program of the National Academies of Sciences, Engineering, and Medicine, with the support of the W.M. Keck Foundation – will award four $20,000 prizes in 2016 to individuals or teams (up to four individuals associated with the creation of the work being nominated) who have developed creative, original works that address issues and advances in science, engineering and/or medicine for the general public. Nominations are accepted in four categories: Book; Film/Radio/TV; Magazine/Newspaper; and Online. The winners will be honored in the Fall 2016 and are expected to attend in person.
http://keckfutures.org/awards/nominate.html
https://fs22.formsite.com/naseo-ca/2016_com_award_nom/index.html
1/27/2016
I AM PROUD TO CONGRATULATE
- Larry H Bernstein, MD, FCAP
- Stephen J Williams, PhD
- Tilda Barliya, PhD
- Dror Nir, PhD
They constitute the TEAM that I nominated for The National Academies 2016 Communication Awards, Keck Futures Initiative – Nomination
- Category: Online
- Subject for Nomination: BioMed e-Series published in 2015 by Leaders in Pharmaceutical Business Intelligence
BioMed e-Series
http://pharmaceuticalintelligence.com/biomed-e-books/
- Cancer Biology & Genomics for Disease Diagnosis,
- Genomics Orientations for Personalized Medicine,
- Metabolic Genomics and Pharmaceutics,
- Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics,
- Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics,
- Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases
100 words
BioMed e-Series published in 2015 e-Books to popularize the Scientific findings of the frontier in Medicine and Life Sciences focusing on the top two Public HealthCare hazards: Cardiovascular Diseases and Cancer. The e-Series consists of medical interpretations of the most challenging causes of mortality and morbidities in Cancer Biology & Genomics for Disease Diagnosis, Genomics Orientations for Personalized Medicine, Metabolic Genomics and Pharmaceutics, the Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics, the Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics. Precision Medicine as EndFragment
1/5/2016
- Accomplishments by Subsidiary #1: Scientific Media
A. The Journal
Our Realization 2014 2015 All Times Total on 1/3/2016
# e-Readers 230,000 300,000 841,700
New Articles 1,087 (+41.58%) 1,316 (+30.95%)
Total # of Articles 2,614 3,929 3,937
B. WE ARE on AMAZON.COM with EIGHT e-Books in Medicine
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
C. Press Coverage
The 11th Annual Personalized Medicine Conference, November 18-19, 2015, Joseph B. Martin Conference Center of the Harvard New Research Building at Harvard Medical School
The 15th Annual EmTech MIT, November 2–4, 2015, MIT Media Lab, Cambridge, MA
Explores technologies highlighted in the recent 10 Breakthrough Technologies list and celebrates the 2015 Innovators Under 35.
9/17/2015 -LIVE – Real Time Coverage of Kailath Lecture and Colloquium 2015 September 17 – 19, Stanford CA – James H. Clark Center, 318 Campus Drive West, Stanford University, CA
9/18/2015 – LIVE – Real Time Coverage of Kailath Lecture and Colloquium 2015 September 17 – 19, Stanford CA – James H. Clark Center, 318 Campus Drive West, Stanford University, CA
Cambridge HealthTech Institute’s 14th Annual Meeting BioIT World – Conference & Expo ’15, April 21 – 23, 2015 @Seaport World Trade Center, Boston, MA
MassBio Annual Meeting 2015, Cambridge, MA, Sonesta Hotel, March 26 – March 27, 2015
Silicon Valley 2015 Personalized Medicine World Conference, Mountain View, CA, January 26, 2015, 8:00AM to January 28, 2015, 3:30PM PST
Subsidiary #2: Funding Early Stage Biotech: IP by others
- Dealings with Yissum — on hold
- No Progress on other ventures, yet
- Average investment needed per venture $10Million and above
Subsidiary #3: Medical 3D BioPrinting (M3DP): Team of 15
Funding needs: $20Million
8/2015 – 12/2015 – Team accomplished a 14 Presentation Series on 3D BioPrinting for
Tissue Engineering, Gene Therapy: Stem Cells and Gene Editing and Drug dosing and printing, artificial organs, MEMS and Programmable Sensors
1/2016 – 3/2016 – Team engaged in Presentations on BioMEMS
4/2016 – 6/2016 – Team engaged in Presentations on Stem Cells
- Gerard manages VARS of BioPrinters and BioInks
Subsidiary #4: U.S. and Int’l Patents
- Funding needed to commercialize,
- Partnerships to license
- Buyers for Sales of IP of Two Team members:
(a) to “corporate accounts”
(b) to “IP and Technology Patents Fund Managers
Subsidiary #5: Joint Venture: SBH & M3DP (same Team as Subsidiary #3)
Funding needs: $10 Million
- Dr. Nir and Aviva manage creation of a pipeline of Product Concepts
@@@@@@@@@
2015
12/2/2015
Please write a Book Review on Amazon.com – for ONE of our e–Books in your domain of expertise in Medicine
The entire BioMed e-Series – Sixteen Titles, is at
http://pharmaceuticalintelligence.com/biomed-e-books/
Series A: e-Books on Cardiovascular Diseases
Content Consultant: Justin D Pearlman, MD, PhD, FACC
Volume One: Perspectives on Nitric Oxide
available on Kindle Store @ Amazon.com
http://www.amazon.com/dp/B00DINFFYC
Sr. Editor: Larry Bernstein, MD, FCAP, Editor: Aviral Vatsa, PhD and Content Consultant: Stephen J Williams, PhD
Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
available on Kindle Store @ Amazon.com
http://www.amazon.com/dp/B018Q5MCN8
Curators: Justin D Pearlman, MD, PhD, FACC, Larry H Bernstein, MD, FCAP, Aviva Lev-Ari, PhD, RN
Volume Three: Etiologies of CVD: Epigenetics, Genetics & Genomics
available on Kindle Store @ Amazon.com
http://www.amazon.com/dp/B018PNHJ84
Curators: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Series B: e-Books on Genomics & Medicine
Content Consultant: Larry H Bernstein, MD, FCAP
Volume One: Genomics and Personalized Medicine
available on Kindle Store @ Amazon.com
http://www.amazon.com/dp/B018DHBUO6
Sr. Editor: Stephen J Williams, PhD
Editors: Larry H Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN
Series C: e-Books on Cancer & Oncology
Content Consultant: Larry H Bernstein, MD, FCAP
Volume One: Cancer and Genomics
available on Kindle Store @ Amazon.com
http://www.amazon.com/dp/B013RVYR2K
Sr. Editor: Stephen J Williams, PhD, Editors: Ritu Saxena, PhD, Tilda Barliya, PhD
Series D: e-Books on BioMedicine & Immunology
Content Consultant: Larry H Bernstein, MD, FCAP
Volume One: Metabolic Genomics & Pharmaceutics
available on Kindle Store @ Amazon.com
http://www.amazon.com/dp/B012BB0ZF0
Author, Curator and Editor: Larry H Bernstein, MD, FCAP
11/11/2015
#1. Investor Relations
1.1 CCP
Class Asset A: Funding Start Ups
Class Asset B: Funding with agreement in place
B.1 ValveCure
B.2 New Medicine, Inc.
B.3 SBH Sciences, Inc.
B.4 Woodland Pharmaceuticals
Class Asset C: US Patents and International Patents of Technology Transfer Office
Class Asset D: US Patents M3DP’s Medical Devices Inventors
D.1 Bill Zurn
D.2 Dr. Pearlman
1.2 Dr. Choppe
1.2.1 Class Asset D: US Patents M3DP’s Medical Devices Inventors
D.1 Bill Zurn
D.2 Dr. Pearlman
1.2.2 M3DP and SBH Sciences, Inc. – Joint Venture: Four Projects
We are developing a Business Plan for the Joint Venture of GDE’s Subsidiary #3: M3DP with our Business Partner for this JOINT VENTURE, DBA, SBH Sciences, Inc.
We are working on Four Projects:
Project #1:
- A Drug/Device of continuous Hormone delivery Stimulant to Insulin production for Type 1 Diabetes (Patients born with deficient Pancreas Beta Cells) and DM Type 2
A Joint Venture of the following Teams:
Technology Management: Aviva Lev-Ari, PhD, RN
Business Management: Gerard Loiseau, ESQ
SBH Sciences, Inc.
Inventor: – CEO, CSO – Dr. Rapahel Nir
and
M3DP
Inventors: Orange – US Patents Holder; Purple – UK Patent Holder
Dr. Pearlman and Bill Zurn on MEDICAL DEVICE DESIGNS
Dr. Codrington and Dr. Dragoi on Nanoparticals and magnetic fields
Dr. Codrington and Dr. Goswami on Molecular Cell Differentiation and Stem Cell Implantation
Dr. Williams, Dr. Tilda, Dr. Irina, Dr. Cohn – on biochemistry, biomechanics, pharmacodynamics and pharmacokinetics of the Drug 3D BioPrinting
Project #2:
- DIAGNOSTICS KIT for Skin Cancer using Nanotechnology
M3DP – Dr. Rosalind Codrington, Oxford, UK, Holder of two Patents issued in the UK
Project #3:
Protected: Invention: Stop MI © JDPearlman 2015
Inventor: Dr. Pearlman, US Patents Holder
Project #4:
Protected: INVENTION: 3D Reparative Transforming BioStent – Concept Description
Inventor: Dr. Pearlman, US Patents Holde
- Series A: All Volumes eTOCs Spanish Audio & Spanish Text & Editorials English Audio
Each Volume: in each series –
- Bi-Lingual eTOCs, NLP, Editorials English Audio
I am so excited about the New Genre Edition on Medical eBooks
UPDATED on 10/16/2021
It is with the highest OWE that I have issued today
LPBI’s first Cerficicate in Medical Text Analysis for COMPLETION OF 18 Months of Academic Training, the Completion of NLP of an entire book
GENOMICS VOLUME 2
Latest in Genomics Methodologies for Therapeutics:
Gene Editing, NGS & BioInformatics,
Simulations and the Genome Ontology
2019
Volume Two
https://www.amazon.com/dp/B08385KF87
Deep Learning NLP
performed by
MADISON DAVIS
Thank you very much for completion of Genomics Volume 2 – This is a COLLOSAL accomplishment.
Genomics, Volume 2 will be LPBI’s 1st e-Book in
LPBI’s NEW GENRE EDITION of Scientific Books with the following format
- Part A: eTOCs in Spanish AUDIO and Bi-Lingual Spanish and English TEXT – Text Source: ORIGINAL Book
- Part B: Deep Learning NLP by Madison Davis – Graphic Visualization
- Part C: Editorials in English AUDIO – Text Source: ORIGINAL Book
AFTER we finish PART B, above, I am advising Madison:
- to consider to start to work on Synthetic Biology Software for Molecular Design for Galectins
https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
- Starting a NEW Internship leading to a New Certificate in Synthetic Biology Software for Molecular Design for Galectins
Detailed description to be found on each Internship page, below
- Medical Text Analysis (Deep Learning NLP)
- IS, IT, CS and Data Science Internship
- Blockchain Knowledge Graph Database Design with Interface to Wolfram NLP
- Finance Internship: Financial Modeling
-
Synthetic Biology Software for Drug Design in Glycobiology Internship
- Journalism and Marketing Communications in Pharmaceutical Media
I am encouraging all INTERNS to complete their assignments
- GET Certificate(s)
- Move to Another Internship – ALL ARE TUITION FREE
UPDATED on 10/7/2021
Tweets and Re-Tweets of Tweets by @pharma_BI @AVIVA1950 at 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021, #WMIF2021
UPDATED on 10/4/2021
Tweets and Re-Tweets of Tweets by @pharma_BI @AVIVA1950 at EmTech MIT 2021, #EmTechMIT, Technology Review’s flagship event, September 28-30, 2021
UPDATED on 10/2/2021
LPBI covered in Real Time the Virtual MIT Technology Review’s flagship event, September 28-30, 2021 – EmTech MIT 2021
- EmTech MIT 2021 – Agenda Overview & Speakers: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
https://event.technologyreview.com/emtech-mit-2021/agenda
- Day 1: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
- Day 2: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
- EmTech MIT 2021 – Day 3: Leading with innovation, Virtual MIT Technology Review’s flagship event, September 28-30, 2021
UPDATED on 9/27/2021
First day for Satwik Sunnam, Research Assistant 3 in our Team LPBI India is 9/27/2021
Assignment 1: Replacement to Dr. Pati on Cancer Volume 1, Chapters: 7,8,9,10,11,12
- Produce Hypergraph V1 – One for each Chapter for Cancer Volume 1, Chapters: 7,8,9,10,11,12
- Produce Tree Diagram Plots – One for each Chapter for Cancer Volume 1, Chapters: 7,8,9,10,11,12
Assignment 2: Replacement to Ms. Amandeep Kaur on Genomics Volume 1, Chapters: 1-21
- Ms. Kaur completed Data preparation Chapters: 1,2,3,4,5 and 21
- Your assignment #2 include:
- Produce Data preparation for Chapters 6 -20
- Produce Deep Learning NLP for Chapters 1 to 21.
UPDATED on 9/22/2021
On 9/20 LPBI had issued the following Certificates:
First Certificate issued in the domain of
Medical Text Analysis with Deep Learning Natural Language Processing
Recipient: Yash Choudhary
On 9/17/2020, LPBI issued the following three Certificates in the domain of
IS, IT and Data Science
for the following Contributions:
Recipients: Abhisar Anand and Srinivas Sriram
for their contribution to IT system solution design for Data Extraction of Article Views
Problem definition:
To extract the views for each of the 6,000+ articles for different time periods. Must be done in a time-efficient manner that retrieves the necessary data for LPBI.
Conceptual solution:
Create a multiple-step process that involves web scraping the data in multiple processes to enhance the speed of the extraction, and use data analysis libraries in Python to format the data in the correct format.
Code Implementation: https://pharmaceuticalintelligence.com/sop-web-stat/
Recipients: Ethan Coomber
For his contributions to Text To Sound conversion of 150 Interviews with Scientific Leaders and for Twitter Analytics on LPBI’s two Twitter handles: @pharma_BI @AVIVA1950
UPDATED ON 9/6/2021
A long weekend ahead of us. Lots of good things to look forward to.
• Labor Day with all its meaning.
• For my culture, the High Holidays.
Blessed to be healthy, very creative and very productive.
What is New at LPBI Group:
1. We got this week all our 18 #books in #medicine translated to #spanish
• Cover Page
• electromic Table of Contents
2. We created the first products using Wolfram #deeplearning
Natural Language Processing #nlp
3. We made advances regarding launching a #blockchain #knowledge #graphdatabases for our
• +6,080 scientific articles
• 18 Books in Medicine (English and Spanish)
• 100 e-Proceeding oh Top Tier Biotech Conferences
• +6,000 Biological Images
4. Completed +150 conversion Text to Sound #TTS, I.e., Podcasts of Interviews with Scientific Leaders
5. Received the code for our Information System allowing for #data–#analytics #extraction of #articles #views per Year
YES: +2MM Views – #bigdata 3.3 Giga Bytes !!!!
6. Made strides in further defining our platform for #syntheticbiology in #drugdiscovery
#biotech #research #language #datascience #translation #ai
So much GOODNESS in one week
UPDATED ON 9/5/2021
Milestones reached on 3Q 2021
- IT & Data Science Internship – LPBI gained the code to run Article Views by any date, 2012 – 2021 – Contributions by Srini and by Abhisar
- Text to Sound: 150 of the 270 Interviews with Scientific Leaders were converted to Podcasts – Contribution by Ethan
- Sign up agreement with SpeechKit – Text to Sound conversion for (a) $204 for 360 podcasts per year (b) Archive bulk conversion 20 cents per Podcast (c) Use API for Spanish Text to Spanish Sound
- ALL 18 BOOKS have a COVER PAGE and an eTOCs in Spanish – Montero competed its Contract and was paid by a Loan Aviva made to LPBI. On 9/1/2021 wired the funds to cover the Invoice.
- Instructions by Madison for all INTERNS on Deep Learning NLP using Yash’s code – is almost ready
- Proof-of-Concept for Cardiovascular text with Deep Learning NLP is ready by Yash using Adina’s Data preparation
- PowerPoint SLIDE DECK for 2.0 LPBI is Ready – Text by Aviva and PPT by Srini and Abhisar
- Completion of Internship Definition and Certificate Design on 9/2/2021 – Joint Work with Robin and Beth https://pharmaceuticalintelligence.com/certificate-1-year/
- LPBI India is seeking additional Leadership to Dr. Saha and additional INTERNS for (a) Medical Text Analysis using Wolfram Deep Learning NLP and (b) Synthetic Biology Software for Drug Discovery
- Synthetic Biology in Drug Discovery – Mission #4 for LPBI USA is Mission #2 for LPBI India: Updated by Dr. Williams on 8/20/2021. He will present on 9/14/2021. See update https://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
UPDATED ON 8/31/2021
August 31, 2021 is a GREAT day for both organizations:
- Montero, Language Services, Madrid for COMPLETION of the Spanish Translation of LPBI Group’s EIGHTEEN Books in Medicine: Books Page Cover and electronic Table of Contents (eTOCs) per Volume
- LPBI Group, Boston for having the EIGHTEEN products of the Spanish Translation as agreed upon
This Spanish Translation serves our quest to
- (1) have the opportunity to REACH to the Medical communities in Spanish speaking countries and to Spanish speaking physicians and allied health professionals in the US, and
- (2) having the ability to re-Publish every book and every e-Series as a New Genre of Scientific Books in several new formats:
Series A, B, C, D, E – per each Series:
- Never published before as eTOCs of all Volumes in a Series
- Never published before in Spanish: Text or Audio
- Never published before in English Audio
All volumes in each Series – Bi-Lingual and Audio eTOCs
Cover Page and electronic Table of Contents
- Spanish & English Bi-Lingual eTOCs in Text – Today the FINAL products delivered
- Spanish eTOCs Translation in Audio [Text to Sound]
- English eTOCs in Audio [Text to Sound]
Per Volume for each of the 18 Books – New Genre of Scientific Books
- Part A: Bi-Lingual eTOCs: Spanish Audio and English Audio
- Part B: Results of Deep Learning Natural Language Processing with Domain Knowledge Expert Interpretation in [English text work-in-progress] and Spanish text to be translation of this English Text [Future Plan]
- Part C: Book original Editorials in English Audio [Text to Sound]
UPDATED ON 8/16/2021
Proof-of-Concept yielded LPBI’s SOPs on Natural Language Processing – How we will use Deep Learning NOT Statistical NLP !!!!!!!!
- Yash’s code.nb
- Deep learning methods
- 25 keywords
- Code file: code.nb
- Hypergraph1.pdf
- Treeplot.pdf
UPDATED ON 8/7/2021
#1:
LPBI Group announces 5th Academic INTERNSHIP as a Verifiable Certificate Program in Financial Modeling
These are the FOUR ACADEMIC INTERNSHIPS as verifiable Certificate Programs One year or One semester: Volunteer base
- NLP – Medical Text Analysishttps://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
- Synthetic Biology in Drug Discovery targeting Galectinshttps://pharmaceuticalintelligence.com/synthetic-biology-in-drug-discovery/
- IT Projects and Administration of IP Asset Classes. we developed a Plan for SOPs for LPBI Group’s IT & Data Science Management Projects https://pharmaceuticalintelligence.com/2021/07/11/plan-for-sops-for-lpbi-groups-it-data-science-management-projects/ Informations technology & systems of LPBI: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images. All the platforms: Authoring, publishing and portals. Business analytics for Internet platforms presence: Twitter Analytics +1,100 followers of two handles and LinkedIn ~8,000 1st degree connections of LPBI’s Founder, including +500 CEOs.
- BLOCKCHAIN Architecture Design: Interface to NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY. Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN. NLP-Blockchain IT Infrastructure is needed. The NLP inferences are part of a knowledge graph database In BurstIQ case is a LifeGraph – the larger architecture of the system functionality [the voice of Erich G., Chief Architect, LPBI Blockchain Mission #2].
#2:
LPBI and Linguamatics are schedule to meet with
- LPBI’s and Linguamatics’ potential NEW two clients:
- Director of Research at an HMO &
- COO/CEO of a Healthcare INSURER on
- August 18, 2021 at 3PM EST
#3:
LPBI’s GLOBAL Monthly Zoom Meeting is on August 10, 2021 at11AM EST to 4PM EST – Please ATTEND
Presentations by
- Dr. Williams
- ALL 2021 SUMMER INTERNS
- Aviva
- External Presenter TBA
AGENDA for August 10, 2021 at 11AM EST to 4PM EST
Link sent on 8/9 at 5PM and on Link REMINDER on 8/10 at 9AM
https://pharmaceuticalintelligence.com/calendar/
UPDATED ON 8/3/2021
LPBI TEam in LPBI India include: 3,4,6,7,8,10,11
UPDATED ON 7/26/2021
We are excited to have new Interns coming onboard with inquisitive minds and motivation to learn new skills and invest in their careers by Experientional learning methods.
LPBI Group runs FOUR MAJOR INTERNSHIPS: Volunteer base
- NLP – Medical Text Analysis
- Synthetic Biology in Drug Discovery targeting Galectins
- IT Project and Administration of IP Asset Classes: Journal, Books, e-Proceedings & Tweet Collections and GALLERY of +6,200 Biological Images
- BLOCKCHAIN Architecture design: Interface of NLP. The powerful aspect is hydrating a knowledge graph with NLP inferences so that they can be used for DISCOVERY.
Storing those inferences on a blockchain have the value of committing the NLP inferences to a blockchain for purposes of provenance. However, the very important part is The INFRASTRUCTURE behind BurstIQ which is NOT JUST A BLOCKCHAIN.
- NLP-Blockchain IT Infrastructure is needed.
- The NLP inferences are part of a graph database
- In BurstIQ case is a LifeGraph – the larger architecture of the system functionality.
LPBI has you and your education goals in mind:
- We Offer esteemed Affiliation, Mentorship by Scientists
- NEW skills development in NLP, ML, AI applications to Medical Text Analysis
- Skills in Synthetic Biology for Drug Discovery
- References and Resume paragraph on accomplishments and goals during the INTERNSHIP
- Opportunity to contribute to Publications and Podcasting
- Explorations of opportunities in Life Sciences in the US
UPDATED ON 7/26/2021
LPBI’s VALUATION is the stream of INNOVATIONS to date while being DEBT free:
- 4/2012 – LPBI is the Launcher of Scientific Curation Methodology for the e-Scientific Publishing industry https://pharmaceuticalintelligence.com/ As late as in 2016 no big publisher, i.e., Elsevier, John Wiley had curation-based publications: Journal, Books, e-Proceedings, Gallery of +6,000 Biological Images as an IP asset class
- At LPBI, Curation of scientific findings was performed in +6,000 articles with +2MM e-Views by Global e-Readers
- 6/2013 – LPBI was the Publisher of the 1ste-book in Medicine in Kindle Store on the Life Sciences & Medicine Shelf – Upload to this shelf by Amazon.com
- 2/2021 – Completion of the 18 volumes, BioMed e-Series in five Specialties in Medicine
- On Amazon.com on 7/2021 – e-books in Medicine enjoy +128,100 PAGE DOWNLOADS – the ONE and ONLY publisher in that range of page downloads
- LPBI launched NLP in 1/2020. Linguamatics/IQVIA performed NLP on 33 articles and 20 Biological Images. RESULTS: +670 entity relations DISCOVERED by Linguamatics and unknown to Pharma and to Insurers, entity relations between:
- Gene-Disease
- Gene-Drug
- Disease-Drug
- These results were presented to a Healthcare Insurer, SLC, UT on 7/13/2021
- LPBI and BurstIQ are architecting NOW the first NLP-Blockchain IT infrastructure in existence
- Linguamatics did not hear of Blockchain and BurstIQ did not have a request for NLP – LPBI PUT THESE TWO TECHNOLOGIES AND PARTIES TOGETHER
- On 7/19/2021 – LPBI had launched LPBI India for Synthetic Biology for Drug Discovery targeting Galectins – Collaboration with Dr. Raphael Nir, ABI Lab and SBH Sciences, Inc., Natick, MA
- On 7/25/2021 – LPBI announced it will have the NEWLY to be published BioMed e-Books As ANEW Publishing GENRE of SCIENTIFIC BOOKS
- Bi-Lingual eTOCs, English & Spanish with Montero Language Services, Madrid and Content promotion by GTO, Madrid
- NLPs results of Medical Text Analysis with domain knowledge expert Interpretations in Foreign Languages and Audio: Spanish and other
- Original English Book – Only Editorials(Preface, Introductions, Summaries and Epilogue] because the Bi-Lingual part is the eTOCs of the e-Book
- New architecture of MULTIMEDIA SCIENTIFIC e-Books
- Based on the Price List for LPBI 1.0 digital products and of LPBI 2.0 – NLP Products https://pharmaceuticalintelligence.com/2020/11/16/data-architecture-for-blockchain-deployment-of-digital-assets-lpbi-ip-asset-classes-iiiiii/we are building
- Scenarios of Product Mix for $500,000 B2B engagements with NLP scaling up alliances: Alliances are Labor component and LPBI is Materials – 25% on top paid by the B2B customer
- B2C on Blockchain will use the Price List.
UPDATED ON 7/19/2021
Official launch of LPBI India – Zoom meeting
On July 19, 2021 at 11AM EST
UPDATED AGENDA
|
Member Name |
Geographical region in India Or Place of Birth in India if now outside of India |
Distance from New Delhi |
LANGUAGES |
|
Dr (Lt Col) Vivek Lal |
Ambuja Nagar, Kodinar (Sasan-Gir) Gujarat. |
1300 kms |
English, Hindi |
|
Yash Choudhary |
Dewas (Madhya Pradesh) |
800 kms |
English, Hindi |
|
Dr. Premalata Pati |
Bhubaneswar, Odisha |
1764 kms |
English, Hindi, Odia |
|
Dr. Sudipta Saha |
Kolkata, West Bengal |
1500 kms |
English, Hindi, Bengali |
|
Dr. Ajay Gupta |
Place of birth: New Delhi |
0 |
English, Hindi |
|
Amandeep Kaur |
Kolkata, West Bengal |
1500 kms |
English, Hindi, Punjabi, Bengali |
|
Indraneel Ghosh |
Vadodara, Gujarat | 1025 kms |
English, Hindi, Bengali, Marathi, Gujarati
|
|
Aditya Bahl |
Lucknow, UP | 500 |
English, Hindi, Punjabi |
|
Srinivas Sriram |
Place of Birth: Chennai, Tamil Nadu |
2,187 kms |
English, Tamil |
|
Abhisar Anand |
Place of Birth: Muzaffarpur, Bihar |
1,042 kms |
English, Hindi |
ANNOUNCEMENT
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston, MA
is Launching LPBI India on 7/19/2021
LPBI India Official Launch
on Zoom on July 19, 2021 at 11AM EST
- I wish to invite you to attend this Zoom meeting using the Zoom Link, above
LPBI India LAUNCH
is on Monday July 19, 2021 at 11AM EST
Aviva – Founder 1.0 LPBI and 2.0 LPBI
- Justifying the Launch of LPBI India today is the Interaction between LPBI USA and LPBI India which is taking place multiple times every day
- Senior level executive talent in India expressed interest to JOIN LPBI USA while living in India
- It was Dr. Lal and Dr. Ghosh interest in joining LPBI USA that impacted Aviva’s Decision toward the Launch of LPBI India: Leadership + Professional Staff
- Interactions among all members across India is mostly encouraged
- We are preparing a MAP with all the locations in India of our VIRTUAL organization
- We are a community of inclusion and excellence challenging and aspiring for expression and growth of the best of our abilities without borders and/or pre-determinants of any kind: age, race, religion or gender
- Interactions with Alumni of LPBI USA is mostly encouraged – we are very proud of each of you,
Congratulatory Remarks, each presenter from their own perspective:
- LPBI USA Board member, Prof. Marc W. Feldman, Stanford University [7/18/2021 – Medical Emergency] <<< – WE WISH YOU SPEEDY RECOVERY, next Global Zoom on August 10, 2021 – Congratulatory remarks will be delivered
- LPBI USA Board member, Prof. Stephen J. Williams, Temple University
- Dr. Ajay Gupta of UC, Irvine, LPBI USA, External Scientific Relations
- Mr. Aditya Bahl, MBA, LPBI USA, External Business Relations to LPBI USA since 1/2020. Mr. Bahl is ex-Novastis and ex-J&J, the Founding Director at RAS Life Science Solutions, based in Frankfurt, Germany
- Dr. Raphael Nir, Founder, ABI Lab and President, SBH, Inc in Natick, MA – We will have in 4Q’2021 a JOINT meeting dedicated to Mission #2, below
Mission #1:
Medical Text Analysis with Natural Language Processing (NLP), Machine Learning (ML), Artificial Intelligence (AI)
The Medical Text includes FOUR corpuses of content created by the Team at LPBI USA since 4/2012:
- Scientific Curation Articles published in our Open Access Journal http://pharmaceuticalintelligence.com
N = +6,070, Views = +2Million, with an ontology of +730 categories of Research in the Life Sciences, Medicine, Pharmaceutics and Healthcare
2. 18 e-Books in Medicine https://lnkd.in/ekWGNqA
128,000 page download on Amazon.com – Cover Pages and electronic Table of Contents (eTOCs) of the 18 books are been translated to Spanish in Madrid, now
3. 100 e-Proceedings of Global Medical and Biotech Conferences generated in Real Time, 2013 – 2021 https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/
4. +6,200 Biological Images with text legend in use by the +6,000 articles – in the Media Gallery of LPBI on WordPress.com cloud. Mission #1 has increased the number of Biological images from 5,100 to +6,200
At LPBI India, been considered for the Leadership function for Mission #1: Dr. Vivek Lal, MD
STRATEGIC PLAN for Mission #1
For scaling up the Text Analysis of these 3.3 Giga Bytes of data we are in alliance with Linguamatics/IQVIA, London https://www.linguamatics.com/what-text-mining-text-analytics-and-natural-language-processing
- We jointly presented their NLP results on our content in oncology to a Top HMO/Healthcare Insurer in UT on July 13, 2021. We are invited for additional meetings with both organizations: the HMO and the Healthcare Insurer
- LPBI USA developed a ten-phase Protocol for our own content been subjected to Medical Text Analysis with NLP, ML, AI using Wolfram language for BioSciences
- LPBI India will be involved in all of the ten-phase Protocol in using NLP, ML, AI
- LPBI is in alliance with BurstIQ, Denver, CO https://www.burstiq.com/ for Blockchain design for a Transactions Network for Content monetization: B2B and B2C. That process involve Indexing and data migration. LPBI India will play a role in these tasks as well
Mission #2:
Applications of Synthetic Biology Software to Galectins for design of new drug molecules.
- Collaboration with Dr. Raphael Nir of ABI Lab and SBH, Inc in Natick, MA. We will have in 4Q’2021 a dedicated meeting on Mission #2.
- LPBI India will play a role in these tasks, please review:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877766/
- LPBI USA has interest in Synthetic Biology Software for Drug Discovery and has two scientists with expertise in Galectins as therapeutic targets
- Scientists love Synthetic Biology – designing drug molecules using Software – igem.org
A repository of open source software tools.
Community driven data exchange standards.
Specific software frameworks built explicitly for synthetic biology.
- LPBI USA will have a DropBox Folder with all the Synthetic Biology Software accessible to LPBI India
- Mentorship and training will be offered by LPBI USA
At LPBI India, been considered for the Leadership function for Mission #2: Dr. Indraneel Ghosh, PhD
STRATEGIC PLAN for Mission #2
- We will have in 4Q’2021 a JOINT meeting between LPBI USA, LPBI India with Dr. Raphael Nir of ABI Lab and SBH, Inc in Natick, MA on Mission #2.
- A collaboration between Dr. Ghosh and Dr. Nir is expected
AGENDA
Zoom of LPBI INDIA Launch on Monday July 19, 2021 at 11AM EST
PRESENTATIONS
- Prof. Stephen J. Williams, LPBI USA, Chief Scientific Officer and Board Member is with LPBI USA since 9/2012 will have presentations
- Aviva will have presentations
Senior Level at LPBI India:
- LPBI India TEAM Members BIO Presentations: Each of the members of LPBI India will present their BIO in <5 minutes, starting with
Dr. Sudipta Saha, PhD Prof. at Amity University, New Delhi. Dr. Saha is with LPBI USA since 9/2012, Expert, Author and Co-Editor
http://www.amazon.com/dp/B08VTFWVKM
Available on Amazon.com since 2/2/2021
https://www.amazon.com/dp/B075CXHY1B
On Amazon.com since September 4, 2017
Dr. Vivek Lal, MD, COO, Ambujanagar Multi-specialty Hospital, Ambujanagar, Dist. Gir-Somnath, Gujarat, India.
- Paper collaboration with Dr. Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN on 9/2013, article has ~15,000 e-Readers https://pharmaceuticalintelligence.com/2013/09/23/do-novel-anticoagulants-affect-the-ptinr-the-cases-of-xarelto-rivaroxaban-and-pradaxa-dabigatran/
Dr. Indraneel Ghosh, PhD – Weizmann Institute PhD, 2000-2007, Hebrew speaker
- CV on LPBI USA Website – Work-in-Progress
Dr. Ajay Gupta of UC, Irvine, Scientific Advisor to LPBI USA, frequent presentation on LPBI’s SCIENCE SIDE – Global Monthly Zoom
- Ten Minutes on on Clinical Trials for RAMATROBAN – Opportunities for Collaboration between His Company in USA & LPBI India, Dr. Lal’s Hospital and other Hospitals in India
Ramatroban is a thromboxane receptor antagonist. It is also a DP₂ receptor antagonist. It is indicated for the treatment of coronary artery disease. It has also been used for the treatment of asthma. Wikipedia
ChemSpider ID: 110413
Molar mass: 416.47 g·mol−1
Formula: C21H21FN2O4S
Members of Technical Staff (MTS) at LPBI India & LPBI USA:
- All LPBI India MTS currently working on Mission #1 and
- All LPBI USA MTS currently working on IT/Data Science Projects
-
- will be invited to considered Mission #2.
- An Up-to-date CV in Biological Sciences REQUIRES DEMONSTRATION of making contributions with mentorship in both areas: Mission #1 and Mission #2
LPBI India and LPBI USA MTS – BIO Presentations: PostDocs, Masters and Students will present their Bios in <4 minutes:
- Dr. Pati, PostDoc. NLP – One year Academic Training
- Ms. Kaur, MSc. NLP – One year Academic Training
- Mr. Choudhary, Student IITK – Summent intern, 6/15/ – 8/15/2021
- Mr. Sriram, Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
- Mr. Anand, Student Westford Academy, MA – Born in India, thus, LPBI USA & LPBI India
- Mr. Ethan Coomber, Middlebury College, VT – Research Assistant 3, Text to Audio Conversion and Twitter Analytics
- Ms. Vaishnavee Joshi, MSc – Joining LPBI India on 8/15/2021
Alumni of LPBI USA are invited to join us on Monday, July 19, 2021, 11AM EST
- Dr. Probodh Kandala, PhD, Regulatory Affairs Manager @ IQVIA Biotech; Drug Development Leader, Expert, Author, Writer with scientific reporting articles in multiple of LPBI e-Books, chiefly Cancer and Immunology
- Dr. Ritu Saxena, PhD, Astellas Pharma US, Co-Editor, LPBI’s Series C, Volume 1 http://www.amazon.com/dp/B013RVYR2K
- Dr. Aviral Vatsa, MD, NHS Education for Scotland, Co-Editor, LPBI’s Series A, Volume 1 http://www.amazon.com/dp/B00DINFFYC
- Aashir Awan, Research Scientist, Bristol Myers Squibb, Expert, Author, Writer (EAW) for PharmaceuticalIntelligence.com
- Anamika Sarkar, Regeneron, EAW at LPBI 2014-2016
Alumni of LPBI USA: Please catch up with us, we thank you for your contributions made to LPBI USA
- Please review our portfolio of Intellectual property of 10 Asset Classes in 2021 https://pharmaceuticalintelligence.com/2019-vista/
- Please review our six strategies for 2021-2025 https://pharmaceuticalintelligence.com/vision/
@@@@@@@@ ALL NEED TO PLAN TO ATTEND 7/21, 2021 – LPBI USA – BUSINESS SIDE
UPDATED ON 7/5/2021
ANNOUNCEMENT of NEW SUMMER INTERN in Medical Text Analysis with NLP – Cardiovascular Content – 2021 Summer Internship in NLP – LPBI India
Yash Choudhary, Research Assistant 3
UPDATED ON 6/20/2021
ANNOUNCEMENT of NEW SUMMER INTERN
Ethan Coomber, Research Assistant III, Data Science and Podcast Library Development
UPDATED ON 6/16/2021
ANNOUNCEMENT of TWO NEW SUMMER INTERNS who also plan to start in 9/2021 the LPBI 2021-2022 Academic Training in NLP for Medical Text Analysis
Abhisar Anand, Research Assistant I
Srinivas Sriram, Research Assistant I
UPDATED ON 5/17/2021
LPBI management wants you to be PROUD about
1. The Spanish Translation 18 volumes (Cover Pages, eTOCs all books) – Alliance with Montero Language Services, Madrid, Spain and their’s Marketing Communication Agency for
1.1 Plans for Content Promotion in Spanish Speaking Countries
1.2 Other Marketing Communications needs of 2.0 LPBI
2. NLP plan for IP Asset Classes I,II, III, V – Consideration of Alliance with Linguamatics/IQVIA for Indexing of +6,000 articles
3. Blockchain Transaction Network for Content monetization system design for Digital Store in a Healthcare Digital Marketplace: B2B, B2C – Collaboration with BurstIQ
4. Insurer Contact and Proof-of-Concept READY for joint Presentation with Linguamatics/IQVIA
5. IB in NYC preparing Proposal for LPBI becoming their Client
6. Working with few Sources to identify C-Suite new Members
- New Management
- New Ownership
- New Company – incorporation as ‘C’
UPDATED ON 5/5/2021
One Pager for 2.0 LPBI Group
For the first time in the ten years of our private ownership, the opportunity to acquire the Inventor of Scientific curation has become a reality, Available for Transfer of ownership.
You can own a portfolio of Intellectual Property Assets that commands ~2MM e-Readers and offers +6,000 of the best interpretive articles in five specialties of Medicine and Life Sciences. Pages of our 18 books have been downloaded ~135,000 times and over 100 of the top biotech and medical conferences were covered in real time and recorded in writing and Tweets. New strategies in AI and Blockchain are now applied on LPBI’s content for INSIGHT searches and pattern recognition by automated Machine Learning algorithms for use in drug discovery and drug repurposing. All of LPBI’s content was created by our Experts, Authors, Writers (EAWs).
- Bold vision for the coming five years includes: All content will be converted by Machine Learning algorithms to search for all hyper-graphs and their expression in WordClouds.
- From text we will convert content to Audio. From English Text we will translate to foreign languages like Japanese, Spanish and Russian.
- From Open Access we will transition to Blockchain transaction networks.
- From Digital Cloud-based biographies we will create audio and video Podcasts
- From a sole owner-operator status we will transition to Joint-Ventures to M&A and Partnerships
Our Transformational transition is two dimensional:
- Our deep expertise and innovations in media platforms and content creation will have new directions: we will focus on other Countries (x,y,z) and Geographical regions: i.e., EU and South-East Asia. Currently the Table of Contents of 18 books is being translated into Spanish for the 22 Countries speaking Spanish.
- Our created content will become the basis of our content mining and the subject of managed computerized text analysis under supervised learning guided by our own team of experts.
We are fundamentally a media system integrator, platform developer and platform customizer; an innovative and creative scientific content creator. We function as a fully vertically integrated BioMed creator and generator of knowledge for health information markets via our own Journal articles, BioMed e-Series of Books, Conference e-Proceedings, Podcasts, and additional five strategies https://pharmaceuticalintelligence.com/vision/
5/5/2021
LPBI Group’s Organizational Chart was updated on 5/5/2021
4/24/2021
REMINDER of important articles in our repository
e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point
Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL. Author and Curator: Aviva Lev-Ari, PhD, RN
Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI MA’76
4/14/2021
Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD
2/26/2021
2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021
Real Time coverage: Aviva Lev-Ari, PhD, RN
2/16/2021
Announcing two new members of the Medical Text Analysis with Machine Learning
Premalata Pati, PhD, PostDoc in Biological Sciences, Medical Text Analysis with Machine Learning
Amandeep Kaur, BSc., MSc. (exp. 5/2021) – Research Associate 2, Medical Text Analysis and IT Infrastructure Python Coder
2/12/2021
Need for Global Response to SARS-CoV-2 Viral Variants
Reporter: Aviva Lev-Ari, PhD, RN
Rise of a trio of mutated viruses hints at an increase in transmissibility, speeding the virus’ leaps from one host to the next
Reporter: Aviva Lev-Ari, PhD, RN
2/8/2021
LIVE – 50th Annual Lewis S. Rosenstiel Award to Katalin Karikó and Drew Weissman for work on messenger RNA, modification of Nucleic Acids applied in the development of COVID-19 Vaccines
Reporter & Real Time Coverage on 2/8/2021:
2/5/2021
Today Series D: Volume 4, LPBI’s #18 Volume is LIVE
Series D: e-Books on BioMedicine – Metabolomics, Immunology, Infectious Diseases and Endocrinology
VOLUME 1: Metabolic Genomics and Pharmaceutics.
(Series D: BioMedicine & Immunology) Kindle Edition
On Amazon.com since 7/21/2015
http://www.amazon.com/dp/B012BB0ZF0
VOLUME 2: Infectious Diseases and Therapeutics
and
VOLUME 3: The Immune System and Therapeutics
(Series D: BioMedicine & Immunology) Kindle Edition. On Amazon.com since September 4, 2017
https://www.amazon.com/dp/B075CXHY1B
VOLUME 4: Human Reproductive System, Genomic Endocrinology and Cancer Types
(Series D: BioMedicine & Immunology) Kindle Edition.
On Amazon.com since February 2, 2021
http://www.amazon.com/dp/B08VTFWVKM
2/3/2021
-
Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc
-
Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD
-
Podcast with Prof. Marcus W. Feldman, PhD, Biology Department, Stanford University, Interview by Gail S. Thornton, PhDc
-
Partners in Health and Biz Radio Interview with Aviva Lev-Ari, Ph.D., R.N., Stephen Williams, Ph.D., and Irina Robu, Ph.D., on 5/2019 on topic of 3D Medical BioPrinting Technology: A Revolution in Medicine. Interview organizer: Gail S. Thornton, PhDc
2/1/2021
Milestone achieved today:
February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical
Thought on the transition
One Possible Strategy for an Acquisition is via a SPAC
1/8/2021
PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views
Hanoch Lev-Ari, PhD and Aviva Lev-Ari, PhD, RN
Total number of articles viewed in any given year depends on:
- The overall Average Article-Viewing Profile (AAVP)
- The number of articles published in the year of interest, and in each one of the preceding years.
In statistics, the article viewing process is known as a “marked point process”: the time-instants of article publication are the events described by the point process, while the “mark” is the subsequent process of viewing each particular article, ongoing from the moment of publication into the future over many years. The article viewing process is assumed to be statistically-independent from the publication time-instants.
1/6/2021
2.0 LPBI Team Welcomes to our Medical Text Analysis Team
Amandeep Kaur, BSc., MSc. (exp. 5/2021) – Research Associate 2, Medical Text Analysis and IT Infrastructure Python Coder
1/6/2021
REUTERS NEXT (Jan 11-14) kicks off 2021 by gathering global leaders and forward thinkers to reimagine solutions to the challenges the new year brings
Reporter: Aviva Lev-Ari, PhD, RN
1/3/2021
Data Architecture for Blockchain Deployment of Digital Assets: LPBI IP Asset Classes I,II,III,V
Author: Aviva Lev-Ari, PhD, RN
Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities
Author: Aviva Lev-Ari, PhD, RN
1/1/2021
Announcing Strategic Transition from 1.0 LPBI to 2.0 LPBI on 1/1/2021: New Management, Marketing Communication and New Scientific/Technical Opportunities
Author: Aviva Lev-Ari, PhD, RN
For your New Opportunity in 2021:
- Management,
- MarkComm and
- Scientific/Technical
CONTACT
Director & Founder
e-Mail: avivalev-ari@alum.berkeley.edu
(M) 617-775-0451
DESCRIPTION
https://pharmaceuticalintelligence.com/vision/
Announcement
Strategic Transition from 1.0 LPBI to 2.0 LPBI on
1/1/2021
We have transitioned from
- 1.0 LPBI was an electronic Scientific Publisher, 2012 – 2020
to
- 2.0 LPBI a Medical Text Analysis (NLP-ML-AI) – SaaS and Content Monetization (Blockchain) – BaaS. A new company profile, 2021 – 2025
Our New NEEDS in Business Development and M&A – Pursue with results:
- Equity Sharing based
Opportunities Map in the Acquisition Arena
Our New NEEDS in Marketing Communication, Media & PR – Produce new Digital mediums
- Equity Sharing based
- The Announcement of 2.0 LPBI Launch
- NEW Website for 2.0 – Initiative #2
- Podcast – Strategy #4 – we wish to publish 2 Podcasts per quarter
- Planning Advertisement for Amazon Books using Amazon Advertising
- NEW documentation on Strategy #2 – Monetization of Journal Articles
- NEW documentation on Strategy #2 – Monetization of other IP Asset Classes
- NEW documentation on Strategy #1, #3, #6
- Reporting on developments in Strategy #5: Joint Ventures & Partnership
Our New Scientific/Technical Opportunities in Natural Language Processing (NLP), Machine Learning (ML) and Artificial Intelligence (AI)
Seeking 10 Students INTERNS for a major Medical Text Analysis using NLP, ML, AI
This is a ONE year VIRTUAL STUDENT INTERNSHIP for
- Computer Science & Biological Sciences or
- PreMed students
- PostDocs will develop the interpretation for the hyper-graphs
This internship is not fee for service – but voluntary and offers
- Mentorship by Scientists
- Letter of recommendation
- Opportunity to publish with lead authors
- Hands on experience with software
- Opportunities to present in corporate business meetings
- Scientific Career guidance
- Access to contacts in Academe and Industry
DESCRIPTION
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
1.0 LPBI Group News
2020
12/31/2020
On December 31, 2020 the Open Access Online Scientific Journal PharmaceuticalIntelligence.com –
- 1,906,438 Views
- 7,524 Scientific Comments
- 5,978 articles
- 723 Research Categories
- 482,474 Views on Top Authors: Aviva Lev-Ari, PhD, RN
12/18/2020
Today’s Meeting of the Medical Text Analysis Team had reached the following conclusions:
| Item | WorditOut | Wolfram | Genomics | Cancer |
| WordCloud | +
Done for each article not for all the 16 article together |
+
All the 16 articles PENDING Madison + Danielle |
+ | + |
| # Words | +
PENDING Madison + Danielle |
+
PENDING Madison + Danielle |
+ | + |
| Visualization
In hyper-graph format with right angles arrow lines |
+
PENDING Madison Then Danielle |
+ | + | |
| Interpretation Hyper-graphs | +
PENDING Dr. Williams |
+ | + |
NEXT STEPS
- Madison & Danielle: Please CALL meeting to Review Visualization
- Madison & Danielle: Please place IMAGES in each Box above
- Dr. Williams will write the interpretation of the Hyper-graphs: GENOMICS and CANCER
- Madison & Danielle: Please CALL meeting to Review Visualization + Interpretation
- JOEL – Please call Customer in Salt Lake City, UT to set up TIME for Presentation
12/18/2020
VENDOR EXTERNAL MEETINGS:
Top Cloud Web Services Vendor:
12/18/2020
1/4 or 1/6 or 1/7
Top NLP Vendor:
12/7
1/18 or 1/20 or 1/21 or 1/25 or 1/27
Top Blockchain Vendor:
12/8, 12/21
Spain – Explorations
12/8 – e-Book Translation
12/23 – Education Sector in Medicine
12/18/2020
PostDoctorants: Computer Science, Pharmaceutical Sciences, Biological Sciences – Added to 2.0 Team
For 2.0 LPBI we are attracting PostDoc level trained young professionals:
-
Computer Science
-
Pharmaceutical Sciences
-
Biological Sciences
12/7/2020
LINGUAMATICS DEMO
12/7 11AM EST
Linguamatics and Pharmaceutical Intelligence
Hosted by Amanda Rudd
https://linguamatics.webex.com/linguamatics/j.php?MTID=m78eb9b7f4f6e826fbb42be13865744f1
Access to DEMO
Monday, Dec 7, 2020 11:00 am | 1 hour | (UTC-05:00) Eastern Time (US & Canada)
Meeting number: 128 983 0471
12/2/2020
Two Site Map Proposals for LPBI’s New Web Site
Curators: Gail S. Thornton, PhD(c) and Aviva Lev-Ari, PhD, RN
https://pharmaceuticalintelligence.com/2020/12/02/two-site-map-proposals-for-lpbis-new-web-site/
11/11/2020
Status of LPBI Documental on 11/10/2020
- 1.0 LPBI Brochure – Version with new Edits by Mr. Bahl received on 11/10/2020
- 2.0 LPBI Brochure
- 1.0 LPBI Prospectus – 200 pps document (+100 pps Appendices) – was edited by Mr. Bahl in May 2020, 26 additional pages were added
- Excel File, three spread sheets – 1.0 LPBI, 2.0 LPBI, COMBINED (1.0 + 2.0)
- Slide deck – Power Point 200 Slides [last 50 are made by Inbar Ofer from Table and Graphs selected by 4 FIT Members from 1.0 and 2.0 LPBI Brochures)
- Elevator Pitch – versions by 2.0 LPBI Team
Versions of LPBI Group’s Elevator Pitch: 2.0 LPBI Group’s Team – In Our Own Words
11/9/2020
- New addition to our INTERNSHIP in Medical Text Analysis
- Will work with Aviva on four IT-related projects before starting the Internship in January 2021
- PowerPoint Library
- 2.0 LPBI New Website
- Yumpu.com Digital Brochures for 2.0 LPBI and 1.0 LPBI
- Deep Web Searches for references on https://pharmaceuticalintelligence.com/ It is needed for one Wikipedia Entry we are working on
Inbar Ofer, Research Assistant 3 – Medical Text Analysis for 2.0 LPBI Group’s TNS #1 – 2021 Academic Internship in Medical Test Analysis (MTA)
Inbar Ofer, Research Assistant 3 – PERSONAL PAGE on 2021 Medical Text Analysis Portal
11/2/2020
Open Data Science Conference, Virtual and In-Person | October 27th – 30th, 2020, Natural Language Processing Track
https://pharmaceuticalintelligence.com/2020/10/26/open-data-science-conference/
10/8/2020
e-Proceedings 19th Annual Bio-IT World 2020 Conference, October 6-8, 2020 Boston
Virtual Conference coverage in Real Time: Aviva Lev-Ari, PhD, RN
Tweets & Retweets by @pharma_BI and @AVIVA1950 at #BioIT20, 19th Annual Bio-IT World 2020 Conference, October 6-8, 2020 in Boston
Virtual Conference coverage in Real Time: Aviva Lev-Ari, PhD, RN
9/29/2020
Precision Cardiology to Benefit from New Atlas of Cells of the Adult Human Heart
Reporters: Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
The Impact of COVID-19 on the Human Heart
Reporters: Justin D. Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN
https://pharmaceuticalintelligence.com/2020/09/29/the-impact-of-covid-19-on-the-human-heart/
9/12/2020
- PharmaceuticalIntelligence.com Journal – Projecting the Annual Rate of Article Views
- 2.0 LPBI Executive Summary | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
https://pharmaceuticalintelligence.com/leaders-in-pharmaceutical-business-intelligence/
Of relevance as background is
- 1.0 LPBI Executive Summary
https://pharmaceuticalintelligence.com/home-website-front-page/
9/9/2020
Bradykinin Hypothesis: Potential Explanation for COVID-19
9/4/2020
e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
Founder & Director, LPBI Group
Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
8/29/2020
2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020
Real Time press coverage: Aviva Lev-Ari, PhD, RN
Tweets by @pharma_BI and @AVIVA1950 @ 2020 State of Possible Conference, MassBio’s VIRTUAL Annual Meeting, August 26 – 27, 2020
Real Time press coverage: Aviva Lev-Ari, PhD, RN
8/23/2020
PERSONAL PORTAL
Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
CV
ACTIVE Member of 2.0 LPBI
Knowledge PORTALS System (KPS) @LPBI
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
8/19/2020
An UPDATE Shared with ALL
We launched on 3/14/2020 the Coronavirus PORTAL https://pharmaceuticalintelligence.com/coronavirus-portal/ which covers 8 topics:
- Breakthrough News Corner
- Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus
- An Epidemiological Approach Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN Lead Curators – e–mail Contacts: sjwilliamspa@comcast.net and avivalev-ari@alum.berkeley.edu
- Community Impact Stephen J. Williams, PhD and Irina Robu, PhD Lead Curators – e–mail Contacts: irina.stefania@gmail.com and sjwilliamspa@comcast.net
- Economic Impact of The Coronavirus Pandemic Dr. Joel Shertok, PhD Lead Curator – e–mail Contact: jshertok@processindconsultants.com
- Voices of Global Citizens: Impact of The Coronavirus Pandemic, Gail S. Thornton, M.A. Lead Curator – e–mail Contact: gailsthornton@yahoo.com
- Diagnosis of Coronavirus Infection by Medical Imaging and Cardiovascular Impacts of Viral Infection, Aviva Lev-Ari, PhD, RN Lead Curator e-mail contact: avivalev-ari@alum.berkeley.edu
- Key Opinion Leaders Followed by LPBI Aviva Lev-Ari, PhD, RN and Dr. Ofer Markman, PhD Lead Curators e-mail contacts: oferm2015@gmail.com and avivalev-ari@alum.berkeley.edu
That effort took 2 months of most intensive work on my part.
STATEMENT
- The economic impact of of the Pandemic DOES HAVE A NEGATIVE EFFECT ON THE M&A MARKET
- In the INTERIM awaiting for more favorable conditions on the market
- we invested in INTERNAL development of IP
We launched FOUR additional PORTALS:
- ArtificiaI Intelligence in Genomics & Cancer
https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/
- 2020 Summer Internship Portal
https://pharmaceuticalintelligence.com/2020-summer-internship/
- Knowledge PORTALS System (KPS) @LPBI
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
- 2021 Medical Text Analysis (NLP)
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
- As an ADJUSTMENT for submitting the documentation to the Investment Banker in 10/2020 vs the original plan 4/2020, we are working on
- The Plan for 2021 – 2025. It involves six new strategies: TNS #1,2,3,4,5,6
TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market
Phase 1: Natural Language Processing(NLP) – 24 months FREE Microsoft AZURE for Health
Phase 2: Piloting the Proof of Concept on 4 of LPBI BioMed 16 volumes:
- Cancer, Volume 1 & 2 and Genomics, Volume 1 & 2
Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:
TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End
TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA
TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL
TNS #5: Joint venture with Dr. Nir for Drug Discovery:
TNS #6: e-Books Translations into Japanese, Spanish, Russian
These are two distinctive entities
- 0 LPBI, 1/2021 – 12/2024 – TNS #1,2,3,4,5,6, above. A new Executive Summary is work-in-progress
- 0 LPBI, 4/2012 – 12/2020 – Executive Summary https://pharmaceuticalintelligence.com/home-website-front-page/
Cumulative Revenue Potential PREDICTION of Journal Articles: Under Two Growth Assumption Regimes and Two Prediction Models
RED & BLUE Lines
A. Rate of Articles published in 2021-2025 is trending 2017, 2018, 2019, 2020 RED Line (Marked Point Process Model) $48MM for Journal Valuation & BLUE Line Conservative Assumption-based Growth Prediction (Joel)
vs
BROWN & GREEN Lines
B. No New Articles after 12/2020 BROWN Line (Marked Point Process Model) & GREEN Line (Joel)
Data Source:
WordPress.com Web Statistics of 1.8 Million Views of 6,000 Scientific Articles, 6/30/2020
[for the Annual 2020 data: the first 6 months x2].
4/2012 – 12/2020 – ACTUALS
2021 – 2025 – FORECAST
Our portfolio of Intellectual Property (IP) include TEN asset classes
| Asset Classes | Type | Quantity |
|
Asset Class I |
The Journal 8/18/2020 Views 1,807,594 |
5,900 articles on 8/18/2020
Valuation [$XXM] done by Joel on Alex WP Data ____________ |
|
Asset Class II |
BioMed e-Series | 16 volumes
Valuation [$5M] done by Joel & Aviva ____________ |
|
Asset Class III |
eProceedings | 60 events
Valuation [$1.4M] done by Dr. Williams & Aviva ____________ |
|
Asset Class IV |
Platform, composition of methods and workflows for the content creation of scientific curations. See Platform:
https://pharmaceuticalintelligence.com/coronavirus-portal/
https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/
https://pharmaceuticalintelligence.com/2020-summer-internship/
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/ |
$4MM |
|
Asset Class V |
Gallery of Biological Images in use in Articles and Books | TBD
____________ |
|
Asset Class VI |
Team of Experts
See Platform: • Knowledge Platform System (KPS) https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/ |
BIOs Final Improvement Team (FIT)
$3MM ____________ |
|
Asset Class VII |
Royalties on BioMed e-Series:Page downloads, Book borrowings and Book sale | 113,716 page downloads in total on 6/14/2020 the equivalent of 49 books to have been sold
____________ |
|
Asset Class VIII |
Subscribers to the Website | 2,549 on 8/18/2020
____________ |
|
Asset Class IX |
INTANGIBLE ASSETS & Intrinsic Value = Good Will | TBD |
|
Asset Class X |
e-VOICES PODCASTING – Audio Library
e-VOICES Podcasting, 2019 – 2021 |
TBD |
We estimate revenue potential of each entity to be
~~ $XX Million for 1.0 LPBI [Above Ten IP Asset Classes]
- Graph above present the Valuation of IP Asset Class I
~~ $XX Million for 2.0 LPBI [Excel Sheet for Financial Projection was developed in 8/2020]
~~ $ XXX Million for 1.0 LPBI plus 2.0 LPBI
The feedback that we will get from the Investment Banker will guide the TIMING and the Strategy
- ALL ACTIVE Member of the Final Improvement Team (FIT) on record for the EXIT will be in constant communication regarding all of the above
- Personal PORTAL for each member of FIT is displayed on https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
- Meg Baker is considering a collaboration in the JOINT VENTURE (LPBI X%) and Dr. Raphael Nir (7X%) on Galectins & Synthetic Biology in Drug Discovery
- Our Podcast Library is growing – See Table, below
Development Plan for e-VOICES Podcasting, 2019 – 2021*
| Podcast Interviewer | INTERVIEWEE(S) | Subject | Date | Audio/Video/
Narrator |
| Gail S. Thornton | Dr. Stephen J. Williams, Dr. Irina Robu & Dr. Aviva Lev-Ari | 3D BioPrinting in Medicine | 5/2019 | Audio |
| Gail S. Thornton | Prof. Feldman | Evolution Biology and Population Genetics | 3/17/2020 | Audio |
| Gail S. Thornton | Dr. Larry H. Bernstein, MD, FCAP | Life Memoirs in Clinical Pathology Told | 7/2020 | Audio
Narrator: Dr. S.J. Williams |
| Gail S. Thornton | Dr. Justin D. Pearlman, MD, PhD | Cardiac Imaging – Evolution of Diagnostic Methods | 4Q 2020 | Audio |
| Gail S. Thornton | Dr. Raphael Nir | From Big Pharma to Biotech Entrepreneurship | 2021 | Audio |
| Gail S. Thornton | Dr. Meg Baker | GlycoBiology in Practice | 2021 | Audio |
| Gail S. Thornton | Dr. Ofer Markman | Memories of Pharmacia | 2021 | Audio |
*Dr. Williams and Aviva – will have their Podcasts in 2021.
8/11/2020
Contributions of Interns to LPBI Publications as Curators on PharmaceuticalIntelligence.com
Participants of LPBI Group’s 2020 Summer Internship in Data Curation and Data Annotation
- These three References will be added to the CV of each Intern upon content entry finalization of editing.
WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com
Curators: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD, Aviva Lev-Ari, PhD, RN
WordCloud Visualization of LPBI’s Top Sixteen Articles on CANCER in eight categories and by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com
Curator: Stephen J. Williams, PhD and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD and Aviva Lev-Ari, PhD, RN
WordCloud Visualization of LPBI’s Top Sixteen Articles on GENOMICS by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com
Curators: Stephen J. Williams, Aviva Lev-Ari, PhD, RN and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD
8/3/2020
Our 16 Books are announced in the Japanese Language
アマゾンおすすめ商品
価格の安い順番
価格の高い順番
レビューの評価順
出版年月が新しい順番
アマゾンおすすめ商品
価格の安い順番
価格の高い順番
レビューの評価順
出版年月が新しい順番
Cancer Biology and Genomics for Disease Diagnosis (Series C: e-Books on Cancer & Oncology Book 1) (English Edition)
Pharmacological Agents in Treatment of Cardiovascular Diseases (Series A: Cardiovascular Diseases Book 5) (English Edition)
Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics (Series E: Patient-Centered Medicine Book 3) (English Edition)
Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases (English Edition)
Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation: The Art of Scientific & Medical Curation (English Edition)
Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics (English Edition)
Metabolic Genomics & Pharmaceutics (BioMedicine – Metabolomics, Immunology, Infectious Diseases Book 1) (English Edition)
Perspectives on Nitric Oxide in Disease Mechanisms (Biomed e-Books Book 1) (English Edition)
7/20/2020
AVIVA’S VISION on 7/19/2020
Three new entries for WIKIPEDIA are created in July-August 2020
Wikipedia entry #1:
1.0 LPBI
This entry was created by Zack and Aviva
- DRAFT is READY for posting by ZACH – Editing of DRAFT by GAIL
Using 12 Word Clouds for CHARTING the KNOWLEDGE MAPS in our 12 TOP VIEWED articles
Wikipedia entry #2:
Aviva Lev-Ari, PhD, RN – Wikipedia entry for
The Founder of 1.0 LPBI and 2.0 LPBI
This entry was created by Zack and Aviva
- DRAFT is ALMOST READY for posting by ZACH – Editing of DRAFT by GAIL
Using 12 Word Clouds for CHARTING the KNOWLEDGE MAPS in our 12 TOP VIEWED articles. Several of them are her own.
Wikipedia entry #3:
2.0 LPBI – 2021 and beyond
This entry will be created by Ofer, Daniel and Aviva
This ENTRY will cover the Three New Strategies (TNS)
TNS #1: Text Analysis with NLP, ML, AI
- Work to continue by Ofer and ALL the INTERNS: current & new
Using 12 Word Clouds for 2.0 LPBI’s HyperGraphDB construction: Biological Pathways, Therapeutics, Indications,
TNS #2: Blockchain infrastructure – The PLATFORM to sell Journal Articles, e-Books, e–Proceedings & Tweet Collections
- Work to start after 7/21/2020 to be led by Daniel and INTERNS: current & new
Using 12 Word Clouds for Wordsmithing the Message to be narrowcasted to communities of scientists on the Categories of Research covered and the Article Titles available for download for $30.
TNS #3: Audio-Video Podcasts Library
- Augmentation of the Work to be continued by Gail & Aviva & Dr. Williams & Irina
Using 12 Word Clouds for Topic Generation for to be initiated NEW Podcasts in 2021 and beyond
New Strategy for WEBSITE DESIGN
We are launching 2.0 LPBI – a NEW WEB SITE about our Three New Strategies
- Work to start by Gail, Aviva in August 2020
OUR HISTORY
- 1.0 LPBI is our Current Website http://pharmaceuticalintelligence.com
- It will become the BACKEND of the New Web Site, aka, 2.0 LPBI
OUR FUTURE
- 2.0 LPBI – will be our NEW WEB SITE about 2021 and BEYOND
- Calling 4/2012 to 12/2020 (1.0 LPBI) – OUR HISTORY
- Work on the New WEBSITE to start in August 2020 by Gail, Aviva
Details on 2.0 LPBI’s Three New Strategies (TNS #1, #2, #3)
TNS #1: Text Analysis with NLP, ML, AI
- Work to continue by Ofer and ALL the INTERNS: current & new
- On 7/21 at 2PM EST – TDP, Palo Alto, CA will present their platform for the Proof of Concept we need to build using our Genomics and Cancer e-Books
Using 12 Word Clouds for 2.0 LPBI’s HyperGraphDB construction: Biological Pathways, Therapeutics, Indications
On Sat, 8 Feb 2020 at 15:22 Aviva Lev-Ari <aviva.lev-ari@comcast.net> wrote:
UPDATED on 7/19/2020
The concept of HyperGraphDB and set of rules are needed to be created for the 1400 curations of Dr. Larry, more than half are about signaling pathways used in therapeutics using receptors.
THEN we will have the software for autoindependent semantic Text analysis of Dr. Larry’s UNIVERSE of articles – this was Dr. Williams great Idea.
(7/19/2020 – 5,875 (all articles) / 1400 (LHB’s Universe = 23.8%) of our IP in Journal articles.
Please read below, article and send me your comment on its relevance to our current search for a Partner with expertise in Machine Learning, Natural Language Processing, AI for text analysis.
https://www.wired.com/story/code-obsessed-novelist-builds-writing-bot-the-plot-thickens/
TNS #2: Blockchain infrastructure – The PLATFORM to sell Journal Articles, e-Books, e–Proceedings & Tweet Collections
- Work to start after 7/21/2020 to be led by Daniel and INTERNS: current & new
Using 12 Word Clouds for Wordsmithing the Message to be narrowcasted to communities of scientists on the Categories of Research covered and the Article Titles available for download for $30.
- We wish to monetize the IP Asset Classes created in 1.0 LPBI: Class I, II, III, IV, V
- Foundry Research is the community of Scientists built by BusrtIQ, Denver, CO – they will present on 7/21 at 3PM EST
The Voice of Daniel Menzin:
“How Blockchain Technology can Assist 2.0 LPBI in monetizing IP Asset Classes created in 1.0 LPBI: Class I, II, III, IV, V”
1. Blockchain may be able to provide us with an organized way to keep track of each 30 dollar transaction. I would imagine their system would provide us with useful data as well which we can analyze like we’ve done with Twitter and WordPress.
2. Since Blockchain is a shared ledger, it can distribute data across sites, institutions, or countries. This would allow us to organize all of our IP assets and transact with our buyer digitally, requiring less work to be done by the buyer in developing our existing infrastructure for their purposes I would imagine.
3. It appears to me that Blockchain would improve the efficiency and ability to track our business transactions and documentation during our exit process. Blockchain claims to provide a shared digital medium for tracking the paperwork and agreements existing between two business parties. It is a shared, immutable ledger meaning that “it is a consensus of replicated, shared, and synchronized digital data geographically spread across multiple sites, countries, or institutions. Unlike with a distributed database, there is no central administrator.” It is immutable, meaning that the data cannot be changed once a consensus is reached (to my understanding). It seems like an automated digital system which serves to improve the organization and efficiency of business transactions by creating “a system” of sorts which organizes information related to these processes.
The Voice of Aviva Lev-Ari, PhD, RN:
“How Blockchain Technology can Assist 2.0 LPBI in monetizing IP Asset Classes created in 1.0 LPBI: Class I, II, III, IV, V”
1. Blockchain may be able to provide us with a platform to narrowcast Word Clouds of 1.0 LPBI Journal articles to the Research Foundry Community
TNS #3: Audio-Video Podcasts Library
- Augmentation of the Work to be continued by Gail & Aviva & Dr. Williams & Irina
Using 12 Word Clouds for Topic Generation for to be initiated NEW Podcasts in 2021 and beyond
Gail’s work:
Interview with Professor Marcus Feldman, Stanford University by Gail S. Thornton
https://pharmaceuticalintelligence.com/audio-podcasts/
Forthcoming
Gail’s Interview with Dr. Larry H. Bernstein, MA, FCAP
- A Narrated Version – Tribute to his life long Contributions to Medicine
- LHB lost his voice in thyroid cancer in 2016, since then on Medical LEAVE @LPBI as CSO and Emeritus, Board Member
and
- On 3/12/2015 – Dr. Williams posted
Podcast Review: Quiet Innovation Podcast on Obtaining $ for Your Startup
Reporter: Stephen J. Williams, Ph.D.
- On 1/25/2016 – Aviva posted
Launching LPBI’s, Fourth Line of Business (D): FIVE Podcast – Audio Series in BioMed
Curator: Aviva Lev-Ari, PhD, RN
- On 3/17/2016 – Aviva posted
CRISPR: A Podcast from Nature.com on Gene Editing
Reporter: Aviva Lev-Ari, PhD, RN
https://pharmaceuticalintelligence.com/2016/03/17/crispr-a-podcast-from-nature-com-on-gene-editing/
7/13/2020
- State of Science on 7/21/2020
New Etiology for COVID-19: Death results from Immune-Mediation (virus-independent immunopathology: lung and reticuloendothelial system) vs Pat
We are proud to have included in LPBI Group’s Coronavirus Portal – Breakthrough News Section: https://pharmaceuticalintelligence.com/coronavirus-portal/ the following: COVID-19: Pandemic Surgery Guidance published by a Global Consortium initiated effort by Björn L.D.M. Brücher, MD, PhD, Prof. Of Surgery, Carl-Thiem-Klinikum, Cottbus, Germany
Reporter: Aviva Lev-Ari, PhD, RN
https://pharmaceuticalintelligence.com/2020/06/13/covid-19-pandemic-surgery-guidance-published-by-a-global-consortium-initiated-effort-by-bjorn-l-d-m-brucher-md-phd-prof-of-surgery-carl-thiem-klinikum-cottbus-germany/